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The work of this dissertation describes the design and synthesis of 1,2,4-triazine ligands 
and other N-containing heterocycles and their use in the copper-catalyzed azide-alkyne 
cycloaddition (CuAAC). A variety of ligands were synthesized to probe the steric and 
electronic demands required for use in the CuAAC reaction. Substituents on the 1,2,4-
triazine were systematically altered and the core 1,2,4-triazine modified to determine the 
most active ligand. Additional experiments explored the variability in the reaction 
conditions, such as solvent choice, use of reducing agents, and optimal stoichiometry. 
Under optimum conditions 5,6-diphenyl-3-(2-pyridyl)-1,2,4-triazine and copper (II) 
tetrafluoroborate in the presence of triethylamine was found to be an effective 
accelerant producing 97% of the desired 1,2,3-triaozle in 1 hour. A broad substrate 
scope was conducted with an assortment of azides and alkynes.  
The use of 1,2,4-triazine-accelerated CuAAC was applied to the synthesis of solid-
supported catalysts on both polystyrene and silica. Immobilized catalysts provide 
advantages over their soluble counterparts in that they can be recycled and can prevent 
metal contamination of 1,2,3-triazole products. Results indicated that 1,2,4-triazines 
appended to solid supports were more effective when compared to 1,2,3-triazole control 
catalysts. In addition, less metal leaching occurred with triazine supports as compared 
to triazole controls.  
The optimal ligand from the homogeneous screening was then used in the synthesis of 
a library of small molecules containing 1,2,3-triazoles and/or 1,2,4-triazoles. Upon 
synthesis, compounds were screened for activity against various histone deacetylase 
(HDAC) enzymes for both activity and selectivity. Although successfully synthesized, 
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Chapter 1.  




1.1. Click Chemistry 
In the realm of synthesis, there are two broad schools of thought. One approach is to 
construct products using combinations of novel reactions regardless of how difficult the 
target might be, as long as a desired activity is present. Natural product synthesis 
usually evokes this process to make the difficult molecules or metabolites, naturally 
occurring in plants, marine species, or other native environments. Sometimes these 
methods are not conducive to scale-up, commercialization, or synthesis of 
corresponding analogues. A second approach is to restrict drug discovery targets to 
molecules that are easy to make and through methods that can be rapidly modified to 
introduce diversity. Researchers estimate that there are on order of between 1062 and 
1063 druglike candidates.1 Druglike candidates are defined as having less than 30 non-
hydrogen atoms, containing C,H, N, O, P, Cl, Br and stable at ambient temperature, in 
the presence of oxygen and water.1 With the amount of probable druglike molecules, it 
is reasonable to attempt synthesis of molecules that can easily be made. This is a shift 
to focus more on the activity than the structure of the desired molecule. If the synthesis 
can be easily modified for diversity elements, one can more rapidly complete a 
structure-activity relationship (SAR) study. 
From this idea, was born the “click chemistry” philosophy described by K.B Sharpless et 
al.2 Reactions that fit into the click chemistry philosophy should be “modular, wide in 
scope, high yielding, generate only inoffensive byproducts removed by 
nonchromatographic methods, and stereospecific.” Reaction conditions should be 
insensitive to water and oxygen, use no solvent, a benign solvent, or an easily removed 
solvent, and be amenable to simple product isolation. Starting materials should be 
readily available to further expedite the process.2 This process should be as simple as 
joining two units together, such as fitting two puzzle pieces together. The reactive 
fragments should only react with one another and the reaction conditions should be 
tolerable to a wide array of functional groups, without the need for protecting group 
chemistry. 
The constraints of click chemistry may seem demanding, but several reactions fit into 
this category. Figure 1.1 shows examples of click chemistry which include oxidative 
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additions to carbon-carbon multiple bonds such as epoxidation, aziridination, and 
dihydroxylation. Michael additions of nucleophiles to unsaturated systems also fit into 
this category, along with nucleophilic ring opening of strained rings, such as aziridines 
or epoxides. Non-aldol additions to carbonyls such as in formation of ureas, amides, or 
oxime ethers are also consistent with the constraints of click chemistry. Non-aldol 
carbonyl chemistry to form aromatic systems also falls within the definition of click 
reactions. Finally, several cycloaddition reactions, including Diels-Alder transformations 
and 1,3-dipolar cycloaddition reactions fit into the framework of click chemistry. With the 
exception of Diels-Alder, the majority of these reactions take advantage of carbon-
heteroatom linkages. These heteroatom linkages can be described as mimics of nature, 
as a large number of diverse compounds (nucleic acids, proteins, polysaccharides) are 




Figure 1.1 Representation of reactions conforming to “click” guidelines. Adapted from 
Moses et. al3 & Kolb et. al4 
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Among these reactions, one has emerged as the centerpiece of “click chemistry” 
sometimes being incorrectly defined as click chemistry, in itself. Since the discovery of 
the copper catalyzed variant of the Husigen azide-alkyne cyclocaddition (CuAAC), the 
field of click chemistry has expanded to include drug discovery,4 biological applications,5 
materials science and polymer chemistry6,7 and has produced a number of reviews in 
various areas.3,8,9 Why has this reaction had such a dramatic impact on the way 
scientists approach these fields? This reaction is highly regioselective, involves two 
relatively unreactive starting materials, and forms a stable product that has implications 
in biological systems. 
 
1.2. 1,2,3-Triazoles as Pharmacophores 
The field of drug discovery has been greatly influenced by the discovery of a copper-
catalyzed azide-alkyne cycloaddition (CuAAC). This has allowed the rapid synthesis of 
a number of 1,2,3-triazole containing molecules for a wide variety of applications. 
Several reviews have summarized the growing trend of triazoles as important 
pharmacophores and their use in biological applications.10-14  
One reason for the growing use of triazoles stems from the suggestion as amide bond 
replacements.15 Evidence suggests that 1,2,3-triazoles can be both electronically and 
spatially similar to amide bonds. Amide bonds, in either the E or Z conformation, can be 
related to disubstituted 1,2,3-triazoles, either in a 1,4- or 1,5-substitution pattern (Figure 
1.2).12 The 1,4-disubstituted-1,2,3-triazoles mimic the Z-amide bond. Electronically, N(2) 
or N(3) of the triazole can serve as a hydrogen bond acceptor similar to the carbonyl 
oxygen of an amide. Both the amide and the triazole can also serve as hydrogen bond 
donors with the C(5)-H of the triazole mimicking the NH of an amide. Both also have 
electrophilic carbons (C-O vs. C-N). Although similar, the triazole has a larger dipole 
moment, making its hydrogen bond donor and acceptor abilities greater than those of 





Figure 1.2 Triazoles as isosteres for amide bonds. Modified from Tron et. al.12 Comparison 




The geometry and spatial arrangement of atoms in a triazole ring are similar to that of 
the amide bond as well, with the triazole spacing being slightly longer by 1.1 Å.12 In 
addition, triazoles have also been demonstrated to retain conformational geometries in 
secondary structures when replacing amide bonds in α-helices16 and β-turns.17 
There are two significant differences between amide bonds and triazoles, both of which 
tip the scales in favor of the triazole: stability and ease of synthesis. Triazoles are stable 
under a wide array of conditions, including resistance to hydrolysis, oxidation, and 
reduction, conditions by which the amide bond is susceptible. Triazoles are compatible 
with either acidic or basic media, and degradation by metabolic pathways does not 
interfere with the triazole scaffold. With the discovery of copper-catalyzed azide-alkyne 
cycloaddition and the analogous ruthenium-catalyzed azide-alkyne cycloaddition, the 
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synthesis of 1,2,3-triazoles is much less laborious and has abounded in a number of 
biologically relevant molecules being synthesized. Because triazole synthesis is 
amenable to a variety of functional groups, diverse libraries of compounds can be 
quickly and efficiently synthesized to screen for a wide array of biological activities. 
The triazole core is present in a variety of drug leads (Figure 1.3) such as antiviral,18 
anti-HIV,19 antituberculosis activity,20,21 antifungal,22 anti-inflammatory,23 and 
antiobesity.24 Additional uses of 1,2,3-triazoles are in the design of histone deacetylase 
(HDAC) inhibitors,25 or resveratrol mimics,26 and anti-cancer therapeutics.27 Some 
triazole containing compounds have undergone clinical trials or are commercially 
available (Figure 1.4). The synthesis of additional triazole molecules is now greatly 








Figure 1.4 Potential pharmaceuticals containing a 1,2,3-triazole.11 Generic and trade names 
listed for commercial products along with supplier. 
 
 
1.3. Azide-Alkyne Cycloadditions 
The azide-alkyne cycloaddition has made it possible to synthesize a large number of 
1,2,3-triazoles. Even prior to the discovery of the copper catalyzed variant, thousands of 
1,4-disubstituted-1,2,3-triazoles had been synthesized. The azide-alkyne cycloaddition 
falls into the family of 1,3-dipolar cycloadditions, which was the topic of extensive 
research by Rolf Huisgen and colleagues.28 1,3-Dipolar cycloadditions provide a general 
method of synthesizing 5-membered heterocycles, starting from a 1,3-dipole, containing 
both electrophilic and nucleophilic atoms and a dipolarophile, containing a multiple 
bond. The azide-alkyne cycloaddition focuses on the azide as the dipole and alkyne as 
the dipolarophile. The first 1,2,3-triazole synthesis was performed by A. Michael in 
1893.29 Further work was explored by Huisgen throughout the 1950s-1970s. The 
original reaction between azides and alkynes was thermally controlled, leading to 
prolonged reaction times, low yields, and low selectivity. Changes to the electronics of 
the azide or alkyne contribute to the overall reactivity, making the scope of the reaction 
limited. With cycloadditions, there are two possible overlaps between the dipole HOMO 
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and dipolarophile LUMO or dipole LUMO and dipolarophile HOMO. Because the 
difference in the molecular orbitals is small, a mixture of regioisomers is formed.9 
Electron deficient alkynes could be used to tune the reaction to achieve better 
regioselectivity, but this again limits the overall diversity attached to the triazole scaffold.  
Although the triazole formation could be slow and non-regiospecific, there was still a 
desire to further investigate the azide-alkyne cycloaddition. Organic azides are unique 
dipoles in that they can be made, handled, and stored as stable compounds. Azides 
and alkynes are relatively non-polar, and can remain hidden from and unreactive with 
most other functionalities, allowing their installation early on in a synthetic scheme. The 
reaction would also be atom-economical, employing accessible dipoles and 
dipolarophiles. Finally, the triazole product is a stable aromatic structure (serving as an 
amide bond replacement).9 If the azide-alkyne reaction could be catalyzed and be tuned 
for regioselectivity, it had potential to find a place in the “click chemistry” world. 
In 2001, the groups of Meldal30 and Fokin and Sharpless31 accomplished this feat and 
discovered the copper-catalyzed variant of the azide-alkyne cycloaddition, which 
exclusively produced the 1,4-disubstituted triazole isomer. The analogous ruthenium 
catalyzed reaction to produce the 1,5-disubstituted isomer (or 1,4,5-trisubstituted isomer 
if internal alkynes are used) was also discovered by Fokin and Sharpless.32 An 
additional method of producing 1,2,3-triazoles was also sought after especially for 
biological applications in which copper toxicity limits applications with living cells. 
Several researchers have explored the use of strained cyclooctyne systems to perform 
selective cycloaddition reactions in living systems.33,34 This copper free process has 
allowed the selective modification of biomolecules to study proteins, lipids, 
bactereriophages, and small organisms, such as zebrafish.34 Although this method can 
produce two regioisomers, this would not have an adverse effect on the biological 
applications. The four methods of producing triazoles from azides and alkynes are 





Figure 1.5 Synthesis of 1,2,3-triazole regioisomers. Synthesis can occur through (A) thermal 
cycloaddition, yielding a mixture of regioisomers, through (B) copper-catalyzed variant 
producing 1,4-disubstituted-1,2,3-triazoles, or through (C) ruthenium-catalyzed variant 
producing 1,5-disubstituted or 1,4,5-trisubsituted triazoles or (D) copper-free cycloaddition of 
strained alkynes  
 
 
1.4. Copper-Catalyzed Azide-Alkyne Cycloaddition 
In addition to providing a regioselective path to 1,2,3-triazoles, the copper-catalyzed 
variant also accelerates the cycloaddition on the order of 106 relative to the uncatalyzed 
reaction.9 This allows the reaction to now take place within a reasonable time frame, 
minutes or hours as opposed to days, and at room temperature. The catalyzed variant 
is also not limited by sterics or electronics of the azide or alkyne component, and most 
organic functional groups are not affected, eliminating the need for protecting groups. 
Due to the rate acceleration and the high regioselectivity, azide-alkyne cycloaddition 
has become a leading method for covalent assembly of molecules, large and small. 
The copper-catalyzed reaction is fairly insensitive to reaction conditions, as long as a 
source of CuI is present. Both aqueous and organic solvents may be employed and the 
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reaction proceeds with solution-phase or solid-supported reagents. An important note is 
that CuI must be present or generated in situ and should be kept at a high level with 
regards to the inactive CuII or Cu0 oxidation states. An extensive list of CuI sources has 
been compiled and summarized by Meldal.8 The CuI can come from three main 
categories, from a CuI salt, from a CuII salt and a reducing agent, or through oxidation of 
Cu0 found in copper wire, turnings, or powders. Of these methods, the most commonly 
employed is the use of copper (II) sulfate in the presence of a reducing agent, 
commonly sodium ascorbate. These reaction conditions allow for less air-susceptibility, 
not requiring dry solvents, or inert atmospheres to carry out the reaction. Copper sulfate 
in the presence of a reducing agent and alkyne can form the active copper-acetylide 
species required for the reaction immediately, but this process is not as facile for copper 
halides such as CuI or CuBr. These salts typically require additional amine base or high 
temperatures to form copper-acetylides. The copper halides favor anhydrous conditions 
and tend to have better solubility in solvents of intermediate polarity such as acetonitrile, 
tetrahydrofuran, and dimethylsulfoxide. The final method is the use of elemental copper. 
The downside to this method is the increased reaction time, since the active species 
must be formed first. The advantage lies in product isolation in which solid copper can 
be easily removed.  
Recent reports have attempted to explain catalysis of azide-alkyne cycloaddition by 
copper (II) salts with the argument that these reactions are catalyzed by copper (II) and 
not the more common copper (I) state.35 According to the experts in the field,9 these 
reports are not accurate. The most likely explanation for these reports is that reduction 
of the starting copper (II) salt is occurring to produce copper (I). Since CuII serves as a 
good oxidizing agent, it is likely that solvent or even starting alkynes are being oxidized, 
resulting in the reduced and catalytically active CuI species. Even a small amount of 
copper (I) in the reaction mixture is sufficient to catalyze the cycloaddition.8 Although 
there has been much success in the field of copper-catalyzed azide-alkyne 
cycloaddition, there was a desire to find better conditions, such that less copper could 
be employed and separation from copper salts was not as tedious or cumbersome.  
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1.5. Ligand-Accelerated CuACC (Homogeneous & Heterogeneous 
Applications) 
Although not a necessity, many researchers have chosen to include a ligand to enhance 
either the reaction rate or to protect the active CuI from oxidation. Additional benefits 
from utilizing ligands are reduced catalyst loadings and improved product purity with 
less copper contamination. Ligands can be especially useful for demanding 
applications. The added ligands can either be soluble homogeneous ligands or ligands 
attached to an insoluble support. A large number of ligands have been synthesized, 
generally including heteroatoms, and reviewed.36 Nitrogen based ligands make up the 
majority of those explored for azide-alkyne cycloaddition. The simplest and earliest 
additives employed were amines such as 2,6-lutidine, triethylamine or 
diisopropylethylamine (DIEA), or proline.37 Other early ligands involved nitriles, 
guanidines, imines, or halides. With the early ligands, two main problems arose. Some 
of these ligands (halides and amines) were too labile and did not protect the copper 
from oxidation to an inactive state. Other ligands (nitriles) were found to bind the metal 
too tightly, resulting in decreased reactivity of the needed copper center.8   Sharpless 
and Fokin38 realized during kinetic investigations that reaction rates of selected 
substrates were extremely high, almost appearing autocatalytic; the triazole product 
could be catalyzing its own formation. Since triazoles had earlier been difficult to 
synthesize, using triazoles as ligands for product triazole formation had previously been 
unexplored. This work began a new approach in designing ligands for CuAAC. TBTA 
(Figure 1.6, 1-1) was found to be an effective ligand.38 From this work, stemmed several 
additional ligands. Finn and coworkers kept the central amine framework the same and 
changed the surrounding heterocycle. The 1,2,3-triazole was exchanged for 
benzimidazole, benzothiazole, pyridine, and related derivatives. A systematic 
exploration of various hybrid ligands was undertaken to determine optimal reaction 
conditions, mechanistic insights, and dependence on solvent and ligand metal 
stochiometries.39 This led to hybrid or mixed ligands similar to TBTA, but with more than 
one different heterocycle attached to the core amine. Bim(Py)2 (1-3) was found to be the 





Figure 1.6 Heterocyclic ligands used for azide-alkyne cycloaddition. 
 
 
Inspired by this work and the results observed, other researchers began to investigate 
tripodal ligands (Figure 1-7). One downfall of the TBTA system was its poor water 
solubility. This leads to difficulty in biological applications as an increased copper 
loading is necessary, resulting in toxicity within living systems. As a potential solution, 
researchers designed additional analogues of TBTA and examined their water solubility, 
azide-alkyne reaction rate, and cytotoxicity.40 Addition of BTTES (1-4) premixed with 
copper sulfate (and reduced with sodium ascorbate) was found to be a more effective 
accelerant of azide-alkyne cycloaddition compared to TBTA-Cu(I) catalyst. In addition, 
cell death was suppressed in BTTES-Cu(I) treated cells compared to Cu(I) treated cells, 
showing a decreased toxicity. Additional work looked at catalysts containing long alkyl 




Figure 1.7 Additional nitrogen containing ligands used for azide-alkyne cycloadditions. 
 
 
previously prepared and used in atom transfer radical polymerization (ATRP) 
reactions.41 Because of the increased stability towards aerobic conditions and its ability 
to be isolated and handled without air-free techniques, it was screened as a catalyst for 
azide-alkyne cycloaddition. This proved to be effective and reusable up to three times 
without a loss in activity. Additional benzimidazole ligands were synthesized by Li and 
Hor42 with 1-6 showing good activity for both azide-alkyne cycloaddition and N-arylation 
reactions. 
Other nitrogen containing ligands have been explored including bipyridines (1-7), 
phenanthrolines, and imidazoles. Imidazoles, such as 1-8 (Figure 1.7) with a long alkyl 
linker were found to give cycloaddition products in good yields when performed neat or 
in water.43 Sulfonated bathophenanthroline (1-9) has proven to be superior to TBTA 




Ligands can also be extended to include other heteroatoms, such as phosphorus, 
sulfur, oxygen, or carbon. NHCs (N-heterocyclic carbenes) contain nitrogens but are 
actually coordinated through a carbon (or more specifically a carbene). Most of the 
studies with NHC-containing ligands focus on methodology, and have not fully been 
explored within the context of complex systems, although promising results are present. 
The best NHC ligand has resulted from the addition of an aromatic nitrogen based 
ligand, such as phenanthroline45 to combine the best of both features in one molecule. 
Figure 1-8 illustrates a mixed NHC-phenanthroline copper complex (1-11) that was used 
in the synthesis of potential metal chelators. In general, there remains work in this field 
to match the abilities of other ligands in azide-alkyne cycloadditions. 
Additional ligands involving other heteroatoms are relatively scarce.  Two notable 
phosphorus complexes are [CuBr(PPh3)3] and [Cu(phen)(PPh3)]NO3.
46,47
 The former 
adhered to strict “click” conditions, using low catalyst loadings, benign solvents, short 
reaction times, and no additional purifications.  Oxygen ligands have also been used, 
most notable are carboxylic acids. Copper (I) acetate has been shown to outperform 
other CuI salts in the absence of other additives. The theory behind this activity was the 
ability of the acetate to effectively coordinate the copper. Other carboxylic acids such as 
benzoic acids (1-12)48 have been shown to act as ligands. Finally, sulfur ligands have 
displayed good activity even if there is not much interest in this area. This ligand (1-13) 




Figure 1.8 Catalysts invovling metal-coordination atoms other than nitrogen. 
15 
 
Attempts have been made to compare the various ligand-accelerated reactions, but 
because of the wide variety of reaction conditions employed it has been difficult to carry 
out a direct comparison. Despite the ability of several ligands to accelerate the 
cycloaddition of simple azide alkyne systems, there remains a need to identify and 
investigate ligands for increasingly demanding applications. 
An additional growing area of research is the use of heterogeneous materials to 
catalyze the azide-alkyne cycloaddition. Heterogeneous ligands and catalysts can have 
distinct advantages over their homogeneous counterparts. The main advantages with 
using solid supports are the ease in product isolation, decreased metal contamination of 
products, and potential recyclability of the catalyst. In addition, a wide range of insoluble 
supports are commercially available. Some heterogeneous materials can be directly 
used in the presence of metal to catalyze the desired cycloaddition reaction. Other 
materials can be easily modified to covalently attach a metal binding ligand, and then 
used for catalytic applications. Surfaces that have been used to catalyze the 
cycloaddition include copper clusters50, copper-aluminum hydrotalcite,51 copper 
zeolites,52 copper nanoparticles on alumina53 and copper in charcoal.54 Although these 
surfaces can coordinate copper, there was an effort to design more steric and 
electronically demanding ligands to match those of homogeneous ligands. Fokin and 
Chan55 developed a solid supported version of TBTA (1-14) to lead the way. The 
structures of a selection of solid supported catalysts are illustrated in Figure 1.9. These 
include other ligands attached to polystyrene resins56 and silica.57,58  These 
heterogeneous catalysts have proven to be useful from a synthetic standpoint. There 
still remain some disadvantages in terms of cost of support-bound catalysts, increased 
reaction times, and increased temperatures. There is still a need to develop better 




Figure 1.9 Examples of heterogeneous ligands used to accelerate CuAAC. 
 
 
1.6. Mechanistic Considerations 
From a mechanistic perspective, it is important to realize that the reaction is fairly 
insensitive to reaction conditions, performing in the presence of CuI, with aqueous or 
organic solvents, and working in either solution- or solid-phase environments. Many 
reports exist in an effort to explain the mechanism of the azide-alkyne cycloaddition. 
Experimental evidence has been collected with regards to copper-catalyzed 
cycloadditions in both the presence and the absence of additional ligands. 
Using pseudo-first order kinetics or through DFT calculations, several mechanistic 
theories have been presented to explain experimental observations. A point of dispute 
between researchers is the nature of the copper intermediate. Copper acetylides and 
copper π-complexes have both been proposed as intermediates. Cantillo and 
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coworkers recently performed a computational analysis using DFT to compare the 
various proposed mechanisms and to compare catalyzed and uncatalyzed pathways.59 
As can be expected, in the uncatalyzed version, no significant energy difference exists 
between the two possible activation energy barriers leading to 1,4- or 1,5-disubstituted- 
1,2,3-triazoles. This explains the lack of regioselectivity in the uncatalyzed version, and 
the high activation energy of 36 kcal/mol for both pathways explains the sluggish 
reaction. From their research, activation energy barriers were calculated for the 
following proposed intermediates: mononuclear copper acetylides, dinuclear copper 
acetylides, mononuclear and dinuclear pi copper complexes, and tetranuclear copper 
acetylides. These values are summarized in Table 1.1. 
The lowest activation energy barrier points to the copper acetylides with two metal 
centers as being a plausible intermediate, which was previously proposed by Fokin et. 
al through kinetic studies.60 Figure 1.11 highlights the catalytic cycle for the copper-
catalyzed azide-alkyne cycloaddition.  The initial step begins with coordination of the 
copper with the alkyne to form the π-alkyne copper complex. The coordination of the 
copper lowers the pKa of the alkyne proton by approximately 10 units, making it much 
more acidic. The alkyne is deprotonated and the copper acetylide forms. It is proposed 
that a second copper interacts with the copper acetylide through a second π-complex. 
The azide then becomes activated by coordination to the copper atom. An unusual six-
membered metallocycle is formed. The ring contraction step is highly favored and 
occurs rapidly to form the copper-triazolyl species. Proteolysis is the final step in which 
the copper is regenerated and the triazole product formed. 
Depending on the conditions employed, byproducts can result during the azide-alkyne 
cycloaddition. Common byproducts are shown in Figure 1.12. These byproducts are a 
result of oxidative couplings which are also catalyzed by copper (I) species. Fortunately, 
methods exist to minimize the amount of byproducts formed by addition of reducing 





Table 1.1 Comparison of activation energy barriers for proposed intermediates in 
CuAAC. 
 Activation Energy Barrier 
(1,4-disubstituted-1,2,3- 
triazole) kcal/mol 
Activation Energy Barrier 
(1,5-disubstituted-1,2,3- 
triazole) kcal/mol 




mononuclear π complex 29.1 34.0 




dinuclear copper acetylides 16.0 20.4 
 
1.7. 1,2,4-Triazines as Ligands 
Previous challenges in our group had included synthesis of 1,2,3-triazoles, even in the 
presence of a supporting ligand. We embarked on a project to pursue ligands to 
improve the efficiency of the copper-catalyzed azide-alkyne cycloaddition. Our 
inspiration for using 1,2,4-triazines was their known ability to coordinate various 
transition metals and several complexes, especially with copper, had been synthesized 
and studied.61-64 Through these studies 5,6-diphenyl-3-(2-pyridyl)-1,2,4-triazine was 
shown to coordinate a copper atom through coordination of N2 of the triazine and the 
nitrogen of the pyridine substituent (Figure 1.12). It could be hypothesized that 
coordination could occur through the N4 position of the 1,2,4-triazine, but the 
substituent at position 5 creates steric bulk disfavoring that conformation. In addition, to 
the binding of copper, it is proposed that triazines can stabilize copper (I) oxidation state 
by disfavoring disproportionation.65,66 Based on the literature precedents, 1,2,4-triazines 











Figure 1.11 Possible byproducts observed during CuAAC. 
 
 
1.8. Scope of this Work 
This dissertation describes the research towards using 1,2,4-triazines as ligands for the 
copper-catalyzed azide-alkyne cycloaddition reaction (CuAAC). Chapter 2 details the 
design and synthesis of 1,2,4-triazines and similar nitrogen containing heterocycles. 
Chapter 3 discusses the catalytic activity of both homogeneous 1,2,4-triazines and 
heterogeneous 1,2,4-triazines, with regards to CuAAC. An extension of the catalytic 
activity was then applied to a small study on one-pot Sonogashira-CuAAC reactions. 
Chapter 4 details the synthesis of small molecules as potential metalloenzyme inhibitors 
using 1,2,4-triazines as ligands. The activity of these synthesized inhibitors in 




























Chapter 2.  




2.1. Background & Significance 
 
1,2,4-Triazines are well established compounds with a number of publications 
describing the preparation, physical or theoretical properties, and applications, including 
a thorough review by Lindsley et al.68 The 1,2,4-triazine core is scarce in natural 
products with compounds 2-169 and 2-270 (Figure 2.1) highlighting two rare naturally 
occurring examples. Despite the lack of natural occurring sources, the triazine core has 
found utility as an intermediate in the synthesis of natural products. It is especially 
useful in the synthesis of pyridine ring systems by undergoing Diels-Alder reactions with 
numerous dienophiles, as can be seen by the synthesis of the pyridine alkaloids of the 
Louisianin family (2-3)71 and phomazarin (2-4).72 The potential uses of triazines are 
encompassing of many areas including molecular probes (2-5),73 potential therapeutics 
for Parkinson’s disease (2-6),74 or cancer treatments (2-7).75  Additional applications of 
1,2,4-triazines include use as metal chelators (2-8),76 dyes, as backbone of polymers (2-
9),68 or as agrochemicals such as the herbicide (2-10).77  A selection of molecules with 
a 1,2,4-triazine scaffold are included in Figure 2.2.  
Of the potential uses of triazines, the metal chelation abilities sparked our interest in the 
triazine scaffold. Several metal complexes have been synthesized, their crystal 
structures analyzed and properties investigated, including complexes of copper,63 iron,78 
and even lanthanide metals.79 Of particular interest were copper complexes of 1,2,4-
triazines.61  Copper complexes of 5,6-diphenyl-3-(2-pyridyl)-1,2,4-triazines showed a 
high CuII-CuI redox potential, which is synonymous with destabilization of CuII. Prior to 
 
 





Figure 2.2 Selected molecules containing 1,2,4-triazine scaffold. 
 
 
this research project, an underlying interest was the synthesis of 1,2,3-triazoles for 
bioorganic research, but that project had struggled due to a lack of an efficient way to 
synthesize the molecules of interest. Our goal became to investigate the abilities of 
1,2,4-triazines to accelerate copper-catalyzed azide-alkyne cycloaddition, and use that 
to synthesize medicinally relevant compounds. Literature is abundant on the uses of 
triazines as metal chelators and the use of various nitrogen ligands as ligands for 
CuAAC, but prior to this work these two had not been merged. Further support for this 
project was gained since the precursors needed for synthesis of triazines were readily 
available and overlapped with precursors needed for other ongoing projects within the 




Figure 2.3 Comparison of retrosynthetic pathways for 1,2,4-triazines and 1,2,4-triazoles. 
 
2.2. Synthetic Strategies for 1,2,4-Triazine Synthesis 
The general synthesis of 1,2,4-triazines can be classified into 5 broad categories 
(Figure 2.4).68 The most common of these methods is the ring closure in which one, 
two, or three N-C bonds are made. Several modifications and variations exist for ring-
closure reactions, making 1,2,4-triazines accessible from a number of starting materials. 
A second method, ring transformation, begins with a nitrogen containing heterocycle 
that is either rearranged or reacted to form 1,2,4-triazines. Substituted pyrazoles, 
imidazoles and tetrazines are common starting materials for ring transformations. A 
third method of substituent modifications alters a substituent on the preformed 1,2,4-
triazine. Depending on the starting nature of the triazine, nucleophilic or electrophilic 
substitution can occur. The starting materials and reagents can be tuned for selective 
substitution. Annulation of a second heterocycle onto an existing 1,2,4-triazine nucleus 
is a common method employed for 1,2,4-triazines fused to other heterocycles, such as 
imidazoles, pyrazoles, or triazoles. Finally, a method commonly employed with di- or 
tetrahydrotriazines or triazine-ones is to aromatize through elaborate oxidative methods 





Figure 2.4 General synthetic strategies for the synthesis of 1,2,4-triazines. 
 
 
From our perspective, there were three major areas that could be manipulated when 
synthesizing 1,2,4-triazines: the substituent at the 3 position, substituents at the 5,6 
positions, and the core triazine (Figure 2.5). The ring closure method would provide us 
with the most versatility to modify these three areas. Ring transformations and 
substituent modifications would allow us to diversify triazines synthesized through ring 
closure reactions. Our goal was to construct a library of triazines consisting of various 
stereoelectronic features and analyze each for catalytic activity in CuAAC reaction. 










2.3. Ring Closure Reactions 
The most common method to form 1,2,4-triazines is through ring closure reactions by 
forming three nitrogen-carbon bonds or forming two nitrogen-carbon bonds depending 
on the starting materials employed. Substituents at the 3, 5, and 6 position can be 
varied and a combinatorial library quickly assembled by altering the two starting 
materials.  
2.3.1. Synthesis of 3-substituted-5,6-diphenyl-1,2,4-triazine 
Our initial synthetic goal was to vary the 3-position of the 1,2,4-triazine while keeping 
the 5,6-positions constant. The formation of two N-C bonds involved a two-step 
procedure (Scheme 2.1), in which nitriles are first converted to amidrazones using 
hydrazine hydrate at room temperature. After isolation, the amidrazone is reacted with a 
diketone, benzil, to afford the desired 1,2,4-triazine in approximately 75% yield. This 
method provided rapid access to 1,2,4-triazines in good yield (70% over two steps) and 
purity. Both the amidrazone intermediate and triazine product were isolated by filtration 
resulting in an easy workup. Various heterocyclic nitriles were available and subjected 
to reaction with hydrazine and condensation with benzil to form a series of 1,2,4-




Scheme 2.1 Synthesis of 3-substituted-5,6-diphenyl-1,2,4-triazines. 
 
In some instances, the nitrile was not available, but instead the corresponding 
carboxylic acids or esters were available. For those cases, a second method was 
utilized to react a hydrazide with a diketone in the presence of ammonium acetate. This 
reaction can be performed thermally, but this leads to slow and sometimes incomplete 
conversion. Initially, this reaction was performed in a conventional microwave using 
phenyl hydrazide and benzil, with low yields (51%) still being the drawback. Literature 
suggested that these reactions could be performed in a microwave reactor to achieve 
higher yields (> 79%) and less side product formation (>75% purity).80 
Upon acquiring a Microwave Synthesizer, we attempted this protocol with 
heteroaromatic compounds to construct triazines containing substituents, such as 
indole, benzofuran, benzothiophene, and benzothiazole. The carboxylic acid or ester 
was converted to the hydrazide using hydrazine hydrate under reflux or microwave 
conditions. The hydrazide was then reacted with a diketone in the microwave in the 
presence of ammonium acetate to afford the desired triazine (Scheme 2.2). The 
reaction to synthesize indole triazine resulted in a higher yield (63%) compared to the 
other heterocyclic triazines, including benzothiophene substituted triazine (28%), 
benzofuran triazine (42%), and benzothiazole triazine (34%). This was due to by-
product formation. While these byproducts were not isolated and characterized, 
additional UV-active spots were observed via TLC. In an attempt to decrease the side 
product formation, the hydrazine was reacted with the diketone at 60°C to form the 
imine. Once the hydrazide was consumed, the reaction was completed in the 
microwave. Unfortunately, this didn’t increase the yields significantly. Decreasing the 
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substrate concentration in the reaction mixture or shorter reaction times could help limit 
the side product formation. 
 
Scheme 2.2 Synthesis of 1,2,4-triazines from carboxylic acids or esters. 
 
These two methods afforded several heterocycles appended to the 3 position of the 
1,2,4-triazine. Based on initial screening results (discussed in the following chapter), the 
3-position was the most influential portion of the molecule. There was a desire to 
substitute other nitrogen based heterocycles, such as an imidazole or a 1,2,4-triazole, 
both known to coordinate metals. To synthesize the imidazole derivative, the initial 
approach was to make the 2-cyano-methylimidazole derivative starting from methyl 
imidazole.  Method A81 (Scheme 2.3) used a mixture of cyanogen bromide and 
dimethylaminopyridine which resulted in desired product but in a low yield. Conditions 
were slightly altered but sufficient yields were not achieved. Method B82 used copper 
cyanide and sodium cyanide as the nitrile source and relied on the addition of 
phenanthroline. This resulted in only recovered starting material. This was likely due to 
low solubility in the recommended solvent of dioxanes and m-xylene. Since installation 
of the nitrile functional group was problematic, other alternatives were sought after. 
Literature methods show that 1,2,4-triazines are electrophilic at the 3-position when a 
good leaving group such as methanesulfonyl was present, and considering that the 
other two positions (5,6) are occupied by phenyl rings.83 Imidazole could be used as a 
nucleophile to replace the SO2Me group. Although this would lead to the formation of an 





Scheme 2.3 Attempted routes to synthesize 3-methylimidazoyl triazine. 
 
The final attempt was to synthesize the hydrazide substituted imidazole since this could 
be used in place of the amidrazone to produce the triazine (Scheme 2.4). Methyl 
imidazole was first converted to the trichloroacetyl methyl imidazole.84 This intermediate 
could then be reacted with hydrazine hydrate to afford the desired hydrazide. The 
hydrazide was then condensed with benzil in the presence of acetic acid and 
ammonium acetate to form the desired imidazole substituted triazine (2-38) in 52% 
yield. The last heterocycle attempted was to position a 1,2,4-triazole in the 3-position 
(Scheme 2.5), beginning from commercially available methyl-1,2,4-triazole-3-
carboxylate. Although a single product was isolated after silica gel column 
chromatography, the low solubility of the product made it difficult to fully characterize by 
NMR. For this reason it was not screened for catalytic activity.  
 




Scheme 2.5 Attempted synthesis of 3-(1,2,4-triazol-3-yl)-triazine. 
 
2.3.2. Synthesis of 3-pyridyl-5,6-disubstituted-1,2,4-triazines 
Up to this point only the substituent at the 3-position had been altered. It was desirable 
to attempt to tune the activity by altering the substituents at the 5,6 positions. Other 
commercial dicarbonyls available were glyoxal, and 2,3-butanedione. These were 
condensed with 2-pyridyl amidrazone (2-14) to yield triazines 2-42 and 2-43 in 83% and 
90% yield (Scheme 2.6A). This allowed exploration of the effect of non-aryl substituents 
and the influence of steric bulk at these positions. Using pyridil as the diketone allowed 
us to construct the tripyridine triazine 2-44 in 95% yield. 
It was also advantageous to explore the effect of substituents at the 5 and 6 positions 
independently. Thus far, we had only used symmetric diketones, so the 5 and 6 
positions were identical. By employing ketoaldehydes, we had hoped to synthesize the 
triazine with substitution at position 5 in one isomer and substitution at the 6 position in 
the other isomer (Scheme 2.6B). The ketoaldehydes were synthesized from substituted 
acetophenones using selenium dioxide. Condensation with the amidrazone (2-14) under 
neutral conditions resulted in a single isomer (2-49) in 82% yield.85 The most 
nucleophilic nitrogen is the terminal nitrogen of the hydrazono group and this will react 
with the more electrophilic carbon of the aldehyde, leading to the substituent at the 5 
position. Attempts to synthesize the other isomer were not successful, although 
literature methods reported that this should be the predominant isomer under acidic 
conditions.86 
In addition to sterics, electronic properties of the triazine substituents were investigated 
by installation of electron withdrawing and electron donating substituents. These 






Scheme 2.6 Synthesis of 3-(2-pyridyl),5,6-disubsituted triazines.  From A) commercial 




Condensation (Scheme 2.6C). The substituted aldehyde was exposed to KCN in 
refluxing EtOH and H2O, followed by refluxing nitric acid. Although this worked for the 
methyl substituent, the Benzoin Condensation failed with strongly withdrawing nitro 
groups. An alternate synthesis involved formation of an oxazole and subsequent 
nitration, and oxidative opening of the oxazole to lead to the formation of the desired 
diketone (Scheme 2.7). Reaction with amidrazone (2-14) yielded the nitro substituted 
1,2,4-triazine derivative (2-59). Although the reaction between amidrazone and diketone 
produced 93% product, the yield over four steps from starting benzoin was a minuscule 
15%. Reduction of the nitro groups resulted in the amine derivative, but difficulties in 
isolation resulted in only 80% purity of 2-60. 
 




Now that we had changed the size of the functional groups and the electronics of the 
groups attached to the 1,2,4-triazine, we next explored syntheses to impact the shape 
of the molecule. At first glance, one might think the molecules synthesized previously 
are planar or flat. The 3-substituent lies within the same plane as the 1,2,4-triazine, but 
the 5 and 6 positions are slightly twisted out of this plane with a dihedral angle of 63° 
between the two phenyl substituents.87 To illustrate this, we examined the lowest energy 
conformation of 2 selected 1,2,4-triaines (Figure 2.6). Sybyl modeling software was 
used to obtain a rough estimation of the geometry of 1,2,4-triazines in the lowest energy 
conformation. In 5,6-diphenyl-3-(2-pyridyl)-1,2,4-triazine (2-17) the lowest energy 
conformation showed twisted phenyl rings as was expected. If the 5,6 substituents were 
connected (2-62) the lowest energy conformation was entirely planar. To see if this 
would alter the catalytic activity, we chose to use diketones that would “lock” these 
substituents into the same plane. Three diketones, phenanthrene-9,10-dione (2-61), 
1,10-phenanthroline-5,6-dione (2-64), and isatin (2-66) were reacted with amidrazone 2-
14 to afford the corresponding triazines in 74%, 75% and 59% yield (Scheme 2.8). 
Encouraged by some of the results from catalytic screening, our next goal was to 
incorporate two 1,2,4-triazines within one molecule, bridged by a pyridine ring. The most 
straight forward route was to construct a bis-amidrazone and react it with two 
equivalents of benzil. (Scheme 2.9) 2,6-Dicyanopryridine was synthesized starting from 
pyridine dicarboxylic acid. The acid was converted into the bisamide followed by 
dehydrating conditions to give the desired 2,6-dicyanopyridine. Reaction with hydrazine 
hydrate resulted in the bis-amidrazone which was reacted with benzil to form the 
desired bis-triazine (2-72) in 92% yield. The overall yield through 5 steps was only 16%, 
but each intermediate was isolated through either filtration or aqueous extraction, 
eliminating the need for column chromatography and allowing the synthesis to be 
completed rather quickly. 
Having synthesized the bistriazine, we were curious if another nitrogen heterocycle 
could be appended in close proximity to the triazine core. One idea was to synthesize a 




   
Figure 2.6 Illustration showing modeling of 1,2,4-triazines in Sybyl. Two phenyl 





Scheme 2.8 Synthesis of triazines using cyclic or fused diketones. 
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Scheme 2.9 Synthesis of bis1,2,4-triazine.  
 
diazotization conditions, using sodium nitrite and sodium azide in acidic media (Scheme 
2.10).88 For this reason, we began with the amino methyl benzoate and converted it into 
the corresponding hydrazide followed by condensation with benzil and ammonium 
acetate under microwave conditions. The amine was left unprotected as the hydrazide 
amine should be much more reactive than the aromatic amine. After converting the 
amine to the azide, a CuAAC reaction with propargyl alcohol installed the 1,2,3-triazole, 




Scheme 2.10 Synthesis of triazole triazine. 
37 
 
One final ring closure reaction was conducted between phenyl hydrazide (2-20) and 
pyridil (Scheme 2.11) to give a triazine with pyridyl substituents in the 5- and 6- 
positions, and a phenyl in the 3-position. The triazine synthesis was carried out in the 
microwave to yield the product (2-78) in 40% yield after column chromatography. This 
does not fit into either of the categories discussed earlier, since all three substituents 
are being modified. The series of triazines including 2-17, 2-44, and 2-78 has the 
pattern of increasing the pyridine substituents from 1 to 2 to 3. The addition of this 
compound could help us to better understand the dependence on the location of the 
pyridine substituent.  
 
Scheme 2.11 Synthesis of 3-phenyl-5,6-di(2-pyridyl)-1,2,4-triazine. 
 
2.4. Substituent Modifications 
Substituent modifications were at first an appealing route to install additional 
heterocycles onto synthesized triazines. Depending on the existing substitution pattern, 
the reactivity pattern for 1,2,4-triazines is C5 > C3 > C6.83 A good leaving group can be 
installed during the initial 1,2,4-triazine formation and displaced at a later point. From 
the observed activities of triazines, we were interested in substituting additional 
heterocycles at the 3-position. This was in response to work by Finn and colleagues in 
their synthesis of tailored tripodal ligands.39 Although we had successfully synthesized a 
1,2,3-triazole and a second 1,2,4-triazine in close proximity to the 1,2,4-triazine core, we 
wanted to install a 1,2,3-triazole, 1,2,4-triazole or 1,2,4-triazine directly attached to the 
triazine core. 
Initially, we synthesized the 3-thiomethyl-1,2,4-triazine through a ring closure reaction 
between benzil and  S-methylisothiosemicarbazide hydroiodide salt 2-79 in 89% yield 
(Scheme 2.12). The methylthiol group was easily displaced by hydrazine hydrate, which 
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was reacted with an aldehyde to form the imine containing triazine (2-82) in 80% yield. 
We then displaced the thiomethyl group using sodium azide as the nucleophile, but all 
attempts at a cycloaddition with propargyl alcohol resulted in recovery of starting 
material. The azide is in equilibrium with the tetrazole formed by reaction with the 
triazine core, with the tetrazole being the dominant form, preventing the cycloaddition 
reaction.89 
 
Scheme 2.12 Synthesis of 1,2,4-triazines by substituent modification. 
 
With the attempt to install a 1,2,3-triazole halted, we moved on to the next heterocycle. 
The substitution by cyanide was not successful from thiomethyl triazine (2-80). This 
required us to oxidize the thiomethyl substituent to the mesyl group, which would serve 
as a better leaving group (2-83). The substitution proceeded in decent yield, but 
unfortunately the reactivity observed was not as expected. Instead of the nucleophile 
reacting at the nitrile carbon, the triazine carbon proved to be more susceptible to 
nucleophilic attack. This led to the displacement of the nitrile functional group by 
nucleophiles such as hydrazine, 2-pyridyl hydrazide, and n-butanol.90 Attempts to 
include a 1,2,3-triazole, 1,2,4-triazole, or a 1,2,4-triazine directly connected to the 3-
position of the existing 1,2,4-triazine were all unsuccessful. 
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2.5. Ring Transformations 
 
Despite unsuccessful attempts in the synthesis of the heterocycles above, there were 
still other triazines and related heterocycles that could be synthesized. Ring 
transformations are a less common way to make 1,2,4-triazines. This method was not 
fully explored to make 1,2,4-triazines, but rather as a way to make other nitrogen 
containing heterocycles. In an attempt to synthesize one of the molecules above, we 
heated 2-cyanopyridine in the presence of hydrazine hydrate. This resulted in an orange 
solid, but did not match the expected spectral data. It was confirmed that we had 
synthesized the dihydrotetrazine (2-85), rather than the expected triazine (Scheme 
2.13). To our advantage, this material could be oxidized to the aromatic tetrazine (2-86) 
and then reacted with an alkyne in an inverse electron-demand Diels-Alder to form the 
pyridazine (2-87) in 77% yield. Changing the dienophile from an alkyne to a nitrile would 
result in a 1,2,4-triazine (2-88), but this reaction wasn’t fully explored. With this route, 
we were also interested in observing if the presence of all three nitrogens of the core 
triazine were necessary for activity. The bipyridine derivative (2-89) was synthesized 
utilizing aza-Diels-Alder to expel nitrogen (N2) and form the bipyridine in 66% yield.
91 
Finally, we included a few additional heterocycles that contained aromatic nitrogens but 
were not classified as triazines (Scheme 2.14). Reaction of amidrazone 2-14 with an 
aldehyde resulted in non-cyclic triazine derivatives (2-92, 2-93) in excess of 80% yield. 
This would allow us to probe the catalytic activity and observe if a closed aromatic ring 
was necessary for activity. Quinoxalines (2-94) are also interesting scaffolds and could 
be made from diketones and 1,2-phenylenediamines. The position of the nitrogen atoms 
appeared able to bind metal. Finally, pyridil was reacted with an aromatic amine to form 
the imine (2-95) in 53% yield after column chromatography. Due to steric bulk, the 
amine only added to one carbonyl of the diketone, even with excess amine and applied 
heat. The proximity of the pyridine from the diketone and the imine from the aromatic 
amine appear to be comparable to the proximity of the pyridine and 1,2,4-triazine core 














Scheme 2.14 Non-1,2,4-triazine heterocycles containing sp2 nitrogens. 
 
2.6. Conclusions 
A series of 1,2,4-triazines was synthesized using ring closure and substituent 
modifications. Ring closure reactions between amidrazones and dicarbonyls were the 
most effective method of synthesizing 1,2,4-triazines, resulting in yields between 70 – 
90%, most of which could be isolated by filtration. Ring closure reactions between 
hydrazides and diketones in the presence of ammonium acetate in the microwave was 
used to synthesize additional 1,2,4-triazines. Yields were much lower, in the range of 28 
– 68%, and triazines required chromatographic purification. Substituent modification 
reactions of preformed triazines led to imine substituted triazines, but failed to provide 
1,2,3-triazoles or 1,2,4-triazines substituted in the 3-position. 
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Additional sp2 nitrogen containing ligands, such as pyridines, pyridazines, imines, and 
quinoxalines were also synthesized using ring closure and ring transformations 
methods. Overall modifications of 1,2,4-triazines were made to the 3-position, 5 and 6 
positions, and to the core 1,2,4-triazine. The activity of the synthesized triazine ligands 
will be explored in Chapter 3. 
 
2.7. Experimental 
Materials and General Methods.  Reagents and solvents were purchased from various 
commercial sources and used without further purification unless otherwise stated.  
Anhydrous solvents were purified using a Grubbs solvent system.  Analytical thin-layer 
chromatography (TLC) was performed using aluminum backed silica gel TLC plates 
with UV indicator from Sorbent Technologies.  Flash column chromatography was 
performed using 40-63 μm (230 x 400 mesh) silica gel from Sorbent Technologies.  1H 
and 13C NMR were recorded at 600 MHz and 151 MHz, respectfully, on a Varian Inova 
spectrometer or at 500 MHz and 125 MHz, on a Varian spectrometer.  All chemical 
shifts were reported in δ units relative to tetramethylsilane using the corresponding 
deuterated solvent as a reference point.  High resolution mass spectra (ESI) were 
obtained on a JEOL AccuTOF DART spectrometer.  Infrared spectra were recorded on 
a Varian 4100 FT-IR using KBr pellets or KBr salt plates.  Absorption spectra were 
collected on a Thermo Scientific Evolution 600.  High pressure liquid chromatography 
(HPLC) was performed using a Beckman Coulter System equipped with a UV-Vis 
detector, autosampler, Varian C18 column, and a mobile phase composed of 
acetonitrile and trifluoroacetic acid. Microwave reactions were performed in sealed vials 
using a Biotage Initiator Microwave Synthesizer.  
 
picolinohydrazonamide (2-14).  2-7 (5g, 48 mmol) was dissolved in EtOH 
(6mL) and hydrazine hydrate (3.26 mL, 67 mmol) and stirred at room 
temperature overnight.  The pale white precipitate was filtered and washed 
with Et2O in 94% yield. 
1H NMR (CDCl3, 600 MHz) δ 8.52 (m, 1H), 8.01 (d, 1H, J = 7.8 
Hz), 7.69 (t, 1H, J = 7.8 Hz), 7.26 (m, 1H), 5.27 (br, 2H), 4.59 (b, 2H).  13C NMR (CDCl3, 
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151 MHz) δ 150.8, 148.7, 147.9, 136.4, 123.8, 119.7.  HRMS (ESI) m/z calculated 
137.08272 (C6H9N4, [M+H]
+), m/z observed 137.08324  (C6H9N4, [M+H]
+). 
 
pyrimidine-2-carbohydrazonamide (2-15).  2-8 (250 mg, 2.38 mmol) was 
dissolved in EtOH (0.3 mL) and hydrazine hydrate (0.163 mL, 3.33 mmol) 
and stirred overnight at room temperature.  Reaction was monitored by TLC.  
The reaction was concentrated in vacuo to yield a yellow oil in quantitative yield.  1H 
NMR (CDCl3, 600 MHz) δ 8.77 (d, 2H, J = 4.8 Hz), 7.26 (t, 1H, J = 4.8 Hz), 5.17 (b, 2H), 
4.83 (b, 2H).  13C NMR (CDCl3, 151 MHz) δ 158.8, 157.2, 146.6, 120.6.  HRMS (ESI) 
m/z calculated 138.07797 (C5H8N5, [M+H]
+), m/z observed 138.07782 (C5H8N5, [M+H]
+). 
 
pyrazine-2-carbohydrazonamide (2-16).  2-9 (250 mg, 2.38 mmol) was 
dissolved in EtOH (0.3 mL) and hydrazine hydrate (0.163 mL, 3.33 mmol) 
and stirred overnight at room temperature.  Reaction was monitored by TLC.  
The pale white precipitate was filtered and washed with EtOH resulting in a 60% yield.  
1H NMR (CDCl3, 600 MHz) δ 9.27 (s, 1H), 8.51 (m, 1H), 8.44 (m, 1H), 5.12 (b, 2H), 4.72 
(b, 2H).  13C NMR (CDCl3, 151 MHz) δ 146.6, 146.4, 144.1, 142.8, 142.3.  HRMS (ESI) 
m/z calculated 138.07797 (C5H8N5, [M+H]
+), m/z observed 138.07783 (C5H8N5, [M+H]
+). 
 
5,6-diphenyl-3-(pyridin-2-yl)-1,2,4-triazine (2-17).  2-10 (500 mg, 
3.67 mmol) and benzil (772 mg, 3.67 mmol) were added to 10 mL of 
EtOH.  The slurry was heated at 80°C for 6 h with complete dissolution.  
Progress of the reaction was monitored by TLC.  The reaction mixture was cooled to 
room temperature and the resulting precipitate was filtered and washed with EtOH and 
Et
2
O resulting in a 76% yield.  1H NMR (CDCl3, 600 MHz) δ 8.91 (d, 1H, J = 4.2 Hz), 
8.70 (d, 1H, J = 7.8 Hz), 7.91 (t, 1H, J = 7.8 Hz), 7.68 (d, 2H, J = 7.8 Hz), 7.64 (d, 2H, J 
= 7.8 Hz), 7.46 (t, 1H, J = 6.6 Hz), 7.43-7.31 (m, 6H).  13C NMR (CDCl3, 151 MHz) δ 
160.7, 156.5, 156.3, 152.9, 150.5, 137.0, 135.6, 135.3, 130.7, 129.9, 129.7, 129.6, 
128.6. 128.5, 125.4, 124.1.  UV-Vis (MeCN) λmax nm (ε M
-1 cm-1): 387 (454.7).  HRMS 
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(ESI) m/z calculated 311.12967 (C20H15N4, [M+H]




5,6-diphenyl-3-(pyrimidin-2-yl)-1,2,4-triazine (2-18).  2-11 (100 mg, 
0.730 mmol) and benzil (153 mg, 0.730 mmol) were added to 2 mL of 
EtOH.  The slurry was heated for 6 h at 80°C.  Progress of the reaction 
was monitored by TLC.  The reaction mixture was cooled to room temperature and the 
resulting yellow precipitate was filtered and washed with EtOH resulting in a 75% yield.  
1H NMR (CDCl3, 600 MHz) δ 9.10 (d, 2H, J = 4.8 Hz), 7.68-7.64 (m, 4H), 7.51 (t, 1H, J = 
4.8 Hz), 7.46-7.43 (m, 2H), 7.41-7.39 (m, 2H), 7.38-7.35 (m, 2H).  13C NMR (CDCl3, 151 
MHz) δ 161.8, 160.2, 158.3, 157.4, 156.7, 135.5, 135.2, 131.0, 130.1, 129.9, 128.8, 
121.9.  UV-Vis (MeCN) λmax nm (ε M
-1 cm-1): 386 (460.4).  HRMS (ESI) m/z calculated 
312.12492 (C19H14N5, [M+H]
+), m/z observed 312.12414 (C19H14N5, [M+H]
+). 
 
5,6-diphenyl-3-(pyrazin-2-yl)-1,2,4-triazine (2-19).  2-12 (100 mg, 
0.730 mmol) and benzil (153 mg, 0.730 mmol) were added to 2 mL of 
EtOH.  The slurry was heated overnight at 80°C.  Progress of the 
reaction was monitored by TLC.  The reaction mixture was cooled to room temperature 
and concentrated in vacuo to quantitatively yield the product as a yellow solid.  1H NMR 
(CDCl3, 600 MHz) δ 9.91 (s, 1H), 8.87 (s, 1H), 8.78 (s, 1H), 7.69 (d, 2H, J = 7.2 Hz), 
7.65 (d, 2H, J = 7.8 Hz), 7.48-7.45 (m, 2H), 7.42-7.37 (m, 4H).  13C NMR (CDCl3, 151 
MHz) δ 159.6, 157.2, 156.7, 148.6, 146.3, 145.7, 145.0, 135.4, 135.1, 131.2, 130.2, 
130.1, 129.8, 128.9, 128.8.  UV-Vis (MeCN) λmax nm (ε M
-1 cm-1): 386 (523.6).  HRMS 
(ESI) m/z calculated 312.12492 (C19H14N5, [M+H]




General Hydrazide Method A:  Methyl (or Ethyl) Ester (1 eq) was dissolved in 
hydrazine hydrate (2.5 eq) and MeOH (or EtOH) (3.5 M) and refluxed overnight.  MeOH 
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(or EtOH) and excess hydrazine hydrate were removed in vacuo.  The precipitated 
product was dried under vacuum.  
 
General Hydrazide Method B:  Carboxylic acid (1 eq) was dissolved in xylenes (0.6 M) 
and hydrazine hydrate (10 eq) was added to the mixture. This was microwaved at 
180°C for 6 hours. The resulting mixture was extracted with DCM and concentrated in 
vacuo.  
 
benzohydrazide (2-25).  Prepared using general hydrazide method A and 
isolated as a white solid.  1H NMR (CD3CN, 600 MHz) δ 8.23 (br), 7.76 (d, 
2H, J = 7.2 Hz), 7.52 (m, 1H), 7.45 (t, 2H, J = 7.2 Hz)  13C NMR (CD3CN, 151 MHz) δ 
168.3, 134.3, 132.3, 129.4, 127.8.  HRMS (ESI) m/z calculated 137.07149 (C7H9N2O, 
[M+H]+), m/z observed 137.07190  (C7H9N2O, [M+H]
+). 
 
benzo[b]thiophene-2-carbohydrazide (2-26). Prepared using general 
hydrazide method B and isolated as a brown solid in 54% yield.  
1H NMR (d6-DMSO, 600 MHz) δ 10.03 (bs, 1H), 8.00 – 8.02 (m, 2H), 7.91 (d, 1H, J = 
7.2 Hz), 7.41 – 7.46 (m, 2H).  13C NMR (d6-DMSO, 151 MHz) δ 161.3, 139.9, 139.2, 
138.4, 126.0, 125.0, 124.9, 124.1, 122.7.  HRMS (ESI) m/z calculated 193.04356 
(C9H9N2OS, [M+H]
+), m/z observed 193.04230. (C9H9N2OS, [M+H]
+). 
 
benzofuran-2-carbohydrazide (2-27). Prepared using general 
hydrazide method B and isolated as a white solid in 63% yield.  
1H NMR (d6-DMSO, 600 MHz) δ 10.02 (bs, 1H), 7.75 (d, 1H, J = 7.8 Hz), 7.63 (d, 1H, J 
= 8.4 Hz), 7.51 (s, 1H), 7.44 (t, 1H, J = 7.8 Hz), 7.32 (t, 1H, J = 7.8 Hz), 4.85 (b, NH2).  
13C NMR (d6-DMSO, 151 MHz) δ 157.8, 154.1, 148.4, 127.0, 126.6, 123.6, 122.6, 
111.7, 108.7.  HRMS (ESI) m/z calculated 177.06640 (C9H9N2O2, [M+H]
+), m/z 





1H-indole-2-carbohydrazide (2-28). Prepared using general hydrazide 
method B and isolated as a pale yellow solid in 64% yield. Used crude 
for next step. HRMS (ESI) m/z calculated 176.08239 (C9H10N3O, 
[M+H]+), m/z observed 176.08134. (C9H10N3O, [M+H]
+). 
 
ethyl benzo[d]thiazole-2-carboxylate (2-24). 2-aminothiophenol (1eq)  
was dissolved in diethyloxalate (2 eq) and heated at 120°C overnight. 
Reaction progress was followed by TLC. Upon consumption of starting material, 
reaction mixture was poured into a mixture of HCl, H2O, and EtOH. Two layers formed. 
Stir biphasic solution. Once solid formation begins, place in chilled water bath. Filter and 
wash solid with small amounts of cold water. Isolated in 72% yield as a pale green solid. 
1H NMR (CDCl3, 600 MHz) δ 8.25 (d, 1H, J = 8.4 Hz), 7.98 (d, 1H, J = 7.8 Hz), 7.58 (t, 
1H, J = 7.8 Hz), 7.54 (t, 1H, J = 7.8 Hz), 4.56 (q, 2H, J = 7.2 Hz), 1.49 (t, 3H, J = 7.2 
Hz). 13C NMR (CDCl3, 151 MHz) δ 160.8, 158.7, 153.4, 136.9, 127.7, 127.2, 125.7, 
122.2, 63.3, 14.4.  HRMS (ESI) m/z calculated 208.04322 (C10H10NO2S, [M+H]
+), m/z 
observed 208.04252. (C10H10NO2S, [M+H]
+). 
 
benzo[d]thiazole-2-carbohydrazide (2-29). Ester 2-24 (1 eq) was 
dissolved in EtOH (0.4 M) and to this mixture was added hydrazine 
hydrate (1.5 eq). This solution was heated overnight at 80°C with complete dissolution. 
Reaction progress was followed by TLC. Upon removal of solution from heat, yellow 
precipitate formed. Filter and wash with small portions of EtOH. Resultant solid dried 
under vacuum. Collected yellow solid in 81% yield.  1H NMR (CDCl3, 600 MHz) δ 10.46 
(s, 1H) 8.22 (d, 1H, J = 7.8 Hz), 8.11 (d, 1H, J = 7.8 Hz), 7.62 (t, 1H, J = 7.8 Hz), 7.57 (t, 
1H, J = 7.8 Hz), 4.72 (bs, 2H, NH2). 
13C NMR (CDCl3, 151 MHz) δ 163.7, 158.1, 152.8, 
135.7, 127.0, 126.7, 123.9, 122.9.  HRMS (ESI) m/z calculated 194.03881 (C8H8N3OS, 





General Triazine Method B: Heterocyclic hydrazide (1.1 eq) was dissolved in AcOH 
(0.25 M). To this mixture was added benzil (1 eq) and NH4OAC (10 eq). This solution 
was heated in a sealed vial using a microwave synthesizer at 180°C. 
 
3,5,6-triphenyl-1,2,4-triazine (2-30).  2-16 (142 mg, 1.05 mmol), benzil 
(200 mg, 0.95 mmol), and ammonium acetate (732 mg, 9.50 mmol) 
were suspended in AcOH (2 mL).  The suspension was heated in a 
conventional microwave at 750W and monitored by TLC until benzil no longer 
remained.  The reaction mixture was concentrated in vacuo and precipitated out of 
EtOH.  The product was isolated as a pale yellow solid in 51% yield.  1H NMR (CDCl3, 
600 MHz) δ 8.67 (s, 1H), 7.67 (d, 2H, J = 7.2 Hz), 7.62 (d, 2H, J = 7.2 Hz), 7.55-7.54 
(m, 3H), 7.44-7.34 (m, 6H).  13C NMR (CDCl3, 151 MHz) δ 161.3, 155.48, 155.46, 
135.9, 135.5, 134.8, 131.5, 130.7, 129.8, 129.5, 129.4, 128.8, 128.6, 128.5, 128.3.  UV-
Vis (MeCN) λmax nm (ε M
-1 cm-1): 385 (480.9).  HRMS (ESI) m/z calculated 310.13442 
(C21H16,N3, [M+H]




Prepared using general triazine method B. The solid formed upon 
heating was centrifuged, washed with AcOH, and purified over silica 
gel, eluting with a gradient of hexanes and ethyl acetate to afford a 
yellow solid in 28% yield.  1H NMR (CDCl3, 500 MHz) δ 8.53 (s, 1H), 7.91 – 7.94 (m, 
2H) 7.66 – 7.70 (m, 2H), 7.60 – 7.62 (m, 2H), 7.37 – 7.50 (m, 8H).  13C NMR (CDCl3, 
125 MHz) δ 159.3, 155.9, 155.6, 142.4, 140.1, 139.8, 135.63, 135.56, 131.0, 130.0, 
129.8, 129.6, 128.8, 128.7, 127.3, 126.4, 125.2, 125.0, 122.9.  HRMS (ESI) m/z 
calculated 366.10649 (C23H16N3S, [M+H]
+), m/z observed 366.10475. (C23H16N3S, 
[M+H]+). 
 
3-(benzofuran-2-yl)-5,6-diphenyl-1,2,4-triazine (2-32). Prepared 
using general triazine method B. The fine solid formed upon heating 
was centrifuged, washed with AcOH, and purified over silica gel, 
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eluting with a gradient of hexanes and ethyl acetate to afford a pale yellow solid in 42% 
yield.  1H NMR (CDCl3, 600 MHz) δ 7.97 (s, 1H), 7.75 (d, 1H, J = 7.8 Hz) 7.71 (d, 1H, J 
= 8.4 Hz), 7.67 (d, 2H, J = 7.2 Hz), 7.62 (d, 2H, J = 7.2 Hz), 7.42 – 7.49 (m, 3H), 7.37 – 
7.41 (m, 4H), 7.33 (t, 1H, J = 7.2 Hz).  13C NMR (CDCl3, 151 MHz) δ 156.5, 156.13, 
156.07, 155.8, 151.4, 135.6, 135.4, 131.0, 130.0, 129.9, 129.7, 128.8, 128.3, 126.9, 
123.8, 122.5, 112.5, 111.3.  HRMS (ESI) m/z calculated 350.12934 (C23H16N3O, 
[M+H]+), m/z observed 350.12765. (C23H16N3O, [M+H]
+). 
 
2-(5,6-diphenyl-1,2,4-triazin-3-yl)-1H-indole (2-33). Prepared 
using general triazine method B. The fine solid formed upon 
heating was centrifuged, washed with AcOH, and purified over 
silica gel, eluting with a gradient of hexanes and ethyl acetate to 
afford a bright yellow solid in 63% yield. 1H NMR (CDCl3, 600 MHz) δ 9.57 (s, 1H), 7.76 
(d, 1H, J = 8.4 Hz) 7.68 (s, 1H), 7.66 (d, 2H, J = 7.2 Hz), 7.59 (d, 2H, J = 7.2 Hz), 7.32 
(t, 1H, J = 7.2 Hz), 7.17 (t, 1H, J = 7.2 Hz), 7.46 – 7.51 (m, 2H), 7.41 – 7.45 (m, 1H), 
7.37 – 7.41 (m, 4H).  13C NMR (CDCl3, 151 MHz) δ 157.0, 156.2, 155.4, 137.7, 135.8, 
135.6, 133.0, 131.0, 130.0, 129.7, 129.6, 128.9, 128.7, 124.9, 122.3, 120.9, 111.9, 
107.1.  HRMS (ESI) m/z calculated 349.14532 (C23H17N4, [M+H]





Prepared using general triazine method B. The solution was diluted 
with water and extracted with DCM (3x). The organic layer was 
concentrated in vacuo and the resultant material was purified over 
silica gel, eluting with a gradient of hexanes and ethyl acetate to afford a yellow solid in 
34% yield.  1H NMR (CDCl3, 600 MHz) δ 8.32 (d, 1H, J = 8.4 Hz), 8.03 (d, 1H, J = 7.8 
Hz), 7.71 (d, 2H, J = 7.8 Hz), 7.65 (d, 2H, J = 8.4 Hz), 7.58 (t, 1H, J = 7.2 Hz, 8.4 Hz), 
7.52 (t, 1H, J = 7.2 Hz, 8.4 Hz), 7.45 – 7.49 (m, 2H), 7.38-7.42 (m, 4H).  13C NMR 
(CDCl3, 151 MHz) δ 164.1, 157.9, 157.5, 156.8, 154.6, 136.8, 135.09, 135.07, 131.3, 
130.3, 130.2, 129.8, 128.9, 128.8, 127.0, 126.9, 125.3, 122.1.  HRMS (ESI) m/z 
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calculated 367.10174 (C22H15N4S, [M+H]




2,2,2-trichloro-1-(1-methyl-1H-imidazol-2-yl)ethanone (2-36). Methyl 
imidazole (1 mmol) was dissolved in DCM (1.3 mL). In a separate flask, 
combine DCM (1.3 mL) and trichloroacetylchloride (1.1 mmol). To a stirred solution of 
methyl imidazole in DCM, and the trichloroacetylchloride in DCM dropwise. Solution 
turned cloudy upon first drops, but quickly turned transparent yellow. Upon stirring 
solution became cloudy yellow. Stir at room temperature overnight. Cool reaction 
mixture in ice bath and dropwise add triethylamine (1.1 mmol). Solution turned from 
thick bright yellow to dark brown upon addition. Concentrate in vacuo and resulting 
residue purified via silica gel chromatography using gradient elution of hexanes and 
DCM. Isolated as a white solid in 72% yield. 
 
1-methyl-1H-imidazole-2-carbohydrazide (2-37). Dissolve 2-36 (1 mmol) 
in dioxanes (5 mL). Cool solution in ice bath, and add hydrazine hydrate (2 
mmol) to cooled solution. Remove ice bath and stir solution at room temperature 
overnight. Reaction progress followed by TLC. Upon completion, reaction mixture was 
concentrated in vacuo to yield an off-white solid in 90% yield. 
 
3-(1-methyl-1H-imidazol-2-yl)-5,6-diphenyl-1,2,4-triazine (2-38). 
Benzil (1 mmol) and  hydrazide 2-37 (1.05 mmol) were combined in 
AcOH (4 mL) in a microwave vessel. Reaction mixture was stirred at 
60°C overnight. TLC shows consumption of starting material. Add NH4OAC (10 mmol) 
and microwave at 180°C for 10 min. Starting materials consumed by TLC. Add H2O and 
extract with DCM. Combine organics and wash with H2O. Concentrate in vacuo and 
purify over silica gel eluting with hexanes, ethyl acetate, and MeOH. Isolated a yellow 
solid in 52% yield.  1H NMR (CDCl3, 600 MHz) δ 7.67 – 7.69 (m, 2H), 7.61 – 7.62 (m, 
2H), 7.42 – 7.45 (m, 2H), 7.38 – 7.40 (m, 2H), 7.32 – 7.36 (m, 3H), 7.15 (s, 1H), 4.28 (s, 
3H).  13C NMR (CDCl3, 151 MHz) δ 156.6, 156.0, 155.6, 141.9, 135.5, 135.4, 131.0, 
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130.6, 130.2, 129.9, 129.6, 128.8, 128.6, 126.2, 37.4.  HRMS (ESI) m/z calculated 
314.14057 (C19H16N5, [M+H]
+), m/z observed 314.14014. (C19H16N5, [M+H]
+). 
 
3-(pyridin-2-yl)-1,2,4-triazine (2-42).  2-14 (500 mg, 3.67 mmol) and 2-39 
(40% by wt in water, 533 mg, 3.67 mmol) were added to 10 mL of EtOH.  
The slurry was heated overnight at 60°C with complete dissolution.  
Progress of the reaction was monitored by TLC.  The reaction mixture was cooled to 
room temperature and filtered.  The filtrate was concentrated in vacuo to yield an 
orange-brown solid in 83% yield.  1H NMR (CDCl3, 600 MHz) δ 9.29 (s, 1H), 8.89 (d, 
1H, J = 4.2 Hz), 8.82 (s, 1H), 8.68 (d, 1H, J = 7.8 Hz), 7.93 (m, 1H), 7.49 (t, 1H, J = 6.6 
Hz) 13C NMR (CDCl3, 151 MHz) δ 163.6, 152.5, 150.7, 149.5, 148.8, 137.4, 126.0, 
124.2.  UV-Vis (MeCN) λmax nm (ε M
-1 cm-1): 388 (376.0).  HRMS (ESI) m/z calculated 
159.06707 (C8H7N4, [M+H]
+), m/z observed 159.06661 (C8H7N4, [M+H]
+). 
 
5,6-dimethyl-3-(pyridin-2-yl)-1,2,4-triazine (2-43).  2-14 (600 mg, 4.17 
mmol) and 2-40 (377 mg, 4.38 mmol) were added to 10 mL of EtOH.  
The slurry was heated at 80°C overnight with complete dissolution.  
Progress of the reaction was monitored by TLC.  After concentration in vacuo, the crude 
product was purified by silica gel chromatography with gradient elution using EtOAc and 
hexanes to yield a pale brown solid in 90.0% yield.  1H NMR (CDCl3, 600 MHz) δ 8.88 
(m, 1H), 8.65 (d, 1H, J = 8.4 Hz), 7.90 (t, 1H, J = 7.8 Hz), 7.46-7.44 (m, 1H), 2.78 (s, 
3H), 2.70 (s, 3H).  13C NMR (CDCl3, 151 MHz) δ 161.5, 159.6, 157.0, 153.0, 150.3, 
137.1, 125.2, 123.8, 22.1, 19.7.  UV-Vis (MeCN) λmax nm (ε M
-1 cm-1): 372 (378.1).  
HRMS (ESI) m/z calculated 187.09782 (C10H11N4, [M+H]




3,5,6-tri(pyridin-2-yl)-1,2,4-triazine (2-44).  2-14 (100 mg, 0.730 
mmol) and 2-44 (150 mg, 0.730 mmol) were added to 2 mL of EtOH.  
The slurry was heated overnight at 80°C with complete dissolution.  
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Progress of the reaction was monitored by TLC.  The reaction mixture was cooled to 
room temperature and the resulting precipitate was filtered and washed with EtOH 
resulting in a 95% yield.  1H NMR (CDCl3, 600 MHz) δ 8.94 (d, 1H, J = 3.6 Hz), 8.75 (d, 
1H, J = 7.8 Hz), 8.36-8.35 (m, 2H), 8.27-8.25 (m, 2H), 7.96 (dt, 1H, J = 7.8, 1.8 Hz), 
7.93-7.87 (m, 2H), 7.52-7.49 (m, 1H), 7.32-7.29 (m, 2H).  13C NMR (CDCl3, 151 MHz) δ 
161.5, 156.37, 156.35, 154.9, 154.8, 152.8, 150.8, 148.93, 148.92, 137.4, 137.21, 
137.19, 125.9, 125.1, 124.70, 124.66, 124.5, 124.0.  UV-Vis (MeCN) λmax nm (ε M
-1 cm-
1): 382 (495.9).  HRMS (ESI) m/z calculated 313.12017 (C18H13N6, [M+H]
+), m/z 
observed 313.11959 (C18H13N6, [M+H]
+). 
 
2-oxo-2-phenylacetaldehyde (2-47).  Selenium dioxide (924 mg, 8.32 mmol) 
was suspended in dioxane (4.2 mL) and water (0.20 mL) and heated at 55°C 
until mostly dissolved.  2-45 (1 g, 8.32 mmol) was then added and the reaction was 
refluxed for 4 h.  After cooling to room temperature, the reaction was filtered and the 
filtrate was concentrated in vacuo.  Purification via silica gel chromatography with 
gradient elution using EtOAc and hexanes was used to further purify the reaction 
mixture.  The crude product was used in further reactions.  MS (ESI) m/z calculated 
135.04460 (C8H7O2, [M+H]
+), m/z observed 135.042 (C8H7O2, [M+H]
+). 
 
2-(4-hydroxyphenyl)-2-oxoacetaldehyde (2-48).  Selenium dioxide (814 
mg, 7.34 mmol) was suspended in dioxane (3.7 mL) and water (0.18 mL) 
and heated at 55°C until mostly dissolved.  2-46 (3 g, 15.0 mmol) was then added and 
the reaction was refluxed for 4 h.  After cooling to room temperature, the reaction was 
filtered and the filtrate was concentrated in vacuo.  Purification via silica gel 
chromatography with gradient elution using EtOAc and hexanes was used to further 
purify the reaction mixture.  The crude product was used in further reactions.  MS (ESI) 
m/z calculated 151.03952 (C8H7O3, [M+H]





5-phenyl-3-(pyridin-2-yl)-1,2,4-triazine (2-49).  2-47 (246 mg, 1.84 
mmol) and 2-14 (250 mg, 1.84 mmol) were added to 5 mL of EtOH.  
The slurry was heated for 4 h at 80°C with complete dissolution.  
Progress of the reaction was monitored by TLC.  The reaction mixture was cooled to 
room temperature and purified by silica gel chromatography with gradient elution using 
EtOAc and hexanes to yield a white solid in 82% yield.  1H NMR (CDCl3, 600 MHz) δ  
9.72 (s, 1H), 8.94 (d, 1H, J = 4.2 Hz), 8.68 (d, 1H, J = 7.8 Hz), 8.31 (d, 2H, J = 8.4 Hz), 
7.95 (t, 1H, J = 7.8 Hz), 7.63-7.59 (m, 3H), 7.50 (m, 1H).  13C NMR (CDCl3, 151 MHz) δ 
162.9, 156.0, 153.2, 150.7, 145.5, 137.3, 133.6, 132.8, 129.6, 128.0, 125.7, 124.3.  UV-
Vis (MeCN) λmax nm (ε M
-1 cm-1): 382 (486.2).  HRMS (ESI) m/z calculated 235.09837 
(C14H11N4, [M+H]
+), m/z observed 235.09829 (C14H11N4, [M+H]
+). 
 
4-(3-(pyridin-2-yl)-1,2,4-triazin-5-yl)phenol (2-50).  2-48 (150 mg, 
1.0 mmol) and 2-14 (136 mg, 1.0 mmol) were added to 3 mL of 
EtOH.  The slurry was heated overnight at 80°C with complete 
dissolution.  Progress of the reaction was monitored by TLC.  The reaction mixture was 
cooled to room temperature and concentrated in vacuo yielding an orange solid in 90% 
yield.  1H NMR (CDCl3, 600 MHz) δ 9.56 (s, 1H), 8.89 (d, 1H, J = 4.2 Hz), 8.72 (d, 1H, J 
= 7.8 Hz), 8.10 (d, 2H, J = 8.4 Hz), 8.00 (t, 1H, J = 8.4 Hz), 7.56 (m, 1H), 6.96 (d, 2H, J 
= 4.8 Hz), 3.49 (s, 1H).  13C NMR (CDCl3, 151 MHz) δ 162.5, 161.6, 156.1, 153.1, 
149.9, 145.1, 130.2, 126.0, 124.8, 124.7, 116.9.  UV-Vis (MeCN) λmax nm (ε M
-1 cm-1): 
385 (1054.7).  HRMS (ESI) m/z calculated 251.09329 (C14H11N4O, [M+H]
+), m/z 
observed 251.09254 (C14H11N4O, [M+H]
+). 
 
1,2-di-p-tolylethane-1,2-dione (2-53).  2-52 (5 g, 41.6 mmol) 
and KCN (1.35 g, 20.8 mmol) was dissolved in EtOH (8 mL) and 
water (4 mL).  The mixture was heated under reflux for 0.5 h.  
After cooling to room temperature, the reaction mixture was poured into an ice bath and 
the crude benzoin intermediate was precipitated.  The solid was then filtered and further 
washed with water.  The crude benzoin intermediate was then refluxed in nitric acid (8 
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mL) for 2 h.  The reaction mixture was poured into an ice bath and the crude benzil 
derivative was precipitated and filtered.  Recrystallization from EtOH yielded a yellow 
solid in 39% yield.  1H NMR (CDCl3, 600 MHz) δ 7.86 (d, 4H, J = 7.8 Hz), 7.30 (d, 4H, J 
= 7.8 Hz), 2.42 (s, 6H).  13C NMR (CDCl3, 151 MHz) δ 194.6, 146.2, 130.9, 130.2, 
129.8, 22.1.  HRMS (ESI) m/z calculated 239.10720 (C16H15O2, [M+H]
+), m/z observed 
152.08191 239.10710  (C16H15O2, [M+H]
+). 
 
3-(pyridin-2-yl)-5,6-di-p-tolyl-1,2,4-triazine (2-54).  2-14 (284 mg, 
2.10 mmol) and 2-52 (500 mg, 2.10 mmol) were added to EtOH (12 
mL).  The slurry was heated at 80°C for 6 h with complete 
dissolution.  Progress of the reaction was monitored by TLC.  After 
concentration in vacuo, the crude product was purified by silica gel chromatography with 
gradient elution using EtOAc and hexanes to yield a pale yellow solid in 41.1% yield.  1H 
NMR (CDCl3, 600 MHz) δ 8.92 (d, 1H, J = 4.8 Hz), 8.70 (d, 1H, J = 7.8 Hz), 7.93 (t, 1H, 
J = 7.8 Hz), 7.62 (d, 2H, J = 8.4 Hz), 7.54 (d, 2H, J = 8.4 Hz), (m, 1H), 7.21 (d, 2H, J = 
7.8 Hz), 7.19 (d, 2H, J = 7.8 Hz), 2.40 (s, 3H), 2.38 (s, 3H).  13C NMR (CDCl3, 151 MHz) 
δ 160.6, 156.5, 156.3, 153.2, 150.6, 141.3, 140.0, 137.2, 133.1, 132.8, 130.1, 129.6, 
129.5, 129.4, 125.4, 124.2, 21.7, 21.6.  UV-Vis (MeCN) λmax nm (ε M
-1 cm-1): 400 
(445.5).  HRMS (ESI) m/z calculated 339.16097 (C22H19N4, [M+H]




2-oxo-1,2-diphenylethyl acetate (2-56).  2-55 (4 g, 18.84 mmol) and 
acetic anhydride (4.33g, 42.40 mmol) were dissolved in AcOH (4 mL).  
Concentrated HCl (0.4 mL) was added dropwise at room temperature.  The reaction 
was then heated at 100°C for 30 min.  After cooling to room temperature, 50 mL of 
water was added and the reaction continued to stir at room temperature for an 
additional 2 h.  The precipitate was filtered and purified by silica gel chromatography 
with gradient elution using EtOAc and hexanes to yield a white solid in 63% yield.  1H 
NMR (CDCl3, 600 MHz) δ 7.93 (d, 2H, J = 7.8 Hz), 7.51 (t, 1H, J = 7.8 Hz), 7.47 (d, 2H, 
J = 7.8 Hz), 7.41-7.34 (m, 5H), 6.87 (s, 1H), 2.21 (s, 3H).  13C NMR (CDCl3, 151 MHz) δ 
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193.8, 170.6, 134.7, 133.7, 133.6, 129.5, 129.3, 128.9, 128.83, 128.76, 77.8, 20.9.  
HRMS (ESI) m/z calculated 255.10212 (C16H15O3, [M+H]




2-methyl-4,5-bis(4-nitrophenyl)oxazole (2-57).  2-56 (1 g, 3.93 
mmol) and ammonium acetate (454 mg, 5.90 mol) were dissolved in 
AcOH (1.3 mL) and refluxed for 2 h.  After warming to room 
temperature, the crude reaction was poured over ice and extracted 
with Et2O.  The organic layer was washed with water and brine, then dried with sodium 
sulfate.  Concentration in vacuo produced the intermediate oxazole as a brown oil.  This 
oil was dissolved in sulfuric acid (3 mL) and nitric acid (3 mL) was added dropwise at 
room temperature.  The reaction was then heated at 55°C for 15 min.  Progress of the 
reaction was monitored by TLC.  After warming to room temperature, ice was added to 
precipitate the product.  Recrystalization from AcOH producted yellow solid in 59% 
yield.  1H NMR (CDCl3, 600 MHz) δ 8.26 (t, 4H, J = 8.4 Hz), 7.82 (d, 2H, J = 8.4 Hz), 
7.74 (d, 2H, J = 8.4 Hz), 2.62 (s, 3H). 13C NMR (CDCl3, 151 MHz) δ 162.4, 147.9, 147.7, 
145.0, 138.3, 136.3, 134.3, 128.9, 127.2, 124.5, 124.3, 14.2.  HRMS (ESI) m/z 
calculated 326.07770 (C16H12N3O5, [M+H]
+), m/z observed 326.07637 (C16H12N3O5, 
[M+H]+). 
 
1,2-bis(4-nitrophenyl)ethane-1,2-dione (2-58).  2-57 (600 mg, 
1.85 mmol) and sodium acetate (1.2 g, 14.8 mmol) were 
dissolved in a combination of AcOH (6.6 mL) and water (0.67 
mL).  Bromine (591 mg, 7.4 mmol) was then added and the reaction was refluxed for 2 
h.  Progress of the reaction was monitored by TLC.  After cooling to room temperature, 
the reaction was poured over ice and filtered.  Recrystalization from AcOH produced a 
yellow solid in 42% yield.  1H NMR (CDCl3, 600 MHz) δ 8.39 (d, 4H, J = 8.4 Hz), 8.21 (d, 
4H, J = 8.4 Hz). 13C NMR (CDCl3, 151 MHz) δ 190.4, 151.7, 136.9, 131.4, 124.4. HRMS 
(ESI) m/z calculated 301.04606 (C14H9N2O6, [M+H]






5,6-bis(4-nitrophenyl)-3-(pyridin-2-yl)-1,2,4-triazine (2-59).  2-14 
(136 mg, 1.0 mmol) and 2-58 (300 mg, 1.0 mmol) were added to 6 
mL of EtOH.  The slurry was heated overnight at 80°C with 
complete dissolution.  Progress of the reaction was monitored by 
TLC.  The reaction mixture was cooled to room temperature and the resulting 
precipitate was filtered and washed with EtOH resulting in a 93% yield.  1H NMR 
(CDCl3, 600 MHz) δ 8.96 (d, 1H, J = 4.2 Hz), 8.75 (d, 1H, J = 7.8 Hz), 8.30-8.27 (m, 
4H), 7.99 (dt, 1H, J = 7.8, 1.2 Hz), 7.86 (d, 2H, J = 7.2 Hz), 7.82 (d, 2H, J = 6.6 Hz), 
7.56-7.54 (m, 1H).  13C NMR (CDCl3, 151 MHz) δ 161.6, 154.7, 154.6, 152.0, 151.0, 
149.5, 149.1, 141.1, 140.7, 137.5, 131.2, 130.8, 126.3, 124.8, 124.33, 124.28.  UV-Vis 
(MeCN) λmax nm (ε M
-1 cm-1): 404 (546.5).  HRMS (ESI) m/z calculated 401.09983 
(C20H13N6O4, [M+H]
+), m/z observed 401.09918 (C20H13N6O4, [M+H]
+). 
 
4,4’-(3-(pyridin-2-yl)-1,2,4-triazine-5,6-diyl)dianiline (2-60).  2-59 
(200 mg, 0.5 mmol), and 5% palladium/carbon (2 mg), and 
hydrazine hydrate (1 mL) were added to 2.5 mL of EtOH.  The 
reaction was refluxed for 6 h and progress was monitored by TLC.  
Upon completion, reaction was filtered through celite and eluted with MeOH.  
Concentration in vacuo yielded the crude product as an orange solid in 85% yield.  
HPLC purity: 80%.  UV-Vis (9:1 MeCN:DMSO) λmax nm (ε M
-1 cm-1): 475 (483.0).  
HRMS (ESI) m/z calculated 341.15147 (C20H17N6, [M+H]




3-(pyridin-2-yl)phenanthro[9,10-e][1,2,4]triazine (2-62).  2-14 (500 
mg, 3.67 mmol) and 2-61 (764 mg, 3.67 mmol) were added to 10 mL of 
ACN.  The slurry was heated at 80°C overnight with complete 
dissolution.  Progress of the reaction was monitored by TLC.  The reaction mixture was 
cooled to room temperature and the resulting precipitate was filtered and washed with 
ACN and Et2O resulting in a 75% yield.  
1H NMR (CDCl3, 600 MHz) δ 9.55 (d, 1H, J = 
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7.8 Hz), 9.49 (d, 1H, J = 7.8 Hz), 9.01 (d, 1H, J = 4.8 Hz), 8.90 (d, 1H, J = 7.8 Hz), 8.61 
(d, 2H, J = 7.8 Hz), 8.01 (t, 1H, J = 7.8 Hz), 7.91 (t, 1H, J = 7.8 Hz), 7.86 (t, 1H, J = 7.8 
Hz), 7.82 (t, 1H, J = 7.2 Hz), 7.78 (t, 1H, J = 7.2 Hz), 7.53 (m, 1H).  13C NMR (CDCl3, 
151 MHz) δ 160.67, 153.7, 150.6, 145.6, 143.3, 137.2, 133.9, 132.6, 131.4, 131.1, 
128.7, 128.1, 127.9, 127.5, 127.2, 125.31, 125.28, 124.3, 123.1, 123.0.  UV-Vis (DCE) 
λmax nm (ε M
-1 cm-1): 424 (381.7).  HRMS (ESI) m/z calculated 309.11402 (C20H13N4, 
[M+H]+), m/z observed 309.11249 (C20H13N4, [M+H]
+). 
 
1,10-phenanthroline-5,6-dione (2-64).  2-63 (500 mg, 2.78 mmol) and KBr 
(700 mg, 5.88 mmol) was added to a mixture of concentrated sulfuric acid (5 
mL) and nitric acid (2.5 mL) at -5°C.  The mixture was stirred at that 
temperature for 15 min and then brought to reflux and heated for 4 h.  The yellow 
solution was allowed to cool and poured over 50 g of ice and carefully brought to pH 9 
by addition of 5 M sodium hydroxide.  The suspension was extracted with CHCl3, dried 
over anhydrous sodium sulfate, and concentrated in vacuo to yield fine yellow needles 
in 84% yield.  1H NMR (CDCl3, 600 MHz) δ 9.14 (d, 2H, J = 4.8 Hz), 8.52 (d, 2H, J = 7.8 
Hz), 7.60 (dd, 2H, J = 7.8, 4.8 Hz).  13C NMR (CDCl3, 151 MHz) δ 178.7, 156.4, 152.9, 
137.3, 128.1, 125.6.  HRMS (ESI) m/z calculated 211.05075 (C12H7N2O2, [M+H]
+), m/z 
observed 211.05055 (C12H7N2O2, [M+H]
+). 
 
3-(pyridin-2-yl)-[1,2,4]triazino[5,6-f][1,10]phenanthroline (2-65).  2-
14 (64 mg, 0.476 mmol) and 2-64 (100 mg, 0.476 mmol) were added 
to 4 mL of DMF.  The slurry was heated at 80°C overnight with 
complete dissolution.  Progress of the reaction was monitored by TLC.  The reaction 
mixture was cooled to room temperature and the resulting precipitate was filtered and 
washed with DMF and Et2O resulting in a 74% yield.  
1H NMR (d6-DMSO, 600 MHz) δ 
9.71 (d, 1H, J = 7.8 Hz), 9.66 (d, 1H, J = 7.2 Hz), 9.35 (s, 1H), 9.31 (s, 1H), 8.96 (s, 1H), 
8.84 (d, 1H, J = 7.8 Hz), 8.17 (t, 1H, J = 7.2 Hz), 8.05 (s, 2H), 7.72 (s, 1H).  13C NMR 
(d6-DMSO, 151 MHz) δ 160.9, 154.4, 153.2, 152.8, 150.4, 149.3, 147.1, 144.5, 142.6, 
137.6, 133.9, 132.1, 126.0, 125.4, 125.1, 124.84, 124.78, 124.5.  UV-Vis (9:1 
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DCE:MeOH) λmax nm (ε M
-1 cm-1): 423 (376.6).  HRMS (ESI) m/z calculated 311.10452 
(C18H11N6, [M+H]
+), m/z observed 311.10452 (C18H11N6, [M+H]
+). 
 
3-(pyridin-2-yl)-5H-[1,2,4]triazino[5,6-b]indole (2-67).  2-14 (500 mg, 
3.67 mmol) and 2-66 (540 mg, 3.67 mmol) were added to 10 mL of 
EtOH.  The slurry was heated at 80°C overnight with complete 
dissolution.  Progress of the reaction was monitored by TLC.  The reaction mixture was 
cooled to room temperature and the resulting orange precipitate was filtered and 
washed with EtOH and Et2O resulting in a 59% yield.  
1H NMR (CDCl3, 600 MHz) δ 8.67 
(d, 1H, J = 4.2 Hz), 8.50-8.47 (m, 2H), 8.02 (bs, 1H), 7.90 (dt, 1H, J = 9, 1.8 Hz), 7.50 
(m, 1H), 7.32 (t, 1H, J = 7.8 Hz), 7.11 (t, 1H, J = 7.8 Hz), 6.90 (d, 1H, J = 7.8 Hz).  13C 
NMR (CDCl3, 151 MHz) δ 166.9, 160.6, 149.6, 148.9, 146.3, 142.4, 137.0, 131.8, 128.9, 
126.1, 123.0, 122.7, 118.5, 110.3  MS (ESI) m/z calculated 248.09362 (C14H10N5, 
[M+H]+), m/z observed 248.09721 (C14H10N5, [M+H]
+). 
 
diethyl pyridine-2,6-dicarboxylate.  2-68 (2 g, 11.97 mmol) was 
suspended in EtOH (5 mL) and HCl (0.5 mL).  The suspension was 
heated in a conventional microwave oven at 750W and monitored by TLC until starting 
material no longer remained.  The reaction mixture was concentrated in vacuo and 
redissolved in water.  After adjusting the pH to 8 with 10 M sodium hydroxide, the 
reaction was extracted with EtOAc (x3) and rinsed with brine.  The solution was dried 
with sodium sulfate and concentrated in vacuo to yield a white solid in 56% yield.  1H 
NMR (CDCl3, 600 MHz) δ 8.28 (d, 2H, J = 6.6 Hz), 8.00 (t, 1H, J = 6.6 Hz), 4.48 (d, 4H, 
J = 6.0 Hz), 1.45 (s, 6 H).  13C NMR (CDCl3, 151 MHz) δ 164.8, 148.8, 138.3, 128.0, 
62.5, 14.4.  HRMS (ESI) m/z calculated 224.09228 (C11H14NO4, [M+H]
+), m/z observed 
224.09179  (C11H14NO4, [M+H]
+). 
 
pyridine,2-6-dicarboxamide (2-69).  Ammonium hydroxide (2.5 mL) 
was added to 2-24 (1.5 g, 6.72 mmol) and warmed at 35°C for 1 h with 
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vigorous stirring.  After cooling to 0°C, the precipitate was filtered and washed with 
water.  The resulting white solid was dried under vacuum in an 80% yield.  1H NMR (d6-
DMSO, 600 MHz) δ 8.87 (s, 2H), 8.19-8.14 (m, 3H), 7.70 (s, 2H).  13C NMR (d6-DMSO, 
151 MHz) δ 165.4, 149.1, 139.1, 124.1.  HRMS (ESI) m/z calculated 166.06165 
(C7H8N3O2, [M+H]
+), m/z observed 166.06152 (C7H8N3O2, [M+H]
+). 
 
pyridine-2,6-dicarbonitrile (2-70).  Anhydrous THF (5 mL) and 
triethylamine (1.58 mL, 11.31 mmol) were added to 2-69 (850 mg, 5.14 
mmol) under nitrogen atmosphere.  The suspension was cooled to 0°C and 
trifluoroacetic anhydride (1.57 mL, 11.31 mmol) was added dropwise.  After 10 min, the 
solution was allowed to stir at room temperature for 3 h.  The reaction was then 
quenched with 5 mL of saturated sodium bicarbonate.  The resulting precipitate was 
filtered and washed with water.  The resulting white solid was dried under vacuum in a 
52% yield.  1H NMR (CDCl3, 600 MHz) δ 8.06 (t, 1H, J = 7.8 Hz), 7.92 (d, 2H, J = 7.8 
Hz)  13C NMR (CDCl3, 151 MHz) δ 138.7, 135.4, 131.0, 115.4.  HRMS (ESI) m/z 
calculated 130.04052 (C7H4N3, [M+H]
+), m/z observed 130.03995 (C7H4N3, [M+H]
+). 
 
pyridine-2,6-bis(carbohydrazonamide) (2-71).  2-26 (288 mg, 2.23 
mmol) was dissolved in EtOH (0.5 mL) and hydrazine hydrate (0.5 mL, 
8.93 mmol) and stirred overnight at room temperature.  EtOH and 
excess hydrazine hydrate were removed in vacuo.  The white solid was dried under 
vacuum and then stored at 0°C in a 73% yield.  1H NMR (d6-DMSO, 600 MHz) δ 7.93 
(d, 2H, J = 7.8 Hz), 7.66 (t, 1H, J = 7.8 Hz), 6.18 (br), 3.29 (br).  13C NMR (d6-DMSO, 
151 MHz) δ 149.6, 146.0, 136.0, 119.1.  HRMS (ESI) m/z calculated 194.11542 
(C7H12N7, [M+H]
+), m/z observed 194.11599 (C7H12N7, [M+H]
+). 
 
2,6-bis(5,6-diphenyl-1,2,4-triazin-3-yl)pyridine (2-72).  2-
71 (288 mg, 1.49 mmol) and benzil (642 mg, 3.05 mmol) 
were added to 4 mL of EtOH.  The slurry was heated 
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overnight at 80°C with complete dissolution.  Progress of the reaction was monitored by 
TLC.  The reaction mixture was cooled to room temperature and the resulting 
precipitate was filtered and washed with EtOH and Et2O resulting in a 92% yield.  
1H 
NMR (CD2Cl2, 600 MHz) δ 8.86 (d, 2H, J = 7.8 Hz), 8.23 (t, 1H, J = 7.8 Hz), 7.73 (d, 4H, 
J = 7.2 Hz), 7.66 (d, 4H, J = 7.2 Hz), 7.51-7.48 (m, 4 H), 7.47-7.40 (m, 8H).  13C NMR 
(CD2Cl2, 151 MHz) δ 160.9, 156.9, 156.5, 153.8, 138.5, 135.9, 135.7, 131.0, 130.1, 
130.0, 129.8, 128.84, 128.75, 125.9.  UV-Vis (9:1 DCE:MeOH) λmax nm (ε M
-1 cm-1): 394 
(1039.0).  HRMS (ESI) m/z calculated 542.20932 (C35H24N7, [M+H]




2-aminobenzohydrazide (2-74).  Prepared using general hydrazide 
method A and isolated as a pale brown solid.  1H NMR (CD3CN, 600 MHz) 
δ 8.04 (br) 7.34 (d, 2H, J = 7.8 Hz), 7.18 (t, 1H, J = 7.2 Hz).  6.71 (d, 1H, J = 7.2 Hz), 
6.59 (t, 1H, J = 7.2 Hz), 4.79 (br).  13C NMR (D2O, 151 MHz) δ 170.8, 146.5, 132.8, 
128.3, 118.5, 117.9, 117.3.  HRMS (ESI) m/z calculated 152.08239 (C7H10N3O, [M+H]
+), 
m/z observed 152.08191  (C7H10N3O, [M+H]
+). 
 
2-(5,6-diphenyl-1,2,4-triazin-3-yl)aniline (2-75).  2-74 (230 mg, 1.52 
mmol), benzil (306 mg, 1.46 mmol), and ammonium acetate (1.02 g, 
13.2 mmol) were suspended in AcOH (3 mL).  The suspension was 
heated in a conventional microwave at 750W and monitored by TLC until benzil no 
longer remained.  The reaction mixture was concentrated in vacuo and precipitated out 
of EtOH.  The product was isolated as an orange solid in 42% yield.  1H NMR (CDCl3, 
600 MHz) δ 8.61 (d, 1H, J = 7.8 Hz), 7.66 (d, 2H, J = 7.8 Hz), 7.60 (d, 2H, J = 7.2 Hz), 
7.46-7.35 (m, 6H), 7.29 (t, 1H, J = 7.2 Hz), 6.84-6.79 (m, 2H), 6.39 (s, 2H).  13C NMR 
(CDCl3, 151 MHz) δ 163.3, 155.3, 154.0, 149.3, 136.2, 135.8, 132.3, 131.0, 130.9, 
130.0, 129.7, 129.6, 128.8, 128.7, 117.5, 117.2, 115.8.  UV-Vis (MeCN) λmax nm (ε M
-1 
cm-1): 373 (5762.7).  HRMS (ESI) m/z calculated 325.14532 (C21H17N4, [M+H]
+), m/z 






yl)methanol (2-77).  2-75 (50 mg, 0.154 mmol) was dissolved in 2 
mL EtOAc.  1 mL of 1.5 M HCl was added and the solution was 
cooled to 0°C in an ice bath.  Sodium nitrite (21 mg, 0.308 mmol) 
was dissolved in 0.5 mL water and added dropwise to the reaction solution while stirring 
at 0°C.  After 15 min, sodium azide (40 mg, 0.616 mmol) was dissolved in 0.5 mL water 
and added dropwise to the reaction solution while stirring at 0°C.  After slowly warming 
to room temperature, the reaction was monitored by TLC.  Upon completion, the 
reaction was extracted with EtOAc (x3), washed with 1 M HCl, water, and brine, and 
dried with sodium sulfate.  After concentration in vacuo, the crude material was 
dissolved in 0.4 mL ACN.  Propargyl alcohol (4.3 mg, 0.077 mmol) and triethylamine 
(10.7 μL, 0.077 mmol) were added to the reaction solution.  5,6-diphenyl-3-(pyridin-2-
yl)-1,2,4-triazine (0.2 mg, 0.77 μmol) and tetrakis(acetonitrile-N)copper(I) 
tetrafluoroborate (0.2 mg, 0.77 μmol) were then added to the reaction solution.  The 
reaction was stirred at room temperature overnight.  After concentration in vacuo, the 
crude product was purified by silica gel chromatography with gradient elution using 
EtOAc and hexanes to yield a pale yellow solid in 57% yield.  1H NMR (CDCl3, 600 
MHz) δ 8.47 (d, 1H, J = 7.2), 7.83 (s, 1H), 7.77-7.72 (m, 2H), 7.59-7.56 (m, 3H), 7.41-
7.29 (m, 9H), 4.73 (s, 2H).  13C NMR (CDCl3, 151 MHz) δ 161.1, 155.4, 155.3, 136.1, 
135.1, 135.0, 132.2, 131.9, 131.5, 130.9, 130.4, 129.8, 129.7, 129.5, 128.6, 128.4, 
127.0, 56.5.  HRMS (ESI) m/z calculated 407.16203 (C24H19N6O, [M+H]




 3-phenyl-5,6-di(pyridin-2-yl)-1,2,4-triazine (2-78). Phenyl 
hydrazide, 2-20 (1 mmol), was dissolved in AcOH (4 mL) in a 
microwave vial. To this was added 2-2’-pyridil (1 mmol) and 
ammonium acetate (10 mmol). The reaction mixture was sealed and microwaved for 4 
hours at 180°C. Consumption of starting materials was confirmed by TLC. H2O and 
DCM were added to the reaction mixture and transferred to a separatory funnel. The 
aqueous layer was neutralized with NaOH, and extracted with DCM (3x). Combined 
organics were dried over sodium sulfate, filtered, and concentrated in vacuo. The 
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resultant solid was purified over silica eluting with hexanes and ethyl acetate to yield a 
yellow solid in 40% yield. 1H NMR (CDCl3, 600 MHz) δ 8.68 – 8.70 (m, 2H), 8.35 (t, 2H, 
J = 4.2 Hz), 8.26 (dd, 2H, J = 7.8 Hz, J = 4.2 Hz), 7.91 (tq, 2H, J = 7.8 Hz, J = 1.8 Hz), 
7.56 – 7.60 (m, 3H), 7.32 (ddd, 1H, J = 7.2 Hz, J = 4.8 Hz, J = 1.2 Hz), 7.30 (ddd, 1H, J 
= 7.2 Hz, J = 4.8 Hz, J = 1.2 Hz).  13C NMR (CDCl3, 151 MHz) δ 161.9, 155.5, 155.4, 
155.2, 155.0, 148.83, 148.76, 137.10, 137.07, 134.7, 132.0, 129.0, 128.7, 124.64, 
124.61, 124.1, 123.7.  HRMS (ESI) m/z calculated 312.12492 (C19H14N5, [M+H]
+), m/z 
observed 312.12461. (C19H14N5, [M+H]
+). 
 
methyl hydrazinecarbimiodthioate hydroiodide  (2-79).   
Thiosemicarbazide (500 mg, 5.49 mmol) was dissolved in 10 mL EtOH 
and heated at 60°C for 30 min.  Iodomethane (0.38 mL, 6.06 mmol) was added portion 
wise and continue stirring at 60°C for an additional 30 min.  After cooling to room 
temperature, the mixture was concentrated in vacuo resulting in a pale brown solid in 
quantitative yield.  The recovered solid was used in further reactions without additional 
purification. 
 
3-(methylthio)-5,6-diphenyl-1,2,4-triazine  (2-80).  2-79 (500 mg, 
2.15 mmol) and benzil (451 mg, 2.15 mmol) were dissolved in 10 mL of 
EtOH and stirred overnight at room temperature.  Progress of the 
reaction was monitored by TLC.  The reaction was quenched by addition of saturated 
sodium bicarbonate and solid sodium sulfate and stirring 30 min.  The mixture was 
filtered and DCM was added to the resulting precipitate.  The DCM solution was filtered 
and the corresponding filtrate concentrated in vacuo.  The product was isolated as a 
yellow solid in 89% yield.  1H NMR (CDCl3, 600 MHz) δ 7.55 (d, 2H, J = 8.4 Hz), 7.52 (d, 
2H, J = 7.8 Hz), 7.44-7.39 (m, 2H), 7.37-7.32 (m, 4H), 2.76 (s, 3H).  13C NMR (CDCl3, 
151 MHz) δ 171.3, 155.6, 153.9, 135.54, 135.52, 131.0, 130.0, 129.57, 129.56, 128.8, 
128.7, 14.2.  HRMS (ESI) m/z calculated 280.09084 (C16H14N3S, [M+H]






3-hydrazinyl-5,6-diphenyl-1,2,4-triazine  (2-81).  2-80 (200 mg, 0.717 
mmol) and hydrazine hydrate (336 mg, 4.30 mmol) were dissolved in 2 
mL of EtOH and heated at 80°C overnight.  Progress of the reaction 
was monitored by TLC.  The reaction mixture was concentrated in 
vacuo and dried under vacuum yielding a green-yellow solid in 84% yield.  1H NMR 
(CDCl3, 600 MHz) δ 7.49-7.48 (m, 2H), 7.43-7.41 (m, 3H), 7.36-7.32 (m, 5H), 6.60 (br, 
1H), 4.17 (br, 2H).  13C NMR (CDCl3, 151 MHz) δ 162.42, 157.3, 151.4, 136.2, 136.1, 
130.7, 129.8, 129.5, 128.8, 128.6.  UV-Vis (MeCN) λmax nm (ε M
-1 cm-1): 353 (2894).  
HRMS (ESI) m/z calculated 264.12492 (C15H14N5, [M+H]





triazine  (2-82).  2-81 (75 mg, 0.285 mmol) and 2-
pyridinecarbaldehye (31 mg, 0.285 mmol) were dissolved in 3 mL 
of EtOH and refluxed for 4 h.  After cooling to room temperature, the resulting 
precipitate was filtered and rinsed with EtOH yielding a yellow solid in 80% yield.  1H 
NMR (d6-DMSO, 600 MHz) δ 8.60 (d, 1H, J = 4.8 Hz), 8.34 (s, 1H), 8.00 (d, 1H, J = 8.4 
Hz), 7.87 (t, 1H, J = 7.8 Hz), 7.05-7.36 (m, 12H).  13C NMR (d6-DMSO, 151 MHz) δ 
158.4, 156.6, 153.6, 151.4, 149.4, 144.3, 136.8, 136.0, 135.8, 130.3, 129.5, 129.1, 
128.5, 128.30, 128.29, 123.8, 119.5.  UV-Vis (9:1 DCE/MeOH) λmax nm (ε M
-1 cm-1): 376 
(13290).  HRMS (ESI) m/z calculated 353.15147 (C21H17N6, [M+H]




3-(methylsulfonyl)-5,6-diphenyl-1,2,4-triazine (2-83).  Dissolved 2-80 
(2.5 g, 8.9 mmol) and tetrabutylammonium bromide (287 mg, 0.89 
mmol) in 60 mL of benzene and 18 mL of AcOH.  Added potassium 
permanganate (2.8 g, 17.9 mmol) as a solution in 90 mL of water to the reaction and 
stirred at room temperature overnight.  Added saturated sodium bisulfite (approx 5 mL) 
until color disappeared.  Neutralized solution with solid potassium carbonate.  Dried 
organic layer with anhydrous sodium sulfate and concentrated in vacuo yielding a 
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yellow solid in 77% yield.  Compound was used immediately or carefully stored away 
from light and in the freezer to prevent decomposition.  1H NMR (CDCl3, 600 MHz) δ 
7.68 (d, 2H, J = 7.2 Hz), 7.62 (d, 2H, J = 7.2 Hz), 7.52-7.49 (m, 2H), 7.43 (t, 2H, J = 7.8 
Hz), 7.37 (t, 2H, J = 7.8 Hz).  13C NMR (CDCl3, 151 MHz) δ 164.5, 159.7, 158.1, 134.2, 
133.8, 132.33, 131.0, 130.4, 129.7, 129.4, 129.0, 128.5.  HRMS (ESI) m/z calculated 
312.08067 (C16H14N3O2S, [M+H]
+), m/z observed 312.08136 (C16H14N3O2S, [M+H]
+). 
 
5,6-diphenyl-1,2,4-triazine-3-carbonitrile (2-84).  Dissolved 2-83 (500 
mg, 1.61 mmol) and finely crushed KCN (210 mg, 3.22 mmol) in 16 mL of 
DMF and stirred at room temperature.  Progress of the reaction was 
closely monitored by TLC and not allowed to stir overnight.  When reaction reached 
completion, added a small amount of water and extracted with DCM.  Purification by 
alumina chromatography with gradient elution using EtOAc and hexanes yielded a 
yellow solid in 75% yield.  1H NMR (CDCl3, 600 MHz) δ 7.63 (d, 4H, J = 7.8 Hz), 7.51 (t, 
2H, J = 7.8 Hz), 7.43 (t, 2H, J = 7.8 Hz), 7.39 (t, 2H, J = 7.8 Hz).  13C NMR (CDCl3, 151 
MHz) δ 158.3, 156.5, 144.8, 134.1, 133.6, 132.3, 131.2, 130.1, 129.8, 129.2, 129.1.  MS 
(ESI) m/z calculated 259.09837 (C16H11N4, [M+H]




3,6-di(pyridin-2-yl)-1,2-dihydro-1,2,4,5-tetrazine (2-85).  2-
cyanopyridine (1.0 g, 10.5 mmol) and hydrazine hydrate (2 mL, 42 
mmol) was dissolved in 8 mL of EtOH and refluxed overnight.  Progress 
of the reaction was monitored by TLC.  The reaction mixture was cooled to room 
temperature and the resulting orange precipitate was filtered and washed with Et2O 
resulting in a 42% yield.  1H NMR (CDCl3, 600 MHz) δ 8.58-8.57 (m, 4H), 8.05 (d, 2H, J 
= 7.8 Hz), 7.75 (dt, 2H, J = 7.2, 1.8 Hz), 7.40-7.34 (m, 2H).  13C NMR (CDCl3, 151 MHz) 
δ 148.5, 147.7, 146.7, 136.9, 125.0, 121.4.  UV-Vis (MeCN) λmax nm (ε M
-1 cm-1): 382 
(350.3).  HRMS (ESI) m/z calculated 239.10452 (C12H11N6, [M+H]






3,6-di(pyridin-2-yl)-1,2,4,5-tetrazine (2-86).  To a stirring suspension 
of 2-85 (500 mg, 2.1 mmol) in 2.5 mL of AcOH at 0°C  was added 
dropwise 0.4 mL of concentrated nitric acid.  The slurry was allowed to 
warm to room temperature overnight.  The mixture was poured over cold water and 
made alkaline by addition of sodium carbonate solution.  The resulting purple precipitate 
was filtered, washed with water, and dried under vacuum in 66% yield.  1H NMR (CDCl3, 
600 MHz) δ 9.00 (d, 2H, J = 3.6 Hz), 8.76 (d, 2H, J = 8.4 Hz), 8.02 (dt, 2H, J = 8.4, 1.8 
Hz), 7.60-7.58 (m, 2H).  13C NMR (CDCl3, 151 MHz) δ 164.0, 151.2, 150.3, 137.6, 
126.7, 124.7.  UV-Vis (MeCN) λmax nm (ε M
-1 cm-1): 539 (351.9).  HRMS (ESI) m/z 
calculated 237.08887 (C12H9N6, [M+H]
+), m/z observed 237.08985 (C12H9N6, [M+H]
+). 
 
4-phenyl-3,6-di(pyridin-2-yl)pyridazine (2-87).  2-86 (260 mg, 0.85 
mmol) and phenylacetylene (173 mg, 1.69 mmol) was dissolved in 5 mL 
of toluene.  The reaction was refluxed for 8 h with progress of the 
reaction monitored by TLC.  Upon disappearance of the starting materials, the reaction 
was concentrated in vacuo and purified by silica gel chromatography with gradient 
elution using EtOAc and hexanes to yield a pale brown solid in 77% yield.  1H NMR 
(CDCl3, 600 MHz) δ 8.81 (d, 1H, J = 8.4 Hz), 8.74 (d, 1H, J = 4.8 Hz), 8.67 (s, 1H), 8.48 
(d, 1H, J = 4.8 Hz), 7.94-7.89 (m, 2H), 7.80 (dt, 1H, J = 9.0, 1.8 Hz), 7.43-7.41 (m, 1H), 
7.34-7.30 (m, 3H), 7.29-7.26 (m, 3H).  13C NMR (CDCl3, 151 MHz) δ 158.5, 157.9, 
156.0, 153.6, 149.6, 149.2, 140.7, 137.4, 137.1, 136.7, 129.1, 128.57, 128.55, 125.8, 
125.04, 124.95, 123.5, 122.1.  UV-Vis (MeCN) λmax nm (ε M
-1 cm-1): 350 (344.8).  HRMS 
(ESI) m/z calculated 311.12967 (C20H15N4, [M+H]




5,6-diphenyl-2,2’-bipyridine (2-89).  2-17 (250 mg, 0.81 mmol) and 
2,5-norbornadiene (746 mg, 8.1 mmol) were added to 5.4 mL EtOH and 
refluxed overnight.  Progress of the reaction was monitored by TLC.  
After concentration in vacuo, the crude product was purified by silica gel 
chromatography with gradient elution using EtOAc and hexanes to yield a white solid in 
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66% yield.  1H NMR (CDCl3, 600 MHz) δ 8.71 (d, 1H, J = 4.8 Hz), 8.60 (d, 1H, J = 7.8 
Hz), 8.45 (d, 1H, J = 7.8 Hz), 7.87 (d, 1H, J = 8.4 Hz), 7.82 (dt, 1H, J = 7.8, 1.2 Hz), 
7.49-7.48 (m, 2H), 7.33-7.27 (m, 7H), 7.25-7.23 (m, 2H).  13C NMR (CDCl3, 151 MHz) δ 
156.4, 156.2, 154.7, 149.2, 140.5, 140.1, 139.7, 137.0, 136.2, 130.3, 129.7, 128.5, 
127.97, 127.96, 127.4, 123.9, 121.6, 119.3.  UV-Vis (DCE) λmax nm (ε M
-1 cm-1): 350 
(240.5).  HRMS (ESI) m/z calculated 309.13917 (C22H17N2, [M+H]




benzylidenepicolinohydrazonamide (2-92).  2-14 (250 mg, 1.84 
mmol) and 2-89 (390 mg, 3.67 mmol) were added to 5 mL of EtOH.  
The reaction was heated overnight at 80°C with progress of the 
reaction monitored by TLC.  The reaction mixture was cooled to room temperature and 
concentrated in vacuo. Purification by silica gel chromatography with gradient elution 
using EtOAc and hexanes yielded a yellow solid in 87% yield.  1H NMR (CDCl3, 600 
MHz) δ 8.61 (d, 1H, J = 4.8 Hz), 8.57 (s, 1H), 8.35 (d, 1H, J = 8.4 Hz), 7.84-7.82 (m, 
2H), 7.80-7.78 (m, 1H), 7.44-7.40 (m, 3H), 7.40-7.37 (m, 1H), 6.57 (br, 2H).  13C NMR 
(CDCl3, 151 MHz) δ 157.2, 156.1, 150.4, 148.5, 136.7, 135.4, 130.3, 128.8, 128.1, 
125.3, 121.5.  UV-Vis (MeCN) λmax nm (ε M
-1 cm-1): 332 (26568).  HRMS (ESI) m/z 
calculated 225.11402 (C13H13N4, [M+H]
+), m/z observed 225.11336 (C13H13N4, [M+H]
+). 
 
 (pyridin-2-ylmethylene)picolinohydrazonamide (2-93).  2-14 (250 
mg, 1.84 mmol) and 2-90 (394 mg, 3.67 mmol) were added to 5 mL of 
EtOH.  The reaction was heated overnight at 80°C with progress of the 
reaction monitored by TLC.  The reaction mixture was cooled to room temperature and 
concentrated in vacuo. Purification by silica gel chromatography with gradient elution 
using EtOAc and hexanes yielded a yellow solid in 84% yield.  1H NMR (CDCl3, 600 
MHz) δ 8.67 (d, 1H, J = 4.2 Hz), 8.63 (s, 1H), 8.60 (d, 1H, J = 4.2 Hz), 8.38 (d, 1H, J = 
8.4 Hz), 8.08 (d, 1H, J = 8.4 Hz), 7.80 (dt, 1H, J = 7.2, 1.2 Hz), 7.31 (dt, 1H, J = 7.2, 1.8 
Hz), 7.40-7.38 (m, 1H), 7.29-7.27 (m, 1H), 7. 6.63 (br, 2H).  13C NMR (CDCl3, 151 MHz) 
δ 157.9, 156.3, 154.4, 150.2, 149.8, 148.5, 136.8, 136.4, 125.5, 124.7, 121.8, 121.7.  
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UV-Vis (MeCN) λmax nm (ε M
-1 cm-1): 332 (32452).  HRMS (ESI) m/z calculated 
226.10927 (C12H12N5, [M+H]
+), m/z observed 226.11020 (C12H12N5, [M+H]
+). 
 
2,3-di(pyridin-2-yl)quinoxaline  (2-94).  1,2-phenylenediamine (50 mg, 
0.472 mmol) and pyridil (2-41) (100 mg, 0.472 mmol) were dissolved in 
2.4 mL of EtOH and refluxed for 6 h.  After cooling to room temperature, 
the reaction mixture was concentrated in vacuo yielding a pale brown solid in 
quantitative yield.  1H NMR (CDCl3, 600 MHz) δ 8.38 (d, 2H, J = 4.8 Hz), 8.23 (dd, 2H, J 
= 3.6, 2.4 Hz), 7.96 (d, 2H, J = 7.8 Hz), 7.84-7.80 (m, 4H), 7.24 (m, 2H).  13C NMR 
(CDCl3, 151 MHz) δ 157.6, 152.6, 148.8, 141.3, 136.8, 130.6, 129.6, 124.4, 123.1.  UV-
Vis (MeCN) λmax nm (ε M
-1 cm-1): 332 (8345).  HRMS (ESI) m/z calculated 285.11402 
(C18H13N4, [M+H]




1,2-di(pyridin-2-yl)-2-(p-tolylimino)ethanone (2-95). 2,2’-pyridil (1 
mmol) was dissolved in EtOH (4 mL). To this was added p-toluidine (2 
mmol). The reaction mixture was stirred at room temperature overnight. Consumption of 
2,2’-pyridil was confirmed by TLC. Reaction mixture was concentrated in vacuo to 
remove EtOH. Residue was purified over silica eluting with hexanes and ethyl acetate to 
yield a yellow solid in 53% yield. 1H NMR (CDCl3, 500 MHz) δ 8.57 (dq, 1H, J = 4.5 Hz, 
J = 1.0 Hz), 8.46 (dq, 1H, J = 5.0, 1.0 Hz), 8.36 (dt, 1H, J = 8.0 Hz, J = 1.0 Hz), 7.97 (dt, 
1H, J = 8.0 Hz, J = 1.0 Hz), 7.83 (td, 1H, J = 7.5 Hz, J = 1.5 Hz), 7.78 (td, 1H, J = 7.5 
Hz, J = 1.5 Hz), 7.37 (qd, 1H, J = 5.0 Hz, J = 1.0 Hz), 7.30 (qd, 1H, J = 5.0 Hz, J = 1.0 
Hz), 6.94 (d, 1H, J = 7.5 Hz), 6.85 (d, 1H, J = 8.5 Hz), 2.21 (s, 3H).  13C NMR (CDCl3, 
125 MHz) δ 198.8, 167.0, 155.4, 152.9, 149.7, 148.9, 137.0, 136.9, 129.3, 127.4, 125.1, 
122.0, 121.6, 120.3HRMS (ESI) m/z calculated 302.1293 (C19H16N3O, [M+H]
+), m/z 


















Chapter 3.  




3.1. Background & Significance 
Despite the ability of copper to catalyze the azide-alkyne cycloaddition, more 
demanding applications have arisen, which have led to the synthesis of ligands to 
further accelerate the cycloaddition reaction. Ligands can be designed to tailor to the 
conditions required. With this in mind, we synthesized a series of 1,2,4-triazine ligands 
to study their ability to catalyze the CuAAC reaction. Depending on the substitution 
pattern of the 1,2,4-triazine, the ligands could be potent accelerants using CuI or CuII 
salts in the presence of a reducing agent. Optimal conditions were determined using a 
model reaction between benzyl azide and phenylacetylene, including amount of base, 
catalyst loading, and stoichiometry between ligand and copper. Additional azide and 
alkyne substrates were then examined. Finally, a study of the catalytic activity of various 
1,2,4-triazines outlined the structural and electronic characteristics necessary to 
catalyze the reaction. 
As an application, the 1,2,4-triazine ligand was used to attach an alkyne bearing triazine 
to different solid supports, polystyrene and silica. These heterogeneous ligands were 
also screened for CuAAC activity, and were found to be effective accelerants. The 
recyclability and the copper retention were also explored, showing some catalysts were 
reusable up to 3 times without loss of activity or significant copper leaching.  
3.2. Optimization of Reaction Conditions for 1,2,4-Triazine Accelerated CuAAC 
Our initial screening for catalytic activity involved the use of several heterocycles. We 
initially screened 1,2,4-triazoles (substituted at both the 1 and 4 positions), 1,2,3-
triazoles, and 1,2,4-triazines. Of these, only 1,2,4-triazines produced an efficient yield of 
the desired 1,2,3-triazole product under ambient conditions. 1,2,4-Triazoles were 
somewhat effective, but required heat in order to form the active copper complex. 
With this knowledge in hand we moved on to further optimize and explore the conditions 
under which 1,2,4-triazines could effectively accelerate CuAAc. We began by evaluating 
the model reaction between benzyl azide and phenylacetylene in acetonitrile. We 
initially tested the catalyst loading and the use of CuI or Cu
II salts. Reactions were 
conducted at room temperature for 1 hour, diluted, and analyzed by LC-MS for yield of 
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triazole product. With addition of ligand, 2-17, a significant enhancement in product 
formation was seen over the control reaction which had copper but no ligand (Table 3.1 
Entry 3 vs. Entry 6). The best results were observed with 1 mole percent of ligand and 
copper using either CuI or Cu
II salts (Entries 3, 7, 8). In order to prevent oxidation to 
CuII, a nitrogen base was also added. This served as a reducing agent to convert the 





- was initially chosen due to its solubility, the compound was 
hydroscopic and unless stored tightly or free from air and water, it became less soluble 
when dissolved for subsequent catalytic trials. Because of this decreased solubility, we 
began to use Cu(BF4)·6H2O in its place. It had a much better solubility. Additional Cu
II 
salts could also be used without significant loss of catalytic activity (Entry 7). After the 
initial LC-MS analysis, work was continued to optimize the reaction conditions. Product 
1,2,3-triazoles were isolated after 1 hour and percent yields reported based on the 
isolated products rather than LC-MS yields.  
 




Simultaneously we examined the effect of substrate concentration and the amount of 
nitrogen base (or reducing agent) required (Table 3.2). Since the pyridine functional 
group is capable of binding copper, we wanted to compare the activity of pyridine to that 
of the synthesized triazine containing a pyridine functional group. We were surprised to 
observe that the addition of pyridine did not result in product formation. Pyridine may 
have been binding to the copper, but possibly it remained in the inactive CuII state.  
Alkyl amines such as triethylamine (Et3N) are employed to reduce Cu
II to the active CuI 
species.92 The addition of Et3N was deemed necessary for this reaction (entry 4), but 
Et3N without triazine 2-17 (Table 3.1, Entry 6) resulted in very minimal product 
formation. From the studies on substrate concentration, very little change occurred 
when the concentration was decreased to 0.1 M. The reaction was still viable at 0.05 M, 
but longer reaction times (3 hrs) were necessary with a decreased overall yield of 64% 
(Table 3.2 Entries 4-6). We also examined if stoichiometric or catalytic amounts of base 
were required. Typical azide-alkyne cycloadditions use excess reducing agent when 
compared to loading of copper catalyst. If the triethylamine is acting as a reducing agent 
alone, the cycloaddition should still work with decreased amounts of amine. At 0.5 eq of 
triethylamine, high yields (97%) were observed within an hour (Table 3.2, Entry 7). With 
0.06 equivalents, the reaction still progressed but at a much slower rate. After 1 hour, 
very little product had formed. Upon stirring for an additional 5 hours, 91% of the triazole 
product was isolated (Table 3.2, Entry 8).  
We also evaluated the solvent scope (Table 3.3). Nonpolar, aprotic solvents appeared 
to be optimal solvents giving the highest isolated yields of 1,2,3-triazole (Entries 1-4, 6-
7) Reactions carried out in polar protic and polar aprotic solvents were met with some 
difficulty. Solvents such as dimethylformamide (DMF) and isopropanol had significantly 
lower yields. The major reason for this was the result of side product formation of bis-
triazole (3-4).93 This reduced the triazole product yield and also made isolation of the 
pure triazole product difficult. One surprising note from this data set was when 
tetrahydrofuran was employed as the solvent. Initially, the reaction did not progress and 
the solution remained green in color. The reaction was left stirring overnight and 
eventually the solution turned dark and product formation was evident by TLC. Possible  
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competition between the THF and triazine ligand for access to the copper or solvation of 
the copper by THF may have caused the delay in the reaction. 
3.3. Substrate Scope 
Having optimized the general conditions, we moved on to test the substrate 
compatibility by examining various azides and alkyne substrates with various 
stereoelectronic properties (Table 3.4). Electron rich and electron poor aromatic azides, 
primary and secondary alkyl azides, and benzylic azides all showed good product yields 
(> 80%). Sterically hindered aromatic azides also produced the corresponding triazoles 
in high yield. Alkyl azides containing an acid functional group surprisingly did not 
undergo the cycloaddition in good yield (Entry 11, 47%). Even with an additional 
equivalent of base, this reaction did not proceed well. Since other alkyl azides had 
produced triazole in efficient yield, the acid functional group was most likely the cause of 
the poor yield in this case. The only azide found to be unreactive was the tertiary 
adamantyl azide which produced very little product even after prolonged reaction times 
(Entry 10).  
While azides were not particularly sensitive to the reaction conditions, alkynes proved to 
be more problematic. Aromatic alkynes containing ether or ester functional groups 
resulted in a second UV active spot observable via TLC. This was determined by NMR 
to be the bis-triazole byproduct, not easily separated from the product triazole, resulting 
in reduced yields or purity. Luckily, this byproduct could be circumvented by use of a 
different solvent, particularly DCM. DCM or DCE were substituted for MeCN to prevent 
side product formation. The yields for triazoles synthesized by varying the 
stereoelectronics of alkynes were more varied as compared to the azide counterpart, 
ranging from 68 – 95%. The only alkyne that did not perform particularly well was the 
alkyl decyne. This resulted in only 23% yield after 1 hour. Possible options to increase 
the yield would be to heat the reaction or increase the reaction time. Despite the lower 
yields with some substrates, reasonable yields were observed with a variety of azide 










3.4. Ligand Scope 
As we were optimizing the conditions for triazine-accelerated CuAAC, we were also 
synthesizing additional 1,2,4-triazines in hopes of finding more active ligands. The 
optimization conditions were all conducted with 5,6-diphenyl-3-(2-pyridyl)-1-2-4-triazine 
which gave 97% isolated yield of product triazole after 1 hour under the best conditions. 
The results from screening of various ligands are compiled in Table 3.5. Since the 
pyridyl substituent was active, we also screened the pyrimidine and pyrazine substituted 
triazines. These turned out to be completely inactive (Entries 2-3), showing that more 
nitrogens isn’t always better. We also wanted to investigate if the pyridine was 
necessary for activity. If pyridine was better than pyrimidine and pyrazine, would a 
phenyl substituent be better than pyridine? When the pyridine was replaced by phenyl, 
the activity significantly decreased to 2% isolated yield (Entry 4). This seemed 
reasonable as coordination of the copper occurs through the pyridine nitrogen. The 2-
pyridyl substituent at the 3 position seemed to be necessary for activity, so we decided 
to investigate other N, O, or S containing heterocycles that could potentially replace the 
pyridine ring. Of the five heterocycles synthesized, benzothiophene, benzofuran, indole, 
and benzothiazole were all inactive, producing only trace amounts of triazole product. 
The only substituent at the 3-position that showed intermediate activity was the 
replacement of the pyridine with methyl imidazole to yield 50% of triazole product in 1 
hour (Entries 5-9). 
The pyridine substituent at the 3 position appeared to be irreplaceable, so we decided 
to move onto the 5,6 position to see if the activity could be tuned with respect to those 
substituents. Other commercial dicarbonyls allowed us to investigate the steric bulk. 
The replacement of the phenyl rings with H decreased the yield, only slightly, from 97% 
to 91%. The methyl substituents at 5 and 6 positions did not fare as well. This product 
was not an easily handled powder like the other triazines, but instead formed a semi-
solid oily residue, making it slightly less soluble, and more difficult to measure out. 
Replacement of the phenyl rings with pyridine to make 3,5,6-tripyridyl-1,2,4-triazine also 








Through our screening it was identified that both phenyl rings were not required as a 6-
phenyl-1,2,4-triazine displayed similar activity to the initial ligand 2-17 (Entry 13). The 
triazine containing an alcohol functional group (2-50) was not active. This compound 
wasn’t very soluble in DCM or DCE, which could have led to the decreased catalytic 
activity. Use of a different solvent for this triazine ligand could improve the activity. The 
addition of the nitro and amine substituents did not have a positive impact on the 
catalytic activitiy (Entries 16-17). The activity decreased for both triazines. Neither of 
these triazines were particularly soluble, so the decreased solubility could have led to 
their decreased activity. 
Locking the conformation of the 5,6 substituents gave similar results (96%) to the 
original triazine 2-17 (Entries 18-19). Surprisingly, the addition of nitrogens in 2-65 did 
not have an adverse effect on the catalytic activity. Since these nitrogens are pointed 
away from the metal binding region of the molecule, it could be proposed that these 
additional nitrogens wouldn’t interfere with copper coordination and access by the azide 
or alkyne components. Contrary to this, the nitrogen in 2-67 is closer to the metal 
binding center and is also more basic than the pyridine nitrogen. This triazine resulted in 
only a trace amount of product formed (Entry 20). 
Somewhat of a disappointment were the results from the bis-triazine and the 1,2,3-
triazolyl-1,2,4-triazine. (Entries 21, 23) Neither of these proved to be active for the 
azide-alkyne cycloaddition. The metal binding site is more crowded now, so this might 
either lead to no binding of the copper by the triazine, or the alkyne cannot access the 
copper once bound. Either of these would prevent the cycloaddition. 
Of the remaining ligands, pyridazine (2-87) showed some modest activity with 63% 
isolated yield over 1 hour (Entry 29). The imine (2-95) resulted in 95% yield but the 
reaction progressed for an additional 4 hours. After 1 hour, the reaction was not 
complete, so longer reaction times were necessary. It would be of interest to explore 




3.5. Mechanistic Considerations 
A limited amount of data was collected in order to explore the copper dependence on 
1,2,4-triazine accelerated CuAAC. The first method was to examine the UV-Vis 
absorption spectra of 5,6-diphenyl-3-(2-pyridyl)-1,2,4-triazine (2-17) with copper (I) and 
copper (II) salts, in the presence or absence of triethylamine (Figure 3.1). For ligand and 
copper (II) containing spectra, an absorbance was present around 700 nm. This is 
characteristic of the d-d transitions in copper (II) complexes. This absorbance band was 
diminished with the addition of base, and a new absorbance peak around 480 nm was 
present. The spectra obtained from a solution containing ligand, copper, and base are 
superimposable when comparing copper (I) to copper (II) salts. The absorbance 
spectrum of copper (I) and ligand alone is similar to the spectrum of the same solution 
with base added. The intensity of the peaks may differ, but the general features are 
similar. From this data we could confidently state that the CuII was being reduced to 
generate the active CuI species.  
Although from our optimization studies (Table 3.2), it was shown that a catalytic amount 
of base was sufficient to convert CuII into CuI and yield the desired triazole product, the 
UV-Vis scan did not show the CuI species. The experiment with catalytic base required 
longer reaction times (> 5 hr) to yield product triazoles in moderate yield. For the UV-Vis 
experiment, scans were conducted immediately after mixing the ligand, copper, and 
base. For a better comparison, the UV-Vis spectrum should be taken at various time 
points. The conversion of CuII to CuI is not instantaneous with catalytic amount of base, 
especially since the reaction mixtures were not being stirred within the UV-Vis. 
The addition of substrates did not affect the features of the absorption spectra as can be 
seen when comparing Figure 3.1B to Figure 3.1A. The intensity of the spectral features 
may have increased slightly, but there was no shift in the wavelength at which the 






Figure 3.1 UV-Vis spectra of 1,2,4-triazine-accelerated CuAAC.   5,6-diphenyl-3-(pyridin-2-
yl)-1,2,4-triazine (0.01 eq) (2-17) in acetonitrile with either tetrakis(acetonitrile-N)copper(I) 
tetrafluoroborate (0.01 eq) or copper(II) tetrafluoroborate hexahydrate (0.01 eq).  The addition of 
triethylamine (0.01 eq or 1.0 eq) was studied without (A) and with (B) benzyl azide (1.0 eq) and 
phenylacetylene (1.0 eq).  
 
 
A preliminary kinetics investigation was undertaken using 1H NMR to monitor the 
reaction between phenylacetylene and benzyl azide. (Figure 3.2) The initial 
observations revealed a reaction order of zero with respect to the azide substrate. 
When concentration of azide was doubled the reaction rate was unaffected. When the 
copper and ligand concentrations were doubled, the reaction rate also doubled. 
Changing the concentration of alkyne was more difficult, as doubling the concentration 
led to the formation of precipitate. Changes to the solvent could potentially eliminate this 
issue. A more thorough investigation and mathematical processing of the data is 
required to provide more concrete evidence about the nature of the mechanism. 
Preliminary electrochemical experiments were also conducted.66 Unfortunately, the 
addition of ligand, copper, and base resulted in a very dark brown solution, which left 
residual components in the frit of the electrode. After a series of experiments, the 
contamination of the frit began to influence the spectral features. A consistent baseline 
and reproducible spectra were no longer possible to collect. To prevent the 
contamination of the frit, more dilute solutions were attempted, but these were too dilute 





Figure 3.2 Kinetic NMR Data of 1,2,4-Triazine-Accelerated CuAAC Reaction.   (A) Standard 
conditions: benzyl azide (0.2 M), phenylacetylene (0.2 M), triethylamine (0.4 M), Cu(MeCN)4BF4 
(0.002 M), and 5,6-diphenyl-3-(pyridin-2-yl)-1,2,4-triazine (2-17) (0.002 M) in deuterated 
acetonitrile.  Concentrations for additional reactions were altered as indicated above.  Ratio is 
percent yield of the indicated reaction divided by that of the standard reaction.  (B) Kinetic array 
for 1,2,4-triazine-accelerated CuAAC reaction under standard conditions.  Disappearance of 
alkyne (3.4 ppm) and benzylic azide protons (4.4 ppm) as benzylic triazole protons (5.6 ppm) 
appear over time.  
 
 
Of the limited amount of data collected, the most useful data was the UV-Vis spectra. 
This confirmed that the initial CuII salts were being converted to the active CuI species 
upon addition of base. For a more complete mechanistic evaluation, additional data is 
required. 
 
3.6. Other Catalytic Applications 
Since 3-(2-pyridyl)-1,2,4-triazines are known to bind various metals, we decided to 
explore other metal catalyzed reactions to see if triazine presence could accelerate 
these reactions. One reaction that we were interested in would be to perform a one-pot 
Sonogashira-CuAAC reaction. The reaction would begin with an aryl iodide, which 
would be converted into a terminal alkyne. The terminal alkyne would then be reacted 
with an azide under 1,2,4-triazine-accelerated CuAAC conditions previously developed. 
Many reports exist on the in situ preparation of azides from bromides for a one-pot 
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CuAAC reaction,94,95 or the in situ preparation of alkynes from iodides for a one pot 
Sonogashira-CuAAC reaction.96 From our experience, synthesis of aryl alkynes is 
usually a lengthier process than for the complimentary azides needed for CuAAC 
reactions. Alkynes usually are purified by silica gel chromatography to remove excess 
palladium and copper salts after the reaction. Our goal was to conduct the Sonogashira 
and azide-alkyne cycloaddition in one pot, in the hopes of speeding up the process and 
isolation of the final product. 
We began the investigation by examining the model reaction between iodobenzene and 
phenylacetylene (Table 3.6). Entry 1 represents the standard conditions employed for 
Sonogashira conditions. This reaction proceeds at room temperature, but did produce 
some oxidative Glaser coupling byproduct. Addition of 1,2,4-triazine (2-17) to 
bis(triphenylphosphine)palladium(II) chloride resulted in decreased yield of the desired 
internal alkyne (3-5) and no change in the selectivity of 3-5 over 3-6. Other available 
palladium sources known to bind 1,2,4-triazines were palladium (II) acetate. On its own 
this palladium source did not catalyze the Sonogashira reaction (Entry 3). Addition of 
1,2,4-triazine (2-17) increases the yield, but not to that of an appreciable amount. We 
next evaluated if the yield could be improved with addition of heat or a change in 
solvent. From optimization experiments with CuAAC, THF was observed to delay the 
reaction. Changing the solvent and increasing the temperature proved to be very 
beneficial. Both acetonitrile and toluene (Entries 10 and 12) displayed modest yields 
with acetonitrile showing the best selectivity thus far, with a ratio of nearly 13 : 1 desired 
product to Glaser byproduct. Since the palladium exists as a trimer, the stoichiometry of 
the added ligand was adjusted to find the optimal ratio between palladium and triazine 
(Entry 10, 13).  
From these initial results, it appeared that this method could be viable. We then tried to 
extend this method to a one-pot reaction in which both the Sonogashira and azide 
alkyne cycloaddition would take place in one pot. Unfortunately, our attempts at a one-
pot Sonogashira-CuAAC only resulted in approximately a 12% isolated yield (Table 
3.7). This product was darker in color than the normal product triazole, indicating likely 
palladium contamination. Unreacted starting material was a culprit in the low yields. 
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From here, we decided to examine the deprotection and cycloaddition steps. In the 
examples above, the aryl iodide was reacted with a TMS-protected alkyne. This alkyne 
must be deprotected before the azide-alkyne cycloaddition can take place. Since the 
Sonogashira reaction was resulting in product, we wanted to isolate the other portions 
of the reaction, to determine where the reaction was stalling. For this, TMS-protected 
phenylacetylene was synthesized and used to screen various deprotection conditions. 
After addition of benzyl azide, triazole product formation was monitored (Table 3.8). We 
also decided to take advantage of the Microwave Synthesizer and performed the 
reactions in Table 3.8 at 120°C in the microwave. We explored various copper sources 
for the cycloaddition and observed that the reaction required larger equivalents of 
copper compared to the standard reaction between phenylacetylene and benzyl azide. 
Increasing the amount of ligand and copper increased the yield, but in the microwave 
the difference between triazine-accelerated and control reaction wasn’t significant (98% 
to 86%, Entries 11, 12). 
Having observed good yields for triazole formation, we decided to move forward and 
once again try a one-pot approach. Using the optimal deprotection conditions, 
iodobenzene was converted into TMS-phenylacetylene. Again a problem arose in the 
deprotection and no triazole product was formed. Protected phenylacetylene was the 
main component in the reaction mixture. This made us begin to question if palladium 
was possibly interfering with the deprotection step. First, we examined the presence of 
bis(triphenylphosphine)palladium (II) chloride during the deprotection of TMS-
phenylacetylene with tetrabutylammonium fluoride. There was a dependence on the 
solvent used for the deprotection as shown in Table 3.9. 
A few more parameters were altered, and now we were able to remove the protecting 
group from the alkyne, but we still were not observing triazole product formation (Table 
3.10). Instead of recovering protected alkyne, we had a free terminal alkyne, but no 
cycloaddition was taking place. The problem appeared to be the addition of palladium 
acetate. We then examined the CuAAC reaction in the presence of palladium to 
determine if the cycloaddition reaction was being hindered by the presence of 
palladium. Using benzyl azide and phenylacetylene as the model system, we added 
palladium (Pd3(OAc)6) and tetrabutylammonium fluoride to the reaction mixture. After an  
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Table 3.10 Re-evaluation of triazine ligand in one pot Sonogashira-CuAAC reaction. 
 
 
hour at room temperature, this reaction showed very little progress. After a prolonged 
time, product formation began to occur, but additional byproducts were observed by 
TLC. This combination was causing a sluggish cycloaddition reaction. Future options 
would be to try a different palladium source. The triazine may be binding too tightly to 
the palladium and not available to bind to copper to catalyze the cycloaddition reaction. 
The last reaction attempted was to use the standard sonogashira conditions 
(bis(triphenylphosphine)palladium(II) chloride and copper iodide. The deprotection was 
performed using tetrabutylammonium fluoride and the cycloaddition reagents were 
copper (II) sulfate and sodium ascorbate. These conditions led to product formation in a 
58% yield. This reaction was conducted in order to check for the azide reduction to 
amine. No free amine was detected, so it was not believed that azide decomposition 
was leading to any prior unreactivities. At this point, it was deemed necessary to place 
this work aside and focus on applications of 1,2,4-triazines in heterogeneous systems 




3.7. Solid-Supported 1,2,4-Triazines 
After observing promising activity with the homogeneous triazines, it was decided to 
make heterogeneous versions of the triazine catalyst by covalently linking the 1,2,4-
triazines to both silica and polystyrene supports. This work was discussed in detail by 
Prince.97 I will highlight the key schemes used to continue this work, and present the 
catalytic activity, recyclability, and copper retention for these heterogeneous supports. 
3.7.1. Overview of Synthesis of Solid-Supported 1,2,4-Triazines and Control 
1,2,3-Triazole Resins 
Commercial Merrifield resin was chosen as a polystyrene support due to its ability to 
swell in a number of solvents, low cost, and easy availability. For the synthesis, we used 
a high loading resin (1.4 mmol/g) and a low loading resin (0.5 mmol/g). Since a triazine 
alkyne was synthesized to attach to the solid support, the polystyrene resin was first 
converted from a chloride to an azide using sodium azide. At this time, we synthesized 
a series of controls (Scheme 3.1). Azide functional groups are known to bind copper, so 
we first coordinated copper (I) and copper (II) to azide derivatized polystyrene. 
Additionally, since triazoles are known to catalyze azide-alkyne cycloaddition, we 
wanted to ensure that the activity being observed was due to the triazine ligand, and not 
due to the presence of the 1,2,3-triazole linker. Therefore, we synthesized two 1,2,3-
triazoles by reacting the azide resin with phenylacetylene and 2-ethynyl pyridine. The 
pyridine derivative would install an additional nitrogen that could be used to bind metal. 
Since we had both high loading and low loading resin each reaction was carried out with 
each support. Each product was then coordinated with a copper (I) or copper (II) salt to 
afford 12 control compounds (Scheme 3.1).  
A similar process was carried out using triazine alkynes and the azido resin to form the 
1,2,4-triazine supported catalysts. The alkyne of the 1,2,4-triazine was located either on 
an aromatic ring at the 3-position or at the 5-position. To synthesize the alkyne 






Scheme 3.1 Synthesis of solid-supported control 1,2,3-triazoles. 
 
converted into the amidrazone (3-26). This was condensed with benzil to afford the 
1,2,4-triazine (3-27). The bromide was then converted to the alkyne using the 
Sonogashira coupling reaction (Scheme 3.2). The alkyne was produced in 45% yield 
over 3 steps. For synthesis of the 5-substituted alkyne triazine, 4-bromoacetophenone 
was converted to the ketoaldehyde (3-30) through oxidation with selenium dioxide. This 
was condensed with the pyridine amidrazone to yield the 1,2,4-triazine (3-31) with a 
bromide on the aryl ring at the 5-position. This bromide was then converted to the 
alkyne through the Sonogashira coupling reaction (Scheme 3.3). The overall yield for 









Scheme 3.3 Synthesis of alkyne on 5-substituent of 1,2,4-triazine. 
 
The alkyne containing triazines were then subjected to a cycloaddition reaction with the 
azide containing solid supports. Triazine 3-28 was attached to both HL and LL 
polystyrene supports. Triazine 3-32 was attached only to the HL polystyrene support. 
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The alkyne triazine precursor synthesis was lower yielding (and with regards to catalytic 
activity was not superior to triazine 3-28).  After carrying out the cycloaddition reaction, it 
was observed that the reaction did not go to completion, leaving some unreacted azides 
on the solid support. This resin was reacted with tin chloride to reduce the unreacted 
azides to free amines. Both the azide and amine containing resins were then complexed 
with copper (I) and copper (II). This resulted in 12 triazine containing heterogeneous 
ligands. A summary of the triazine ligands to be discussed in the results is presented in 
Figure 3.3 and Figure 3.4. 
3.7.1. Catalytic Activity of Solid Supported 1,2,4-Triazines 
With the synthesis of triazine catalysts and appropriate controls completed, we began to 
evaluate their catalytic activity. To determine the copper loading, each heterogeneous 
support was heated in a solution of either copper (I) or copper (II) for two hours. The 
heterogeneous support was filtered and washed thoroughly. The filtrate was 
concentrated and rediluted in 2% nitric acid. The filtrate was then analyzed for copper 
content using ICP-OES. By difference the copper loading was calculated. The loading 
for copper (I) and copper (II) is illustrated in Table 3.11. The triazine ligands (Entries 1-
5) were all efficient at binding copper to a much better extent than the azide derivative 
(Entry 6) or the simple 1,2,3-triazole with a phenyl substituent (Entries 7-8). The copper 
binding ability of the pyridine substituted 1,2,3-triazole was surprisingly greater than the 
binding ability of the 1,2,4-triazines when the high loading polystyrene resin was used 
(Entry 9). When low loading resin was used a decrease in copper loading was observed 
with both triazines and triazoles. In general copper (II) catalysts had a slightly higher 
copper content than their copper (I) counterparts. Supports with residual amine showed 
slightly more copper loading when compared to the analogous residual azide supports. 
Once the copper loading was determined, the various functionalized supports were 
screened for activity using the model system of benzyl azide and phenylacetylene. DCE 
was added to 5 mg of the appropriate resin followed by the addition of azide, alkyne, 
and triethylamine. Reactions were allowed to proceed for 4 hours at 60°C and the 1,2,3-
triazole product was separated from the resin by filtration. Concentration in vacuo 





















observed for the copper loading. Copper (II) catalysts outperformed the copper (I) 
derivatives in all cases with about a 10% difference in the isolated yields. The activity 
between triazines substituted through the 3-position was very similar to the activity of 
triazines attached through the 5-position with a slight favoring of the 3-substituted 
triazine linker. 
One surprising note was the activity of the 1,2,3-triazole with a phenyl substituent (Entry 
7) on a high loading resin. This was only slightly less active than the 1,2,4-triazine 
supports. When the 1,2,3-triazole supported on a low loading resin was screened, there 
was no appreciable activity (Entry 8). It was hypothesized that the higher density of 
triazoles on the high loading resin was catalyzing the azide-alkyne cycloaddition.38,55 
This was supported by the absence of activity for the low loading triazole resin. 
Additionally, the pyridine substituted 1,2,3-triazole also displayed a high activity, 
recovering 99% product from the high loading resin and 99% using a low loading resin 
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with copper (II) (Entries 9-10). The increased activity at using the low-loading resin was 
surprising, but can be explained since the pyridine adjacent to the triazole is able to 
chelate the copper to assist in the azide-alkyne cycloaddition. 
Since the initial results were promising, we next investigated if the solid supports could 
be reused for multiple catalytic cycles. We were interested to see if the simple phenyl or 
pyridyl substituted 1,2,3-triazoles were active for multiple cycles. After each 
cycloaddition reaction, catalyst resin was filtered, rinsed, and reused without any 
additional treatment. Catalysts were reused for up to 4 consecutive reactions. The 
isolated product yields were reported (Table 3.12). For these studies only the triazine 
appended to the solid support through the 3-position was examined. Since there was 
not an appreciable difference in the activity between the two triazines, we elected to 
continue studies using the support which was easier to synthesize (the triazine with an 
alkyne at the 3-position). For the two triazine ligands (Entries 1-2) moderate yields were 
displayed for two cycles with the copper (I) catalyst, while moderate yields were 
illustrated for three cycles for the copper (II) catalysts. The 1,2,3-triazole substituted with 
a phenyl ring had showed modest activity after one cycle with 73% isolated triazole 
product, but trying to reuse the catalyst resulted in very minimal product formation 
(Entry 3). The 1,2,3-triazole substituted with a pyridyl ring was active for two 
consecutive cycles when the high loading resin was used, but failed to give any 
substantial product in cycle 3 (Entries 4-5). The low loading resin with a pyridyl 1,2,3-
triazole (Entries 6- 7) was only active for one cycle. 
Directly related to the recyclability of the resin, is the copper retained by the 
heterogeneous catalyst. Since one advantage of heterogeneous catalysts is to prevent 
copper contamination in the products, we examined the percentage of copper leached 
after consecutive reactions. The isolated triazole product was diluted in 2% nitric acid 
and the amount remaining on the solid support was determined by difference from the 
ICP-OES results. The copper retention studies (Table 3.13) follow the same pattern 
seen in the recyclability studies. As the yield decreased, it can be seen that the 
percentage of copper remaining on the polystyrene support was also decreasing. For 
the 1,2,3-triazoles without triazines appended, the copper retention decreased to a 
range of 11-50% after one cycle. Triazines, by comparison, retained between 80 and 
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90% of the original loaded copper. This data makes sense in that as copper is leached 
the catalyst support will not be as effective in a catalytic reaction, since the level of 
copper has decreased dramatically. These results were encouraging in that the triazines 
could be reused, while the non-triazine controls were more limited. 
Additional results not presented here showed that 1,2,4-triazines attached to silica 
supports displayed higher isolated yields of 1,2,3-triazole product, and could be used for 
up to four cycles while maintaining greater than 90% yields, without significant copper 
leaching. Some catalysts were even effective without the addition of triethylamine. 
As an extension to this work, an evaluation of solvent was conducted with selected 
polystyrene and silica catalysts. Organic solvents such as MeCN, DCE, t-BuOH, and 
toluene had been previously evaluated.97 Silica catalysts performed much better over a 
wider array of solvents. The polystyrene catalysts were not as effective in solvents such 
as tert-butanol or toluene. An additional experiment was conducted to see the activity of 
the solid supports in water. Surprisingly, both the polystyrene and silica catalysts 
performed well in the presence of water with isolated yields of 98-99% (Table 3.14 Entry 
5). We had not explored the use of water as a solvent with homogeneous ligands, since 
the substrates did not dissolve in aqueous medium. In this case, the reaction was stirred 
to ensure reaction of the nonpolar substrates with the triazine catalyst. The isolation of 
the product was also rather simple, as the reaction was filtered, and the resin rinsed 
with DCM to dissolve the product triazole. Using water would be more advantageous 
especially from a “click” perspective. Additional experiments should be carried out with 
the solid supports in water, specifically a study to look at recyclability of catalysts and 
the copper retention when water is used for the reaction media. The dependence of 
base when reactions are carried out in water would also be a worthwhile experiment. 
Finally, since the homogenous ligands were not used with water, it would be 












In summary, several parameters were evaluated with respect to the use of 
homogeneous triazines as ligands for CuAAC. Optimization studies, evaluation of 
substrate scope, and ligand scope were all conducted to explore the feasibility of 1,2,4-
triazines as ligands for CuAAC. Optimization studies revealed that homogeneous 3-(2-
pyridyl)-1,2,4-triazines with either copper (I) or copper (II) salts could be used effectively 
in the presence of a reducing agent, triethylamine, giving isolated 1,2,3-triazole product 
in 97% yield. Best results were observed with an excess of reducing agent (0.5 to 1.0 
equivalents) although 0.06 equivalents of triethylamine produced reasonable yields 
(91%), but required longer reaction times (5 hours). The substrate concentration could 
be reduced to 0.1 M without adverse effects to the catalytic activity, but further 
decreasing to 0.05 M decreased the catalytic activity greatly. 
The scope of the reaction seems to encompass a wide array of substrate azide and 
alkynes. Aryl and alkl azides in general underwent cycloadditions with phenylacetylene 
in good yields (>80%). Alkyl acids only gave modest triazole products, and tertiary 
azides, such as adamantly azide resulted in minimal product formation. Variations in 
azides were more tolerable compared to their alkyne counterparts. Alkyne substituents 
were more apt to formation of bistriazole products, requiring modifications to the solvent 
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choice, using DCM in place of MeCN. Yields with alkynes, in general, were slightly 
lower ranging from 68 – 95%. The exception was the long alkyl alkyne, decyne which 
showed poor results. With regards to solvent, the choices were somewhat limited, 
working best in nonpolar non-coordinating solvents. Solvents that could coordinate 
metals such as DMSO, DMF, or THF led to decreased yields, increased by-product 
formation, or longer reaction times. 
A ligand scope was also conducted in search of more active nitrogen containing ligands. 
The 3-(2-pyridyl)-substituent was deemed necessary for activity. Triazines lacking this 
group were inactive with isolated yields less than 10%, with the exception of the 
imidazoyl substitutent that produced 50% of triazole product in 1 hour. Modifications to 
the 5,6-substitutents proved to be less detrimental to the activity, but did not surpass the 
activity of the triazine used for optimization studies (2-17). Replacing the 1,2,4-triazine 
core with other heterocycles such as tetrazines, pyridines, or imines did not yield 
triazole product in a catalytic fashion. The two exceptions were pyridizine (2-87) which 
resulted in 63% yield and imine (2-95) which resulted in 95% yield of the triazole 
product. The imine ligand did require longer reaction times compared to 3-(2-pyridyl)-
1,2,4-triazines.  
Two applications utilizing the homogenous triazine ligand were evaluation in other metal 
catalyzed reactions, such as the Sonogashira reaction and use in synthesis of solid 
supported catalysts. The application of triazines to a one-pot Sonogashira-azide-alkyne 
cycloaddition reaction was not fully optimized. Further work is still needed to make this 
route viable. Options include changing the palladium source and possibly the copper 
salt. 
The second application, the synthesis and catalytic activity of the solid-supported 
triazines proved to be much more valuable. Good to excellent yields were observed with 
polystyrene and silica catalysts containing 1,2,4-triazines. Although heat was needed for 
the reaction to proceed, the high yields, easy product isolation, and copper retention by 
the support, made this an efficient and viable synthetic route. 1,2,4-triazines were more 
effective at binding copper and were able to be recycled compared to 1,2,3-triazoles 
which were synthesized as controls. In addition, both polystyrene and silica supported 
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1,2,4-triazines worked efficiently in water, affording >98% yield of 1,2,3-triazole product. 
Further exploration of this method to the application of more challenging substrates 
would be a worthwhile expedition. 
 
3.9. Experimental 
Materials and General Methods.  Reagents and solvents were purchased from various 
commercial sources and used without further purification unless otherwise stated.  
Anhydrous solvents were purified using a Grubbs solvent system.  Analytical thin-layer 
chromatography (TLC) was performed using aluminum backed silica gel TLC plates 
with UV indicator from Sorbent Technologies.  Flash column chromatography was 
performed using 40-63 μm (230 x 400 mesh) silica gel from Sorbent Technologies.  1H 
and 13C NMR were recorded at 600 MHz and 151 MHz, respectfully, on a Varian Inova 
spectrometer or at 500 MHz and 125 MHz on a Varian spectrometer.  All chemical shifts 
were reported in δ units relative to tetramethylsilane or the corresponding deuterated 
solvent.  High resolution mass spectra (ESI) were obtained on a JEOL AccuTOF DART 
spectrometer.  Liquid chromatography mass spectra were obtained on a QSTAR XL 
Hybrid LC/MS/MS equipped with a Vydac C18 column and a mobile phase composed of 
acetonitrile and formic acid.  Infrared spectra were recorded on a Varian 4100 FT-IR 
using KBr pellets or KBr salt plates.  Absorption spectra were collected on a Thermo 
Scientific Evolution 600.  High pressure liquid chromatography (HPLC) was performed 
using a Beckman Coulter System equipped with a UV-Vis detector, autosampler, Varian 
C18 column, and a mobile phase composed of acetonitrile and trifluoroacetic acid. 
Copper was quantified by inductivel coupled plasma – optical emission spectroscopy 
(ICP-OES) using a Perkin Elmer Optima 2100 DV.   
 
WARNING:  Low molecular weight azides are potentially explosive.  Appropriate 




LC/MS Methodology.  All reactants and reagents were added as stock solutions unless 
otherwise noted.  The concentrations of these stock solutions were determined by UV-
Vis spectroscopy.  Reactants and reagents were added in the following order:  excess 
solvent, azide, alkyne, base, ligand and copper source.  After 1 h the reactions were 
diluted in acetonitrile to a final concentration range of 15 – 25 μM and analyzed by LC-
MS using a Vydac C18 column.  The isocratic mobile phase was composed of 45% 
acetonitrile and 0.5% formic acid.  Percent yields were determined based on product 
formation using an external calibration curve.  All reactions containing a standard 
deviation were run in triplicate unless otherwise noted. 
 
General Azide Method A:  Aromatic Azides.  The aniline derivative (approx 2 g, 16.24 
mmol) was dissolved in 80 mL of EtOAc.  40 mL of 1.5 M HCl was added and the 
solution cooled to 0°C in an ice bath.  Sodium nitrite (1.68 g, 24.36 mmol) was dissolved 
in 20 mL water and added dropwise to the reaction solution while stirring at 0°C.  After 
15 min, sodium azide (3.17 g, 48.72 mmol) was dissolved in 20 mL water and added 
dropwise to the reaction solution while stirring at 0°C.  After slowly warming to room 
temperature, the reaction was monitored by TLC.  Upon completion, the reaction was 
extracted with EtOAc (x3) and washed with 1 M HCl, water, and brine.  The solution 
was then dried with sodium sulfate and concentrated in vacuo to yield the 
corresponding aromatic azide.  Yields:  80 – 94%. 
 
General Azide Method B:  Aliphatic/Benzylic Azides.  The bromine derivative 
(approx 2 g, 11.17 mmol) was dissolved in 25 mL of dimethylformamide.  Sodium azide 
(799 mg, 12.28 mmol) was added and the reaction was stirred overnight at room 
temperature.  Progress of the reaction was monitored by TLC and GC-MS.  Upon 
completion, the reaction was quenched with 50 mL of water (exothermic) and stirred 
until reaching room temperature.  The solution was then extracted with diethyl ether (x3) 
and washed with water (x2), copper sulfate (x1), and brine.  The solution was then dried 
with sodium sulfate and concentrated in vacuo to yield the corresponding aliphatic 




 (azidomethyl)benzene (3-1a).  Prepared using general azide method B 
and isolated as a colorless oil.  1H NMR (CDCl3, 600 MHz) δ 7.40-7.37 (m, 
2H), 7.35-7.31 (m, 3H), 4.33 (s, 2H).  13C NMR (CDCl3, 151 MHz) δ 135.5, 129.0, 
128.44, 128.35, 54.9.  IR (film) νmax 2099 cm
-1.  MS (ESI) m/z calculated 106.066 
(C7H8N, [M-N2+H]
+), m/z observed 106.064  (C7H8N, [M-N2+H]
+). 
 
azidobenzene (3-1b).  Prepared using general azide method A and isolated as a 
brown oil.  1H NMR (CDCl3, 600 MHz) δ 7.35 (t, 2H, J = 7.8 Hz), 7.14 (t, 1H, J = 
7.8 Hz), 7.03 (d, 2H, J = 7.8 Hz).  13C NMR (CDCl3, 151 MHz) δ 140.0, 129.8, 
124.9, 119.1.  IR (film) νmax 2129 cm
-1.  MS (ESI) m/z calculated 92.050 (C6H6N, [M-
N2+H]
+), m/z observed 92.048  (C6H6N, [M-N2+H]
+). 
 
1-azido-4-methoxybenzene (3-1c).  Prepared using general azide method A 
and isolated as a brown solid.  1H NMR (CDCl3, 600 MHz) δ 6.95 (d, 2H, J = 9 
Hz), 6.89 (d, 2H, J = 9 Hz).  13C NMR (CDCl3, 151 MHz) δ 157.0, 132.3, 120.0, 
115.1, 55.6.  IR (film) νmax 2110 cm
-1.  MS (ESI) m/z calculated 122.061 
(C7H8NO, [M-N2+H]
+), m/z observed 122.060  (C7H8NO, [M-N2+H]
+). 
 
methyl 4-azidobenzoate (3-1d).  Prepared using general azide 
method A and isolated as an orange-brown solid.  1H NMR (CDCl3, 
600 MHz) δ 8.05 (d, 2H, J = 7.4 Hz), 7.07 (d, 2H, J = 7.4 Hz), 3.91 
(s, 3H).  13C NMR (CDCl3, 151 MHz) δ 166.4, 144.9, 131.6, 126.8, 119.0, 52.3.  IR (film) 
νmax  2125 cm
-1.  MS (ESI) m/z calculated 150.056 (C8H8NO2, [M-N2+H]




1-azido-2,4-dimethylbenzene (3-1e).  Prepared using general azide method 
A and isolated as a brown oil.  1H NMR (CDCl3, 600 MHz) δ 7.03-6.97 (m, 3H), 
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2.29 (s, 3H), 2.17 (s, 3H).  13C NMR (CDCl3, 151 MHz) δ 135.6, 134.2, 131.9, 129.3, 
127.6, 117.8, 20.8, 17.2.  IR (film) νmax 2122 cm
-1.  MS (ESI) m/z calculated 120.081 
(C8H10N, [M-N2+H]
+), m/z observed 120.081  (C8H10N, [M-N2+H]
+). 
 
2-azido-1,3-dimethylbenzene (3-1f).  Prepared using general azide 
method A and isolated as a brown oil.  1H NMR (CDCl3, 600 MHz) δ 7.02-
7.00 (m, 3H), 2.36 (s, 6H).  13C NMR (CDCl3, 151 MHz) δ 137.0, 132.1, 
128.9, 125.7, 18.2.  IR (film) νmax 2129 cm
-1.  MS (ESI) m/z calculated 120.081 (C8H10N, 
[M-N2+H]
+), m/z observed 120.081 (C8H10N, [M-N2+H]
+). 
 
1-azidoheptane (3-1g).  Prepared using general azide method B 
and isolated as a clear oil.  1H NMR (CDCl3, 600 MHz) δ 3.26 (t, 2H, J = 6.6 Hz), 1.62-
1.58 (m, 2H), 1.38-1.27 (m, 8H), 0.89 (t, 3H, J = 6.6 Hz).  13C NMR (CDCl3, 151 MHz) δ 
51.5, 31.7, 28.8, 26.7, 22.6, 14.1, 14.0.  IR (film) νmax 2099 cm
-1.  MS (ESI) m/z 
calculated 114.128 (C7H16N, [M-N2+H]
+), m/z observed 114.128  (C7H16N, [M-N2+H]
+). 
 
2-azidoheptane (3-1h).  Prepared using general azide method B and 
isolated as a clear oil.  1H NMR (CDCl3, 600 MHz) δ 3.43-3.40 (m, 
1H), 1.52-1.27 (m, 8H), 1.25 (d, 3H, J = 6 Hz), 0.89 (t, 3H, J = 6 Hz).  13C NMR (CDCl3, 
151 MHz) δ 58.2, 36.3, 31.7, 25.9, 22.7, 19.6, 14.1.  IR (film) νmax 2110 cm
-1.  MS (ESI) 
m/z calculated 114.128 (C7H16N, [M-N2+H]




6-azidohexanoic acid (3-1k).  Prepared using general azide 
method B and isolated as a clear oil in 98.1% yield.  1H NMR 
(CDCl3, 600 MHz) δ 3.29 (t, 2H, J = 7.2), 2.38 (t, 2H, J = 7.2 Hz), 1.70-1.60 (m, 4H), 
1.47-1.42 (m, 2H).  13C NMR (CDCl3, 151 MHz) δ 179.50, 51.32, 33.94, 28.65, 26.28, 
24.29.  IR (film) νmax 2098.55 cm
-1.  MS (ESI) m/z calculated 130.087 (C6H12NO2, [M-
N2+H]




General Alkyne Method.  Aryl iodide (10 mmol), dichlorobis- 
(triphenylphosphine)palladium(II) (0.25 mmol), and CuI (0.15 mmol) were combined in a 
round bottom flask and flushed with N2.  Anhydrous THF was added (12.5 mL) followed 
by a dropwise addition of triethylamine (15 mmol) and trimethylsilylacetylene (15 mmol) 
in anhydrous THF (12.5 mL).  Reaction was stirred at room temperature and monitored 
by TLC.  Upon completion, solvent was removed in vacuo and purified by silica gel 
chromatography to yield the corresponding trimethylsilyl protected alkyne.  To the 
protected alkyne (10 mmol) in MeOH (20 mL) was added solid K2CO3 (1.5 mmol) and 
the resulting suspension stirred at room temperature, with reaction progress monitored 
by TLC.  Upon completion, the reaction was concentrated in vacuo, and the residue 
brought up in DCM and water.  The aqueous layer was extracted with DCM (x3).  The 
combined organic layers were washed with water (x1), sat’d NaHCO3, and brine.  The 
solution was dried over sodium sulfate, concentrated in vacuo and purified by silica 
column chromatography to yield corresponding terminal alkyne. 
 
1-ethynyl-2,4-dimethylbenzene (3-2e).  Prepared using general alkyne 
method from 1-iodo 2,4-dimethylbenzene.  Purified by silica 
chromatography using gradient elution of hexanes and ethyl acetate to 
yield a red oil in 61% yield. 1H NMR (CDCl3, 600 MHz) δ 7.35 (d, 1H, J = 7.8 Hz), 7.02 
(s, 1H), 6.95 (d, 1H, J = 7.8 Hz), 3.22 (s, 1H), 2.42 (s, 3H), 2.32 (s, 3H).  13C NMR 
(CDCl3, 151 MHz) δ 140.7, 139.0, 132.6, 130.4, 126.5, 119.0, 82.9, 80.3, 21.6, 20.6.  
HRMS (ESI) m/z calculated 131.08608 (C10H11, [M+H]




1-ethynyl-4-methoxybenzene (3-2f).  Prepared using general alkyne 
method from 4-iodoanisole.  Purified by silica chromatography using 
gradient elution of hexanes and ethyl acetate to yield a yellow oil in 
65% yield. 1H NMR (CDCl3, 500 MHz) δ 7.43 (d, 2H, J = 7 Hz), 6.85 (d, 2H, J = 7 Hz), 
3.82 (s, 3H), 2.99 (s, 1H).  13C NMR (CDCl3, 125 MHz) δ 160.1, 133.7, 114.3, 114.1, 
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83.8, 75.9, 55.4.  HRMS (ESI) m/z calculated 133.06534 (C9H9O, [M+H]
+), m/z 
observed 133.06486.  (C9H9O, [M+H]
+). 
 
methyl 4-ethynylbenzoate (3-2g).  Prepared using general alkyne 
method from methyl-4-iodobenzoate.  Purified by silica column 
chromatography using gradient elution of hexanes and ethyl acetate 
to yield an off-white solid in 91% yield. 1H NMR (CDCl3, 600 MHz) δ 8.00 (d, 2H, J = 8.4 
Hz), 7.55 (d, 2H, J = 8.4 Hz), 3.92 (s, 3H), 3.23, (s, 1H).  13C NMR (CDCl3, 151 MHz) δ 
166.6, 132.2, 130.3, 129.6, 126.9, 82.9, 80.2, 52.4.  HRMS (ESI) m/z calculated 
161.06025 (C10H9O2, [M+H]
+), m/z observed 161.05971.  (C10H9O2, [M+H]
+).  
 
methyl 2-ethynylbenzoate (3-2h).  Prepared using general alkyne method 
from methyl-2-iodobenzoate.  Purified by silica column chromatography 
using gradient elution of hexanes and ethyl acetate to yield an orange oil in 
88% yield. 1H NMR (CDCl3, 600 MHz) δ 7.94 (dd, 1H, J = 7.8, 1.2 Hz), 7.63 (dd, 1H, J = 
7.8, 1.2 Hz), 7.48 (td, 1H, J = 7.8, 1.2 Hz), 7.41 (td, 1H, J = 7.8, 1.2 Hz), 3.94 (s, 3H), 
3.40 (s, 1H).  13C NMR (CDCl3, 151 MHz) δ 166.6, 135.1, 132.6, 131.9, 130.4, 128.6, 
122.8, 82.4, 82.2, 52.3.  HRMS (ESI) m/z calculated 161.06025 (C10H9O2, [M+H]
+), m/z 
observed 161.06039.  (C10H9O2, [M+H]
+). 
 
General Triazole Method A:  Azide (1 mmol), alkyne (1 mmol), and triethylamine (1 
mmol) were dissolved in acetonitrile (5 mL).  (1) (10 μmol) and tetrakis(acetonitrile-
N)copper(I) tetrafluoroborate (10 μmol) were added to the reaction solution and stirred 
at room temperature for 18 hours.  Concentration in vacuo and purification yielded 
desired 1,2,3-triazole product. 
 
General Triazole Method B:  Azide (1 mmol), alkyne (1 mmol), and triethylamine (1 
mmol) were dissolved in dichloromethane (5 mL).  (1) (10 μmol) and copper(II) 
tetrafluoroborate hexahydrate (10 μmol) were added to the reaction solution and stirred 
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at room temperature for 18 hours.  Concentration in vacuo and purification yielded 
desired 1,2,3-triazole product. 
 
General Triazole Method C:  Azide (1 mmol), alkyne (1 mmol), and triethylamine (1 
mmol) were dissolved in dichloroethane (5 mL).  (1) (10 μmol) and copper(II) 
tetrafluoroborate hexahydrate (10 μmol) were added to the reaction solution and stirred 
at room temperature for 1 hour.  Reaction mixture was poured directly onto silica and 
purification yielded desired 1,2,3-triazole product. 
 
1-benzyl-4-phenyl-1H-1,2,3-triazole (3-3a).  Prepared using 
general triazole method C. Purified by silica column 
chromatography using gradient elution of hexanes and ethyl acetate as a white solid in 
97% yield.  1H NMR (CDCl3, 600 MHz) δ 7.80 (d, 2H, J = 8.4 Hz), 7.66 (s, 1H), 7.41-
7.37 (m, 5H), 7.32-7.31 (m, 3H), 5.58 (s, 2H).  13C NMR (CDCl3, 151 MHz) δ 148.4, 
134.8, 130.7, 129.3, 128.9, 128.3, 128.2, 125.8, 119.6, 54.4.  HRMS (ESI) m/z 
calculated 236.11877 (C15H14N3, [M+H]
+), m/z observed 236.11898  (C15H14N3, [M+H]
+). 
 
1,4-diphenyl-1H-1,2,3-triazole (3-3b).  Prepared using general 
triazole method A.  Precipitated from 5% nitric acid as a brown 
solid in 95% yield.  1H NMR (CDCl3, 600 MHz) δ 8.20 (s, 1H), 
7.93 (d, 2H, J = 6.6 Hz), 7.81 (d, 2H, J = 7.8 Hz), 7.55 (t, 2H, J = 7.8 Hz), 7.48-7.46 (m, 
3H), 7.38 (t, 1H, J = 7.8 Hz).  13C NMR (CDCl3, 151 MHz) δ 148.6, 137.2, 130.4, 129.9, 
129.1, 128.9, 128.6, 126.0, 120.7, 117.7 .  HRMS (ESI) m/z calculated 222.10312 
(C14H12N3, [M+H]
+), m/z observed 222.10280 (C14H12N3, [M+H]
+). 
 
1-(4-methoxyphenyl)-4-phenyl-1H-1,2,3-triazole (3-3c).  
Prepared using general triazole method A.  Precipitated 
from 5% nitric acid as a brown solid in 83% yield.  1H NMR 
(CDCl3, 600 MHz) δ 8.11 (s, 1H), 7.91 (d, 2H, J = 7.2 Hz), 7.69 (d, 2H, J = 7.8 Hz), 7.46 
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(t, 2H, J = 7.2 Hz), 7.37 (t, 1H, J = 7.2 Hz), 7.05 (d, 2H, J = 7.8 Hz) 3.88 (s, 3H).  13C 
NMR (CDCl3, 151 MHz) δ 160.0, 148.4, 130.7, 130.5, 129.0, 128.5, 126.0, 122.3, 118.0, 
115.0, 55.8.  HRMS (ESI) m/z calculated 252.11369 (C15H14N3O, [M+H]
+), m/z observed 




3d).  Prepared using general triazole method A.  
Precipitated from 5% nitric acid as a yellow solid in 91% 
yield.  1H NMR (d6-DMSO, 600 MHz) δ 9.46 (s, 1H), 8.21 
(d, 2H, J = 9 Hz), 8.15 (d, 2H, J = 8.4 Hz), 7.97 (d, 2H, J = 7.8 Hz), 7.52 (t, 2H, J = 7.8 
Hz), 7.41 (t, 1H, J = 7.8 Hz), 3.91 (s, 1H).  13C NMR (d6-DMSO, 151 MHz) δ 165.4, 
147.6, 139.8, 131.1, 130.0, 129.4, 129.1, 128.4, 125.4, 119.8, 119.7, 52.4.  HRMS (ESI) 
m/z calculated 280.10860 (C16H14N3O2, [M+H]
+), m/z observed 280.10883 (C16H14N3O2, 
[M+H]+). 
 
1-(2,4-dimethylphenyl)-4-phenyl-1H-1,2,3-triazole (3-3e).  
Prepared using general triazole method A.  Purified by silica 
column chromatography using gradient elution of hexanes and 
ethyl acetate as a white solid in 90% yield.  1H NMR (CDCl3, 600 MHz) δ 7.92 (d, 3H, J 
= 9 Hz), 7.46 (t, 2H, J = 7.8 Hz), 7.36 (t, 1H, J = 7.2 Hz) 7.27 (d, 1H, J = 7.8 Hz), 7.20 
(s, 1H), 7.15 (d, 1H, J = 7.8 Hz), 2.41 (s, 3H), 2.23 (s, 3H).  13C NMR (CDCl3, 151 MHz) 
δ 147.6, 140.1, 134.3, 133.6, 132.2, 130.6, 129.0, 128.4, 127.6, 125.92, 125.91, 121.3, 
21.3, 18.0.  HRMS (ESI) m/z calculated 250.13442 (C16H16N3, [M+H]
+), m/z observed 
250.13462  (C16H16N3, [M+H]
+). 
 
1-(2,6-dimethylphenyl)-4-phenyl-1H-1,2,3-triazole (3-3f).  
Prepared using general triazole method A.  Purified by silica 
column chromatography using a gradient elution of hexanes and 
ethyl acetate as a white solid in 83% yield.  1H NMR (CDCl3, 600 MHz) δ 7.94 (d, 2H, J 
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= 8.4 Hz), 7.87 (s, 1H), 7.47 (t, 2H, J = 7.2 Hz), 7.37 (t, 1H, J = 7.8 Hz), 7.34 (t, 1H, J = 
7.2 Hz), 7.21 (d, 2H, J = 7.8 Hz), 2.07 (s, 6H).  13C NMR (CDCl3, 151 MHz) δ 147.8, 
136.1, 135.6, 130.6, 130.2, 129.1, 128.6, 128.5, 125.9, 121.4, 17.6.  HRMS (ESI) m/z 
calculated 250.13442 (C16H16N3, [M+H]
+), m/z observed 250.13497  (C16H16N3, [M+H]
+). 
 
1-heptyl-4-phenyl-1H-1,2,3-triazole (3-3g).  Prepared 
using general triazole method A.  Purified by silica 
column chromatography using gradient elution of hexanes and ethyl acetate as a white 
solid in 88% yield.  1H NMR (CDCl3, 600 MHz) δ 7.84 (d, 2H, J = 7.8 Hz), 7.74 (s, 1H), 
7.42 (t, 2H, J = 7.8 Hz), 7.33 (t, 1H, J = 7.8 Hz), 4.39 (t, 2H, J = 7.2 Hz), 1.97-1.92 (m, 
2H,), 1.35-1.27 (m, 8H), 0.88 (t, 3H, J = 7.2 Hz).  13C NMR (CDCl3, 151 MHz) δ 147.9, 
130.9, 128.9, 128.2, 125.8, 119.5, 50.6, 31.7, 30.5, 28.8, 26.6, 22.7, 14.2.  HRMS (ESI) 
m/z calculated 244.18137 (C15H22N3, [M+H]
+), m/z observed 244.18152  (C15H22N3, 
[M+H]+). 
 
1-(heptan-2-yl)-4-phenyl-1H-1,2,3-triazole (3-3h).  
Prepared using general triazole method A.  Purified by 
silica column chromatography using gradient elution of 
hexanes and ethyl acetate as a white solid in 80% yield.  1H NMR (CDCl3, 600 MHz) δ 
7.85 (d, 2H, J = 7.8 Hz), 7.74 (s, 1H), 7.42 (t, 2H, J = 7.8 Hz), 7.32 (t, 1H, J = 7.2 Hz), 
4.74-4.68 (m, 1H), 1.97-1.92 (m, 1H), 1.86-1.82 (m, 1H), 1.60 (d, 3H, J = 6.6 Hz), 1.28-
1.18 (m, 6H), 0.86 (t, 3H, J = 6.6 Hz).  13C NMR (CDCl3, 151 MHz) δ 147.7, 131.0, 
128.9, 128.1, 125.8, 117.4, 57.7, 37.4, 31.5, 25.8, 22.6, 21.6, 14.1.  HRMS (ESI) m/z 
calculated 244.18137 (C15H22N3, [M+H]
+), m/z observed 244.18197  (C15H22N3, [M+H]
+). 
 
 2-((4-phenyl-1H-1,2,3-triazol-1-yl)methyl)pyridine (3-3i). 
Prepared using general triazole method C. Purified by silica 
column chromatograph using gradient elution of hexanes and ethyl acetate and isolated 
as white solid in 88% yield. 1H NMR (CDCl3, 500 MHz) δ 8.62 (d, 1H, J = 5.0 Hz), 7.94 
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(s, 1H), 7.83 (d, 2H, J = 7.5 Hz), 7.70 (t, 1H, J = 7.5 Hz), 7.41 (t, 2H, J= 8.0 Hz), 7.32 (t, 
1H, J= 7.0 Hz) 7.23 – 7.29 (m, 2H), 5.71 (s, 2H).  13C NMR (CDCl3, 125 MHz) δ 154.7, 
149.9, 148.4, 137.6, 130.7, 129,0, 128.3, 125.9, 123.6, 122.6, 120.3, 55.9.  HRMS (ESI) 
m/z calculated 237.11402 (C14H13N4, [M+H]




1-(adamantan-1-yl)-4-phenyl-1H-1,2,3-triazole (3-3j).  Prepared 
using general triazole method A.  Purified by silica column 
chromatography using gradient elution of hexanes and ethyl 
acetate as a white solid in 5% yield.  1H NMR (CDCl3, 600 MHz) δ 7.85-7.82 (m, 3H), 
7.41 (t, 2H, J = 6.0 Hz), 7.31 (t, 1H, J = 6.0 Hz), 2.30 (s, 9 H), 1.82 (s, 6 H).  13C NMR 
(CDCl3, 151 MHz) δ 146.9, 131.3, 128.9, 128.0, 125.8, 116.1, 59.7, 43.2, 36.1, 29.6.  
HRMS (ESI) m/z calculated 280.18137 (C10H20N3O, [M+H]




 (1-benzyl-1H-1,2,3-triazol-4-yl)methanol (3-3l) Prepared using 
general triazole method A.  Purified by silica column 
chromatography using gradient elution of ethyl acetate and methanol to yield a white 
solid in 76% yield. 1H NMR (CDCl3, 600 MHz) δ 7.44 (s, 1H), 7.37 (m, 3H), 7.27 (d, 2H, 
J = 9 Hz), 5.51 (s, 2H), 4.76 (s, 2H), 2.49 (s, 1H).  13C NMR (CDCl3, 151 MHz) δ 148.2, 
134.6, 128.3, 129.0, 128.3, 121.7, 56.7, 54.4.  HRMS (ESI) m/z calculated 190.09804 
(C10H12N3O, [M+H]
+), m/z observed 190.09876. (C10H12N3O, [M+H]
+). 
 
2-(1-benzyl-1H-1,2,3-triazol-4-yl)propan-2-ol (3-3m) Prepared 
using general triazole method A.  Purified by silica column 
chromatography using gradient elution of hexanes and ethyl 
acetate to yield a white solid in 80.0% yield. 1H NMR (CDCl3, 600 MHz) δ 7.39-7.36 (m, 
3H), 7.34 (s, 1H), 7.28 (d, 2H, J = 7.2 Hz), 5.50 (s, 2H), 2.41 (s, 1H), 1.61 (s, 6H).  13C 
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NMR (CDCl3, 151 MHz) δ 156.1, 134.7, 129.3, 128.9, 128.3, 119.0, 68.7, 54.3, 30.6.  
HRMS (ESI) m/z calculated 218.12934 (C12H16N3O, [M+H]





Prepared using general triazole method A.  Purified by silica 
column chromatography using gradient elution of hexanes and 
ethyl acetate to yield a white solid in 79% yield. 1H NMR (CDCl3, 600 MHz) δ 7.37 (d, 
3H, J = 9 Hz), 7.34 (s, 1H), 7.27 (d, 2H, J = 9 Hz), 5.50 (s, 2H), 2.24 (s, 1H), 1.94 (t, 2H, 
J = 10.8 Hz), 1.85 (d, 2H, J = 13.2 Hz), 1.69-1.75 (m, 2H), 1.59-1.65 (m, 1H), 1.53-1.55 
(m, 2H), 1.31-1.37 (m, 1H).  13C NMR (CDCl3, 151 MHz) δ 156.2, 134.8, 129.3, 128.9, 
128.3, 119.5, 69.8, 54.3, 38.3, 25.5, 22.1.  HRMS (ESI) m/z calculated 258.16064 
(C15H20N3O, [M+H]




Prepared using general triazole method A.  Purified by silica 
column chromatography using gradient elution with hexanes 
and ethyl acetate to yield a white solid in 68.4% yield.  1H NMR (CDCl3, 600 MHz) δ 
7.63 (d, 1H, J = 7.8 Hz), 7.52 (s, 1H), 7.36-7.40 (m, 3H), 7.31 (d, 2H, J = 7.8 Hz), 7.1 
(m, 2H),  5.60 (s, 2H), 2.39 (s, 3H), 2.34 (s, 3H).  13C NMR (CDCl3, 151 MHz) δ 147.8, 
135.4, 135.0, 131.7, 129.3, 128.9, 128.8, 128.1, 127.2, 126.9, 121.5, 54.3, 21.4, 21.3.  
HRMS (ESI) m/z calculated 264.15007 (C17H18N3, [M+H]





Prepared using general triazole method B.  Purified by 
silica column chromatography using gradient elution of hexanes and ethyl acetate to 
yield a white solid in 87% yield. 1H NMR (CDCl3, 600 MHz) δ 7.72 (d, 2H, J = 8.4 Hz), 
7.57 (s, 1H), 7.35-7.41 (m, 3H), 7.30-7.32 (m, 2H), 6.93 (d, 2H, J = 9 Hz), 5.57 (s, 2H), 
107 
 
3.83 (s, 3H).  13C NMR (CDCl3, 151 MHz) δ 159.7, 148.3, 134.9, 129.3, 128.9, 128.2, 
127.2, 123,4, 118.8, 114.3, 55.5, 54.4.  HRMS (ESI) m/z calculated 266.12934 
(C16H16N3O, [M+H]
+), m/z observed 266.13042. (C16H16N3O, [M+H]
+). 
 
methyl 4-(1-benzyl-1H-1,2,3-triazol-4-yl) benzoate (3-
3q)  Prepared using general triazole method B.  Purified 
by silica column chromatography using gradient elution of hexanes and ethyl acetate to 
yield a white solid in 86% yield. 1H NMR (CDCl3, 600 MHz) δ 8.07 (d, 2H, J = 8.4 Hz), 
7.88 (d, 2H, J = 8.4 Hz), 7.74 (s, 1H), 7.36-7.42 (m, 3H), 7.32-7.33 (m, 2H), 5.59 (s, 2H), 
3.92 (s, 3H).  13C NMR (CDCl3, 151 MHz) δ 166.9, 147.3, 135.0, 134.6, 130.3, 129.7, 
129.4, 129.1, 128.3, 125.6, 120.5, 54.5, 52.3.  HRMS (ESI) m/z calculated 294.12425 
(C17H16N3O2, [M+H]
+), m/z observed 294.12490. (C17H16N3O2, [M+H]
+). 
 
methyl 2-(1-benzyl-1H-1,2,3-triazol-4-yl)benzoate (3-3r)  
Prepared using general triazole method B.  Purified by silica 
column chromatography using gradient elution of hexanes and 
ethyl acetate to yield an off-white solid in 89% yield. 1H NMR (CDCl3, 600 MHz) δ 7.81 
(d, 1H, J = 7.8 Hz), 7.77 (d, 1H, J = 7.8 Hz), 7.72 (s, 1H), 7.54 (td, 1H, J = 7.8, 1.2 Hz), 
7.35-7.41 (m, 4H), 7.31-7.32 (m, 2H), 5.59 (s, 2H), 3.72 (s, 3H).  13C NMR (CDCl3, 151 
MHz) δ 168.9, 146.3, 135.0, 131.6, 130.5, 130.4, 130.3, 129.3, 128.9, 128.2, 122.7, 
54.3, 52.3.  HRMS (ESI) m/z calculated 294.12425 (C17H16N3O2, [M+H]




  2-(1-benzyl-1H-1,2,3-triazol-4-yl)pyridine (3-3s). Prepared 
using general triazole method C. Purified by silica column 
chromatography using gradient elution of hexanes and ethyl acetate to yield a white 
solid in 92% yield.  1H NMR (CDCl3, 500 MHz) δ 8.45 (d, 1H, J = 4.0 Hz), 8.18 (d, 1H, J 
= 8.0 Hz), 8,04 (s, 1H), 7.77 (tt, 1H, J = 8.0, 2.0 Hz), 7.30-7.40 (m, 5H), 7.21 (t, 1H, J = 
6.5 Hz), 5.58 (s, 2H).  13C NMR (CDCl3, 125 MHz) δ 150.4, 149.5, 148.9, 137.0, 134.5, 
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129.3, 123.0, 122.0, 120.4, 54.6.  HRMS (ESI) m/z calculated 237.11402. (C14H13N4, 
[M+H]+), m/z observed 237.11410. (C14H13N4, [M+H]
+). 
 
1-benzyl-4-octyl-1H-1,2,3-triazole (3-3t). Prepared 
using general triazole method C. Purified by silica 
column chromatography using gradient elution of hexanes and ethyl acetate to yield a 
white solid in 23% yield. 1H NMR (CDCl3, 500 MHz) δ 7.34 – 7.39 (m, 2H), 7.24 – 7.26 
(m, 3H), 7.17 (s, 1H), 5.49 (s, 2H), 2.68 (t, 2H, J = 8.0 Hz), 1.63 (q, 2H, 7.5 Hz), 1.2 – 
1.4 (m, 10H), 0.869 (t, 3H, J = 7.0 Hz).  13C NMR (CDCl3, 125 MHz) δ149.2, 135.2, 
129.2, 128.7, 128.1, 120.6, 105.2, 54.1, 32.0, 29.6, 29.4, 29.3, 25.9, 22.8, 14.2.  HRMS 
(ESI) m/z calculated 272.21267 (C17H26N3, [M+H]





Prepared using general triazole method C. Purified by 
silica column chromatography using gradient elution of hexanes and ethyl acetate to 
yield a white solid in 95% yield.  1H NMR (CDCl3, 500 MHz) δ 7.91 (d, 2H, J = 9.0 Hz), 
7.74 (s, 1H), 7.69 (d, 2H, J = 8.5 Hz), 7.37 – 7.43 (m, 3H), 7.31 – 7.34 (m, 2H), 5.60 (s, 
2H).  13C NMR (CDCl3, 125 MHz) δ 146.5, 135.1, 134.4, 132.8, 129.4, 129.2, 128.3, 
126.2, 120.7, 118.9, 111.7, 54.6.  HRMS (ESI) m/z calculated 261.11402 (C16H13N4, 




4).  Isolated as by-product when using general triazole method 
A.  Purified by silica column chromatography using gradient 
elution of hexanes and ethyl acetate to yield a white solid in 3% 
yield. 1H NMR (CDCl3, 600 MHz) δ 7.42–7.46 (m, 4H), 7.22–7.25 (m, 2H), 7.18–7.22 
(m, 4H), 7.11–7.16 (m, 2H), 7.08 (t, 4H, J = 7.2 Hz), 6.80 (d, 4H, J = 7.2 Hz), 4.69 (d, 
2H, J = 15 Hz), 4.62 (d, 2H, J = 15 Hz). 13C NMR (CDCl3, 151 MHz) δ 148.0, 133.1, 
129.4, 129.1, 129.0, 128.92, 128.86, 128.3, 126.0, 120.0, 52.8. HRMS (ESI) m/z 
calculated 469.21407 (C30H25N6, [M+H]




5-bromopicolinohydrazonamide (3-26).  To a stirring suspension 
of 3-25 (1.0 g, 5.5 mmol) in 5 mL of EtOH was added hydrazine 
hydrate (0.584 mL, 7.7 mmol).  The suspension was stirred at room 
temperature for 72 h and progress of the reaction was monitored by TLC.  The pale 
yellow precipitate was then filtered and washed with Et2O in 79% yield.  
1H NMR 
(CDCl3, 600 MHz) δ 8.57 (s, 1H), 7.91 (dd, 1H, J = 8.4, 2.4 Hz), 7.81 (dt, 1H, J = 9.0, 
2.4 Hz), 5.16 (bs, 1H), 4.60 (bs, 1H).  13C NMR (CDCl3, 151 MHz) δ 149.6, 149.0, 
147.9, 139.2, 121.14, 121.08.  HRMS (ESI) m/z calculated 214.99323 (C6H8BrN4, 
[M+H]+), m/z observed 214.99251 (C6H8BrN4, [M+H]
+). 
 
3-(5-bromopyridin-2-yl)-5,6-diphenyl-1,2,4-triazine (3-27).  
3-26 (800 mg, 3.72 mmol) and benzil (782 mg, 3.72) were 
added to 15 mL of EtOH.  The slurry was heated overnight at 
80°C with complete dissolution.  Progress of the reaction was 
monitored by TLC.  The reaction mixture was cooled to room temperature and the 
resulting precipitate was filtered and washed with EtOH and Et2O resulting in a 91% 
yield.  1H NMR (CDCl3, 600 MHz) δ 8.97 (s, 1H), 8.62 (dd, 1H, J = 9.0,1.8 Hz), 8.07 (dt, 
1H, J = 8.4, 3.0 Hz), 7.67 (d, 2H, J = 6.6 Hz), 7.64 (d, 2H, J = 7.2 Hz), 7.47-7.44 (m, 
2H), 7.41-7.36 (m, 4H).  13C NMR (CDCl3, 151 MHz) δ 160.4, 156.8, 156.6, 151.8, 
151.5, 139.9, 135.6, 135.3, 131.0, 130.1, 130.0, 129.7, 128.81, 128.79, 125.4, 123.6.  
MS (ESI) m/z calculated 389.04018 (C20H14BrN4, [M+H]




3-(5-ethynylpyridin-2-yl)-5,6-diphenyl-1,2,4-triazine (4-16).  
4-15 (1.0 g, 2.57 mmol), 
dichlorobis(triphenylphosphine)palladium(II) (90 mg, 0.13 
mmol), copper iodide (24 mg, 0.13 mmol), and anhydrous 
THF (13 mL) were combined and placed under nitrogen.  
Triethylamine (780 mg, 7.71 mmol) and ethynyltrimethylsilane (757 mg, 7.71 mmol) 
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were added and the reaction was heated overnight at 80°C.  Reaction progress was 
monitored by TLC.  After concentration in vacuo, the crude intermediate was purified by 
silica gel chromatography with gradient elution using EtOAc and hexanes.  The 
intermediate was then dissolved in 8 mL of EtOH, 4 mL of MeOH, and 4 mL DCM.  
Potassium carbonate (0.1 eq) was added the reaction was allowed to stir overnight at 
room temperature with reaction progress monitored by TLC.  Upon completion, the 
reaction was concentrated in vacuo and purified by silica gel chromatography with 
gradient elution using EtOAc and hexanes to yield a yellow solid in 62% yield.  1H NMR 
(CDCl3, 600 MHz) δ 9.00 (s, 1H), 8.70 (d, 1H, J = 8.4 Hz), 8.01 (dd, 1H, J = 8.4, 1.8 Hz), 
7.67 (d, 2H, J = 7.2 Hz), 7.63 (d,  2H, J = 7.2 Hz), 7.47-7.44 (m, 2H), 7.41-7.36 (m, 4H), 
3.38 (s, 1H).  13C NMR (CDCl3, 151 MHz) δ 160.4, 156.7, 156.6, 153.5, 152.2, 140.3, 
135.7, 135.3, 131.0, 130.1, 130.0, 129.8, 128.80, 128.78, 123.5, 121.2, 82.8, 80.5.  MS 
(ESI) m/z calculated 335.12967 (C22H15N4, [M+H]
+), m/z observed 335.12451 
(C22H15N4, [M+H]
+).   
 
2-(4-bromophenyl)-2-oxoacetaldehyde (3-30).  Selenium dioxide 
(1.67 g, 15 mmol) was suspended in dioxane (7.5 mL) and water (0.36 
mL) and heated at 55°C until mostly dissolved.  1-(4-
bromophenyl)ethanone (3 g, 15.0 mmol) was then added and the reaction was refluxed 
for 3 h.  After cooling to room temperature, the reaction was filtered and the filtrate was 
concentrated in vacuo.  The crude product was used in further reactions.  MS (ESI) m/z 
calculated 212.95512 (C8H6BrO2, [M+H]
+), m/z observed 212.986 (C8H6BrO2, [M+H]
+). 
 
5-(4-bromophenyl)-3-(pyridin-2-yl)-1,2,4-triazine (3-31).  3-
30 (782 mg, 3.7 mmol) and picolinohydrazonamide (500 mg, 
3.7 mmol) were added to 14 mL of EtOH.  The slurry was 
heated overnight at 80°C with complete dissolution.  Progress of the reaction was 
monitored by TLC.  The reaction mixture was cooled to room temperature and the 
resulting precipitate was filtered and washed with EtOH resulting in a 46% yield.  1H 
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NMR (CDCl3, 600 MHz) δ 9.70 (s, 1H), 8.94 (d, 1H, J = 4.2 Hz), 8.68 (d, 1H, J = 7.8 Hz), 
8.20 (d, 2H, J = 7.8 Hz), 7.96 (t, 1H, J = 7.8 Hz), 7.75 (d, 2H, J = 6.6 Hz), 7.51 (t, 1H, J 
= 6.0 Hz).  13C NMR (CDCl3, 151 MHz) δ 132.6, 132.48, 132.45, 132.1, 131.7, 131.5, 
131.2, 130.2, 88.9, 87.5.  MS (ESI) m/z calculated 313.00888 (C14H10BrN4, [M+H]
+), m/z 
observed 313.00791 (C14H10BrN4, [M+H]
+). 
 
5-(4-ethynylphenyl)-3-(pyridin-2-yl)-1,2,4-triazine (3-32).  
3-31 (594 mg, 1.9 mmol), 
dichlorobis(triphenylphosphine)palladium(II) (67 mg, 0.1 
mmol), copper iodide (18 mg, 0.1 mmol), and anhydrous THF 
(7.5 mL) were combined and placed under nitrogen.  Triethylamine (577 mg, 5.7 mmol) 
and ethynyltrimethylsilane (560 mg, 5.7 mmol) were added and the reaction refluxed 
overnight.  Reaction progress was monitored by TLC.  After concentration in vacuo, the 
crude intermediate was purified by silica gel chromatography with gradient elution using 
EtOAc and hexanes.  The intermediate was then dissolved in a 0.5 M alcohol solution (2 
EtOH : 1 MeOH) and 0.1 eq of potassium carbonate was added.  The reaction was 
allowed to stir at room temperature and reaction progress was monitored by TLC.  Upon 
completion, the reaction was concentrated in vacuo and purified by silica gel 
chromatography with gradient elution using EtOAc and hexanes to yield a pale brown 
solid in 44% yield.  1H NMR (CDCl3, 600 MHz) δ 9.72 (s, 1H), 8.95 (d, 1H, J = 4.8 Hz), 
8.69 (d, 1H, J = 7.8 Hz), 8.30 (d, 2H, J = 8.4 Hz), 7.96 (dt, 1H, J = 7.8, 1.8 Hz), 7.71 (d, 
2H, J = 8.4 Hz), 7.52–7.50 (m, 1H), 3.3 (s, 1H).  13C NMR (CDCl3, 151 MHz) δ 163.0, 
155.1, 153.1, 150.7, 145.3, 137.3, 133.7, 133.2, 127.9, 126.8, 125.9, 124.4, 82.9, 80.8.   
HRMS (ESI) m/z calculated 259.09837 (C16H11N4, [M+H]




General 1,2,4-Triazine-Accelerated Sonogashira Reaction.  Iodobenzene (0.10 
mmol), phenylacetylene (0.10 mmol), and triethylamine (0.10 mmol) were added to the 
triazine ligand (variable) and palladium source (variable) at 0.4 M, with respect to 
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substrates, in solvent.  Reactions were heated 5.5 hours at 60°C, cooled to room 
temperature, and analyzed by HPLC using a C18 column with an isocratic mobile phase 
of 80% acetonitrile.  Percent yields were determined using an external calibration curve. 
 
Polystyrene-Supported Azide Method.  Merrifield resin (14 mmol), sodium azide (42 
mmol), tetrabutylammonium iodide (14 mmol) were added to 60 mL of NMP and 10 mL 
of water.  Reaction was heated at 80°C overnight.  After cooling to room temperature, 
the resin was filtered, washed with NMP, water, DCM, MeOH, and Et2O, and air dried. 
 
Heterogeneous CuAAC Method A.  A solution of phenylacetylene (1.07 mmol), 
triethylamine (1.07 mmol), 2-17 (9.72 μmol), and tetrakis(acetonitrile-N)copper(I) 
tetrafluoroborate (9.72 μmol) dissolved in 1 mL of ACN and 4 mL of DCE was added to 
the supported azide (0.972 mmol).  Reaction was heated at 60°C for 4 h.  After cooling 
to room temperature, the support was filtered and washed with DCE, water, MeOH, and 
Et2O and air dried.   
 
Heterogeneous CuAAC Method B.  The corresponding alkyne-substituted 1,2,4-
triazine (2.38 mmol), triethylamine (2.38 mmol), 2-17 (22.0 μmol), and 
tetrakis(acetonitrile-N)copper(I) tetrafluoroborate (22.0 μmol) were dissolved in 4.4 mL 
of ACN and 8.8 mL of DCE and added to the supported azide (2.16 mmol).  Reaction 
was heated at 60°C for 18 h.  After cooling to room temperature, an aliquot of the 
reaction solution was appropriately diluted and analyzed by HPLC to determine loading 
of the 1,2,4-triazine.  The support was then filtered, washed with DCE, water, MeOH, 
and Et2O and air dried.   
 
Heterogeneous CuAAC Method C.  A solution of 2-ethynyl pyridine (1.07 mmol), 
triethylamine (1.07 mmol), 2-17 (9.72 μmol), copper(II)tetrafluoroborate (9.72 μmol) 
dissolved in 1 mL of ACN and 4 mL of DCE was added to the supported azide (0.972 
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mmol).  Reaction was heated at 60°C for 4 h.  After cooling to room temperature, the 
support was filtered and washed with DCE, water, MeOH, and Et2O and air dried.   
 
Polystyrene-Supported Complexation Method.  A 10 mM stock solution of the 
corresponding copper source in 1:1 ACN:DCE was prepared.  Copper (0.0594 mmol) 
was added to the resin (0.054 mmol) and heated at 60°C for 2 h.  An equivalent volume 
of copper stock solution was concentrated and analyzed by ICP-OES as a control.  After 
cooling to room temperature, the resin was filtered, washed with ACN, DCM, MeOH, 
and Et2O and air dried.  The filtrate was concentrated in vacuo, analyzed by ICP-OES, 
and compared to the ICP-OES value of the aforementioned control solution. 
 
Silica-Supported Complexation Method.  A 10 mM stock solution of the 
corresponding copper source in ACN was prepared.  Copper (0.0226 mmol) was added 
to the silica (0.0205 mmol) and heated at 60°C for 2 h.  An equivalent volume of copper 
stock solution was concentrated and analyzed by ICP-OES as a control.  After cooling 
to room temperature, the silica was filtered, washed with ACN, DCM, MeOH, and Et2O 
and air dried.  The filtrate was concentrated in vacuo, analyzed by ICP-OES, and 
compared to the ICP-OES value of the aforementioned control solution. 
 
ICP-OES Methodology.  The filtrate recovered from complexation reactions was 
redissolved in 2% nitric acid and 1% MeOH to a final concentration of 75 ppm copper 
(assuming all copper from the reaction was still present).  Samples from the initial 10 
mM copper stock solutions were treated in the same manner.  All samples were heated 
at 60°C for 10 min and left undisturbed at room temperature overnight to ensure all 
copper was dissolved.  Quantification of copper was determined using an external 




General Heterogeneous 1,2,4-Triazine-Accelerated CuAAC Reaction.  Benzyl azide 
(0.25 mmol), phenylacetylene (0.25 mmol), and triethylamine (0.25 mmol) were added 
to the heterogeneous catalyst (1 mol% copper) at 0.2 M, with respect to substrates, in 
acetonitrile.  Reactions were heated at 60°C for 4 h, cooled to room temperature, and 
filtered to remove catalyst.  The filtrate was concentrated in vacuo to yield 1,2,3-triazole 
as a white solid.   
 
Recyclability of Heterogeneous Catalysts.  After CuAAC reaction was complete and 
filtered, the catalyst was rinsed with dichloromethane, methanol, and ether.  Catalyst 
was air dried and reused without additional treatment. 
 
Copper Retention of Heterogeneous Catalysts.  A solution of 2% HNO3 (4 mL) and 
MeOH (0.04 mL) were added to isolated 1,2,3-triazole products.  After heating at 60°C 
for approximately 10 min, the suspension was left standing at room temperature 
overnight.  After filtration, the filtrate was analyzed by ICP-OES in order to calculate the 
percent of copper retained by the catalyst.  Copper was quantified using an external 





















Chapter 4.  





4.1. Background and Significance of Histone Deacetylase (HDAC) 
 
Cancer has been a difficult target for researchers, owing to its ability to avoid 
therapeutic strategies, propagate through the body, and circumvent normal cell cycle 
regulatory processes.98 Through years of research much information has been gained 
about causes and effects of cancer, but a cure for all cancer subtypes is still out of 
reach. 
Mutations to healthy cells in which the genetic information is permanently changed is 
one target of cancer therapy. Another is the regulation of non-mutated DNA through 
epigenetic modifications. Epigenetics look at inheritable changes in gene expression 
without altering the coding sequence.99 Epigenetics encompasses a wide range of 
regulating mechanisms, including DNA methylation, post-translational modification of 
histone proteins,99 chromatin remodeling,100 transcription factors,101 and noncoding 
RNA.102  Post-translational modification of histone and non-histone proteins has drawn 
much attention over the past 15 years, specifically with regards to histone deacetylase 
enzymes. Why are histone proteins important and how do chemical modifications effect 
regulation of DNA? 
Histones are chromatin-associated proteins where chromatin is the tightly packaged 
genetic material made of repeating nucleosome units. This condensed package 
regulates transcription, DNA replication and repair, mitosis, and apoptosis.99 Within 
each nucleosome unit is DNA that has been wound around a histone octamer, where 
histones are small basic proteins, containing an abundance of lysine and arginine 
residues (Figure 4.1). The location of the lysine tails is of upmost importance in 
regulating transcription. The lysine side chains extend toward the outer edges of the 
nucleosome, leaving them available for an array of post-translational modifications, 
such as acetylation, methylation, or phosphorylation, to name a few. Histones can be 
either acetylated or deacetylated, in processes controlled by the action of HAT (Histone 
Acetyl Transferase) or HDAC (Histone Deacetylase) enzymes. As the name suggests, 
one is responsible for transferring the acetyl group to the lysine of the histone protein 
and the other removes the acetyl group. The two states control the accessibility of DNA 
and therefore, transcription. 
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In the deacetylated form (Figure 4.1), the lysine residues will be positively charged 
amines at physiological pH. This will lead to an electrostatic interaction with the 
negatively charged phosphates of the DNA backbone. This causes the chromatin to 
condense, leaving it inaccessible to transcription factors. In the acetylated form, the 
lysine residues are now neutral weakening the interaction between DNA and histone. 
The chromatin adopts a relaxed state, allowing space for transcriptional factors, and 
thereby activating transcription. Although the name implies the deacetylase activity only 
occurs at histone proteins, there are at least 50 non-histone substrates which have 
been linked to the HDAC enzyme.103 The equilibrium between these acetylation and 
deacetylation mechanisms is required for the delicate balance of a host of nuclear 
processes. The improper regulation has been implicated in a variety of cancer 
subtypes,104 as well as neurodegenerative diseases,105 and immune disorders.106 
 
 
Figure 4.1 Equilibrium between transcriptional repression and transcriptional activation.  
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Overexpression of HDACs has been found in a variety of cancers. This can lead to 
silencing of guardian proteins and mediate tumor cell proliferation.107 Studies on 
inhibition of HDACs have shown a promising ability to affect processes that have gone 
awry in neoplastic cells, including an ability to induce cell cycle arrest, or induce 
apoptosis by expression of tumor suppressor proteins.107,108 
For this reason, much research has been devoted to development of histone 
deacetylase inhibitors, with end goals as promising pharmaceuticals, especially in the 
fields of anti-cancer agents, neuroprotective agents, or anti-inflammatory agents. The 
first interest in histone deacetylase inhibitors (HDACi) was sparked about 35 years ago 
during research to elucidate why DMSO caused terminal differentiation in 
erythroleukemia cells.109,110 Since that time a number of researchers have developed 
interest in design, synthesis, and studies of histone deacetylase inhibitors. 
In order to target HDACs effectively, it is important to know about their structure and 
physiological relevance. Fortunately, some structural and functional knowledge has 
been determined. Eighteen known HDAC isoforms exist and they are divided between 
four structural categories depending on their sequence similarities and cellular 
locations. Class I, II, and IV are all zinc dependent while Class III is mediated by 
nicotinamide adenine dinucleotide (NAD+) and often referred to as sirtuins. Sirtuins will 
not be focused on for this work. Class I includes HDAC isoforms HDAC-1,-2, -3, and -8, 
and are found within the nucleus of many cell types. Class II is further broken down into 
IIa (HDAC-4,-5,-7,and-9) and IIb (HDAC-6,-10). Class IIa are able to shuttle between 
nuclear and cytoplasmic locations while IIb are primarily located in the cytoplasm. Class 
IIb is unique due to the presence of two active enzyme sites. Class IV consists of 
HDAC-11 and exhibits properties of both Class I and II HDACs. Very little is known 
about this isoform. 
The specific functions of each HDAC are not completely understood, but mammalian 
studies using knockout and transgenic mice, along with siRNA techniques have 
highlighted some key roles for the various isoforms. The information about the various 
HDAC isoforms is highlighted in Table 4.1. 
119 
 
Table 4.1 Features of the various isoforms of HDAC Class I, II and IV.  Modified from 







Physiological role Crystal 
Structure 
HDAC1 nucleus 483 
proliferation, development, gene 
regulation 
0 
HDAC2 nucleus 488 cardiac development, proliferation 1 
HDAC3 nucleus 428 regulation of mitosis 0 






















1011 cardiac development 1 
HDAC6 cytoplasm 1215 
controls status of tubulin, 
microtubules, and HSP90 
0 
HDAC10 cytoplasm 669 NA 0 






Some structural information regarding the zinc-dependent HDACs has become 
available in the past ten years. The first structural insights were gained from the crystal 
structure of a histone deacetylase-like protein (HDLP) complexed with inhibitors and 
isolated from a bacteria species with approximately 35% similarity to human HDAC-1.113 
The first human HDAC structure to be co-crystallized with inhibitors was HDAC-8. From 
the table above, it can be seen that an abundance of HDAC-8 crystal structures have 
been determined while some HDACs such as HDAC-1, HDAC-6, have shown limited 
success in obtaining crystal structures, although structures of bacterial homologues 
exist. The reason for this disproportionality is that most HDACs occur as high molecular 
weight multiprotein complexes, rather than individual monomeric proteins making it 
difficult to obtain a crystal structure of the HDAC protein.111 
From the crystal structure of HDAC-8 and HDLP, some general features of HDAC active 
sites have been inferred. The active site contains a hydrophobic tunnel of 11-14 Å, with 
the exact length varying between isoforms. Contained within this tunnel are residues 
which are conserved across the class I HDACs (Phe152, Phe208, His180, Gly151, and 
Tyr306). The catalytic site lies at the bottom of the tunnel containing a Zn2+ ion 
coordinated to Asp178, His180 and Asp267.114 Tyrosine, histidine, and aspartic acid 
residues within the catalytic site interact with one another, substrate, or inhibitors. The 
proposed interaction between the zinc ion, amino acids, and either the substrate or a 
known inhibitor is shown in Figure 4.2. 
The structural insight gained has been used recently to develop the new inhibitors for 
HDAC activity. This was not always the case in designing inhibitors. Prior to the 
availability of crystal structure evidence, several inhibitors had been designed or 
isolated from natural products. The design of early inhibitors, coupled with the structural 
information known, has allowed researchers to investigate structure-activity 






Figure 4.2 Representation of binding with A) substrate (proposed) and with B) 
hydroxamate inhibitor.  Amino acids are shown in green, substrate, or hydroxamate inhibitor 
in blue, and interactions in red.114 
 
4.2. Histone Deacetylase Inhibitors (HDACi) 
There is a common theme in a large majority of HDAC inhibitors to begin with a 
common scaffold, consisting of a zinc-chelating functional group, linker region to occupy 
the hydrophobic tunnel, and a surface recognition unit, or cap group (Figure 4.3). This 
scaffold mimics the natural substrate, an acetylated lysine residue. The zinc binding 
group can further divide inhibitors into hydroxamic acid and non-hydroxamic acid 
inhibitors. Some non-hydroxamic acid inhibitors include small carboxylic acids, 
benzamides, ketones, cyclic peptides, and depsipeptides. A collection of inhibitors is 
shown in Figure 4.4. A significant amount of the literature and research has focused on 
hydroxamate inhibitors, but an increasing amount of work has surfaced in an attempt to 
determine other zinc binding groups of comparable potency and increased selectivity. 
A comprehensive list of molecules designed and synthesized for HDAC inhibition is 
outside the scope of this work, and has been the focus of other reviews,99,108,111 but a 












Figure 4.4 Selected HDAC inhibitors 
123 
 
Some of the most recognizable inhibitors are SAHA (suberoylanilide hydroxamic acid) 
and TSA (trichostatin A). SAHA is one of many HDAC inhibitors that have entered 
clinical trials. SAHA is unique in that is one of two HDAC inhibitors approved by the FDA 
for treatment of cutaneous T-cell lymphoma (CTCL) with the other being FK-228.115 
SAHA is the standard by which most HDAC inhibitors are compared and has been 
mimicked and modified in efforts to discover potent and selective inhibitors. Typical 
modifications involve changing the linker region, in distance by adding methylene 
groups, in rigidity by adding unsaturation, aromatic groups, or cinnamoyl linkers, or in 
hydrophobicity, by modifying linker substituents. Reviews comparing the activity of the 
various modified structures have been written.111,116 The cap group is also amenable to 
modifications. This area seems to be accepting of the most diversity. It is not restricted 
by size of the tunnel, as the linker region is, allowing extensive substitution. By these 
modifications, the activity of the molecule can be tuned. Although some more potent 
molecules have been discovered, a downfall to this is the decrease in isoform 
selectivity, or off-target toxicity. TSA, a natural product, is a strong nanomolar inhibitor 
that suffers from the drawback of being too potent for multiple isoforms. 
In general, most of the inhibitors thus far have been pan-inhibitors unable to distinguish 
between the multiple isoforms. SAHA and TSA fall into this category. Because of the 
conserved sequence homology between HDAC isoforms, design and synthesis of 
isoform selective inhibitors has been difficult. Some inhibitors have emerged to have a 
slight selectivity for one class over the others. Class specificity is the first target of 
selectivity, and then isoform specificity. FK228 (Figure 4.4), the other FDA approved 
HDACi, is a prodrug depsipeptide that releases an alkyl thiol in vivo by reduction of the 
disulfide bond117 and has shown selectivity for Class I HDACs. MS-275 and other 
related benzamides have also shown promise as Class I selective HDAC inhibitors. The 
selectivity has been a trade-off for potency as the IC50 now resides in the micromolar 
region instead of nanomolar region of hydroxamic acids. With the decreased potency, 
there has also been a decrease in the off-target side effects such as cardiac toxicity.98 
 Tubacin, although not a good drug candidate, (Figure 4.4) was found to be an inhibitor 
of HDAC6 and also led to a linking of HDAC-6 to tubulin deacetylase activity. This 
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paved the way for Tubastatin A to be discovered with a nanomolar inhibition and 1000-
fold selectivity for HDAC6. 
In addition to hydroxamic acids, carboxylic acids such as butyric acid and valproic acids 
were observed to inhibit cancer cell growth and induce apoptosis, but in general 
carboxylic acids were not particularly potent (requiring millimolar concentrations), not 
selective, and had low bioavailability.99 The downfalls to HDAC inhibitors thus far are 
their ineffectiveness against solid tumors. Majority of patients did not respond to 
treatment and side effects were high. Some patients did experience stabilization of their 
disease, so there is opportunity for inhibitors to be used in combination with other 
chemotherapeutic drugs for treatment of solid tumors.  
Some of the keys to overcoming the barriers that have prevented more HDAC inhibitors 
from progression through clinical trials, are targeted therapy and selective delivery.98 
This is of course easier to suggest than it is to carry out. If HDACs could be targeted by 
an inhibitor for a single isoform, the effectiveness should increase and off-target toxicity 
should decrease. Designing tools to selectively deliver these molecules to the location 
of interest is another pathway that should be explored. 
 
4.3. Strategies for Synthesis 
The use of triazoles for biological applications has greatly emerged with the discovery of 
copper-catalyzed azide-alkyne cycloaddition. The field of HDAC inhibitors is no 
exception. As a mimic of SAHA, three independent research groups incorporated a 
triazole in order to increase the affinity in the inhibitor cap region with the HDAC enzyme 
active site. The major goal was to create isoform selectivity, since a major downfall of 
most HDAC inhibitors is a lack of specificity between various HDAC isoforms.  
Researchers at  University of Illinois, Chicago25 reconfigured the cap group of SAHA by 
incorporating a triazole attached to the phenyl group of SAHA. They examined both 1,4 
and 1,5-disubstituted triazoles (Figure 4.3, 4-1) in their efforts to find selective and 
potent HDAC inhibitors. Two additional research groups decided to substitute a 1,2,3-
triazole as an isostere of the amide bond (4-2) in order to increase affinity in the cap 
region of HDAC enzymes.118,119 Both references report similar findings that replacement 
125 
 
of the amide with a triazole led to an increase in the HDAC inhibition. Further 
modifications to the cap group revealed even more potent inhibitors. These compounds 
still contained a hydroxamic acid as the zinc binding group. While hydroxamic acids are 
among the most common zinc binding group used in HDAC inhibitors, they can suffer 
from short clearance in vivo and often lack isoform specificity. There are many other 
zinc metalloenzymes so lack of specificity could lead to adverse side effects. This has 
led researchers to investigate non-hydroxamic zinc binding groups, although finding a 
similar strong affinity group is not an easy task.  
To this end, researchers manipulated an oxazole scaffold, which was shown to have 
HDAC and antitumor activity,120 to incorporate a 1,2,3-triazole (4-3).121 This molecule 
doesn’t have a strict zinc binding functionality. While not screened directly against 
HDAC activity, it did show antiproliferative activity against several cancer cell lines. The 
final inspiration for this work incorporated the triazole into the linker and moved it in 
closer proximity to the hydroxamic acid. While the triazole adjacent to the hydroxamic 
acid was not particularly active, moving the triazole within the linker displayed similar 
activity as SAHA.122 
From the previous work and as a further modification of this scaffold, we decided to 
incorporate a 1,2,3-triazole into the zinc binding domain. By examining electrostatic 
potential maps of hydroxamic acids in relation to the endogenous lysine substrate and 
to 1,2,3-triazoles (Figure 4.6), it was hypothesized that the latter could serve as an 
efficient, stable replacement of the previously known zinc binding group. The nitrogen of 
the triazole could serve as a hydrogen bond acceptor similar to that of the hydroxamic 
acid carbonyl. The alcohol appended to the triazole could serve as a hydrogen bond 
donor or acceptor similar to that of the hydroxamic acid oxygen. Due to the structural 
similarities and increased stability of 1,2,3-triazoles, their incorporation into a histone 











Figure 4.6 Electrostatic potential map comparing 1,2,3-triazoles to hydroxamic acids. 
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4.3.1. Solid Phase Approach 
The original synthetic scheme utilized solid phase organic synthesis. The envisioned 
plan was to construct the HDAC inhibitor beginning with the zinc binding group and 
concluding with the cap group. Three different resins (Figure 4.7) were to be employed:  
Wang resin, Weinreb amide resin, and Fmoc-Hydroxylamine 2-chlorotrityl resin with 
each resulting in a different functional group upon cleavage (alcohol or acids, 
aldehydes, and hydroxamic acids). Various alkynes were chosen to anchor to the solid 
support. Known protocols were chosen to attach propargyl alcohol, homopropargyl 
alcohol, and propionic acid to Wang resin.123 This resulted in terminal alkynes on a solid 
support. Two consecutive CuAAC reactions were then carried out first with a diazide 
and then with an aryl alkyne. This scheme could potentially be rapidly modified with 
various diazides to adjust the linker length between cap group and zinc binding group. 
In addition the aryl alkyne could be easily changed to rapidly assemble a small library of 
compounds. Upon cleavage from the solid support, this would result in terminal alcohols 








Scheme 4.1 Solid phase synthetic scheme for HDAC inhibitors. 
 
In addition, synthesis of a hydroxamic acid substituted triazole was also planned using 
2-chlorotrityl resins and propionic acid. The CuAAC steps would proceed as described 
above to furnish the desired compound. Finally, an aldehyde substituted triazole was 
proposed by using Weinreb amide resin loaded with propionic acid. As a control, a 
traditional hydroxamic acid lacking a 1,2,3-triazole was also envisioned via a solid 
phase route. 
Although some of the solid phase syntheses appeared promising, as confirmed by TLC, 
HPLC, and HRMS, difficulties arose in obtaining a sufficient amount of pure material. 
Products cleaved from the solid support contained trace byproducts that would need to 
be removed either through recrystallization or column chromatography. This did not 
result in enough product material for full characterization and enzyme testing. It was 
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perceived to be a more expensive route to scale up the solid phase approach, and 
therefore, a complementary solution phase approach was designed.  
4.3.2. Solution Phase Approach 
The solution phase approach would utilize many of the same precursors used for the 
solid phase approach, but it would eliminate the loading of propargyl alcohols onto a 
solid support. This method could be readily scaled up and purification performed after 
each step if desired. Although this resulted in a longer synthesis, the solution phase 
route allowed for the synthesis of pure material in a quantity that could be fully 
characterized and tested. Two routes were planned in order to obtain the final product. 
The initial solution phase scheme was to synthesize the desired HDAC inhibitor in a 
one-pot reaction involving two alkynes and one diazide linker (Scheme 4.2). This 
approach successfully led to the formation of the desired product (4-6) but also resulted 
in two additional byproducts, the unreacted triazole azide (4-5) and the symmetric 
bistriazole (4-7). This decreased the yield of the desired product to 38%. Separation of 
the three products was achieved by column chromatography and identity of the three 





Scheme 4.2 One pot procedure for synthesis of HDAC inhibitors. 
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 A two-step sequence was also investigated simultaneously (Scheme 4.3). Excess 
diazide was reacted with phenylacetylene to obtain the desired azido triazole. This was 
then reacted with propargyl alcohol to produce the desired product. This route involved 
two steps with chromatography after each one. This allowed for better control and less 
side product formation so this route was taken to synthesize a small library of 
compound in which the linker diazide length and alkynol were varied.  
 
 
Scheme 4.3 Two-step synthesis for HDAC inhibitors containing 1,2,3-triazoles. 
 
Through this route we were able to synthesize a series of 8 compounds containing 
1,2,3-triazoles in both the cap group region as well as in the zinc binding group domain. 
The initial step of converting dibromides to diazides was high yielding (> 86%). The 
synthesis of monoazide triazoles resulted in lower yields ranging from 27% of 4-12 to 
68% of 4-14. The decreased yields resulted from formation of the bistriazole (4-7) where 
phenylacetylene reacted with both of the azides on a single alkyl linker. For the 
bistriazoles, 4-16 to 4-23, better isolated yields resulted, since only one azide was 
available to react. Initially, column chromatography was used to separate the product 
triazoles from any residual copper or other slight byproducts. Upon scale-up, this led to 
some difficulties in that the bistriazoles were not very soluble in organic solvents such 
as DCM or MeOH, leading to broad elution from silica gel chromatography. Since the 
triazoles were not soluble, but the copper salts were, we could isolate the triazole 
product by filtration in both higher yield and purity than was observed from column 
chromatography. By filtration we recovered 82% yield of 4-16. Yields of compounds 
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isolated by chromatography ranged from 48% (4-17) to ~80% (4-18, 4-19, 4-20, 4-23). 
Yields over 3 steps ranged from 18% for compound 4-20 to 51% for compound 4-18. 
This solution phase scheme allowed access to the alcohol substituted triazoles, but did 
not allow for synthesis of the aldehyde or acid substituents for the triazole zinc binding 
group. Due to the primary alcohol functional group appended to the triazole, it was 
hypothesized that this could be oxidized to the corresponding acid or aldehyde, 
depending on the reagents employed. A series of test reactions were conducted with a 
simplified triazole (3-3l) before using the more complicated bistriazoles (4-16 to 4-23). 
Two methods were utilized: Jones Reagent to oxidize the alcohol to the carboxylic acid 
or Swern oxidation to afford the aldehyde. Both methods resulted in consumption of the 
starting material in the model systems. When applied to the more complicated 
bistriazoles, neither of these methods proved to be effective leading to recovery of only 
starting materials. Additional oxidants, such as TEMPO and oxone, were also tried, but 
these failed. The low solubility of these bistriazoles in organic solvents is a possible 
reason that the oxidations failed to work on this system. Because of the struggles with 
this chemistry, this route was abandoned and the focus moved to other potential zinc 
binding domains. 
Since the 1,2,3-triazoles had been successfully synthesized, we decided to incorporate 
a 1,2,4-triazole to test their ability to function as a zinc binding group. Both are five 
membered rings with three nitrogen atoms, but we felt that the difference in geometry 
might make a difference in the zinc binding ability. Furthermore, work by lab mates had 
previously explored synthesis of 1,2,4-triazoles, and several intact 1,2,4-triazoles were 
commercially available. This synthesis could rely on some of the starting materials used 
for the 1,2,3-triazole synthetic scheme so it was a logical progression.   
In this scheme (Scheme 4.4), dibromides were used for a linker as before, but were 
converted to monoazides instead of diazides in the initial step. The monoazides were 
not purified prior to use, so a lower overall yield was observed in these reactions.  A 
CuAAC reaction resulted in an aryl triazole with a terminal bromide at the end of an alkyl 
linker (compounds 4-28 to 4-31). These compounds were isolated in ~30% yield, with 
the low yield attributed to using the crude azidobromoalkane. The bromide was then 
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displaced by a suitable nucleophile. In this case, commercial triazoles were chosen as 
the nucleophiles. Previous work in our group had illustrated this reaction was indeed 
regioselective, reacting preferentially at the N1, and using the intact triazole was easier 
than synthesizing the 5-membered heterocycle.  
This led to the quick synthesis of 4 additional molecules containing both 1,2,3- and 
1,2,4-triazoles using commercially available 1,2,4-triazole. The displacement of the 
bromide with 1,2,4-triazole resulted in the product in 76 – 84% yield, with the 4-carbon 
linker resulting in only 44% yield. We also tried using 3-amino-1,2,4-triazole as the 
nucleophile, but this led to a 50/50 mixture of products by NMR. The two products 




Scheme 4.4 Synthetic scheme for synthesis of 1,2,4-triazole containing HDAC inhibitors. 
 
As a final compound in this series, we chose to synthesize a previously published 
HDAC inhibitor molecule containing the triazole in the cap region with the standard 
hydroxamic acid as the zinc binding group to serve as a synthesized positive control 
(Scheme 4.5). The precursor for this molecule had been synthesized during the catalytic 
studies from Chapter 3. The acid functional group was converted into the methyl ester in 
85% yield, and conversion to the hydroxamic acid under MW irradiation resulted in the 




Scheme 4.5 Synthesis of previously published HDAC Inhibitor. 
 
It was also of interest to explore other 1,2,4-triazoles positioned in the zinc binding 
domain. For the next series of molecules, we decided to leave the amide bond of SAHA 
intact, and instead just manipulate the zinc binding domain (Scheme 4.6). First, the 
amide bond was synthesized in 82% yield by reacting aniline with 5-bromovaleric acid 
that had been converted to the more active acyl chloride with DMF and oxalyl chloride. 
The resultant bromoanilide could then be subjected to a solution of the desired triazole 
with K2CO3 in DMF. The triazole chosen as the nucleophile was 3-methyl-1,2,4-triazole 
carboxylate. This reaction proceeded to produce the 1,2,4-triazole with a methyl ester 
appended to the three position. Two regioisomers were possible, but only one of the two 
was isolated in 39% yield. The position of the substituent was confirmed by 2D NMR, by 
examining the HMBC correlations. The lower yield for this step can be attributed to 
difficulty in removing all the DMF from the product. In the final step, methyl esters are 
easily converted to the hydroxamic acid using hydroxylamine hydrochloride and K2CO3 
in MeOH under microwave conditions. This reaction proceeded smoothly and product 
was easily isolated with an aqueous workup in 58% yield. Prior experience with 1,2,4-
triazoles had shown that the functional groups attached are not nearly as reactive when 
compared to other aromatic systems. We hoped to use this to our advantage to create a 
hydroxamic acid-like compound that could match the potency, but with decreased 





Scheme 4.6 Synthesis of 1,2,4-triazole hydroxamic acid compound. 
 
 
Since the 1,2,4-triazole compound above was synthesized using a bromoanilide, it was 
decided that a similar process should be used to make a 1,2,3-triazole compound 
containing an amide in the cap region. This would be complementary to the 1,2,4-
triazole compound, so the activities could be directly correlated. The amide bond was 
made between aniline and 6-bromohexanoic acid using DMF and oxalyl chloride in 85% 
yield. The bromide was displaced with sodium azide and an azide-alkyne cycloaddition 
performed using propargyl alcohol to afford the desired triazole compound in 40% yield 





Scheme 4.7 Synthesis of 1,2,3-triazole anilide. 
 
 
4.4. Screening of Synthesized Small Molecules for HDAC inhibition 
Upon synthesis, the molecules were subjected to a commercial high throughput assay 
to determine their relative activities for three different HDAC isoforms, HDAC-1, -6, and 
-8 using human recombinant HDAC enzymes. A comparison of HDAC-1 and HDAC-6 
will allow us to determine if any selectivity is observed between different classes of 
enzymes while two isoforms from Class I (HDAC-1 and -8) were screened to see if any 
selectivity between isoforms existed. 
The commercial assay is designed with a fluorogenic substrate based on p53 residues 
379-382 that includes an acetylated lysine side chain. When incubated with HDAC, the 
acetyl group is removed, leaving a free amine to react with the proprietary developer 
which generates a fluorophore. Fluorescence of samples containing inhibitor is 
compared to samples with no inhibitor to determine percent inhibition. If HDAC enzyme 
is active, a large fluorescence signal is observed. If reduced fluorescence is observed 
compared to the no inhibitor control, then inhibition of the HDAC enzyme is occurring. 
4.4.1. General procedure for performing enzyme inhibition assays:  
 
Enzyme kits were purchased from EnzoLife Sciences. Upon receipt of enzyme kit, 
components were defrosted and aliquotted into microcentrifuge tubes and refrozen with 
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liquid nitrogen to avoid multiple freeze/thaw cycles. All components were stored at -
80°C until used.  
HDAC Assay Buffer II was defrosted and allowed to warm to room temperature. Test 
inhibitors were diluted to 10 mM with DMSO. Test inhibitors were further diluted down 
with HDAC Assay Buffer II to a concentration of 100 μM, which is 5X the concentrations 
used in the assay. A known inhibitor, Trichostatin A, was diluted with DMSO to an initial 
concentration of 2 μM with DMSO. Further dilutions were performed with HDAC Assay 
Buffer II to a final concentration of 31.25 nM. Finally, DMSO was diluted to 1% with 
HDAC Assay Buffer II to match the concentration of DMSO found in the inhibitor 
samples. 10 μL of each test inhibitor was added to low retention microcentrifuge tubes. 
For the no-inhibitor control, 10 μL of DMSO was instead added. Microcentrifuge tubes 
were sealed and added to incubator at 33°C. Fluor de Lys-SIRT1 Deacetylase 
Substrate was diluted with HDAC Assay Buffer II to give a substrate concentration of 20 
μM and placed in incubator at 33°C for 10 minutes. HDAC Enzyme was thawed and 
chilled enzyme was diluted into warm HDAC Assay Buffer II. 15 μL of HDAC Enzyme 
was then added to all samples, except the no enzyme control, mixed, and incubated at 
33°C. After 10 minutes, 25μL of the diluted substrate was added to all samples, mixed 
thoroughly, and incubated for 40 minutes at 33°C. While samples were incubating, Fluor 
de Lys-Developer II Concentrate was thawed and diluted 5-fold with HDAC Assay 
Buffer I. Trichostatin A was then diluted 100-fold in the 1x developer just prepared. 
Diluted developer was stored on ice until ready for use. After the HDAC, inhibitor, 
substrate mixture was allowed to react for the desired time, 50 μL of developer was 
added to all samples. Samples were then incubated at room temperature for 45 
minutes. Samples were then transferred to a white ½ volume microplate and 
fluorescence measured using a Biotek Synergy platereader with excitation filters of 
360/40 and emission filters of 440/30. Samples were read with a top 50% mirror or 
dichroic 410 mirror. 
Data analysis: Fluorescence reading from no enzyme control well (background) was 
subtracted from all sample readings. The sample fluorescence values were compared 
to the no inhibitor control  
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4.5. Analysis of Enzyme Inhibition Results 
The inhibition of each HDAC enzyme was evaluated with each of the 14 synthetic 
compounds. To our dismay and disappointment, none of the 1,2,3-triazole zinc binding 
groups showed any inhibition with regards to any of the enzymes studied (Figure 4.8). 
The samples containing test compounds were not statistically different from the sample 
with no inhibitor present. The positive control with TSA, showed approximately 50% 
inhibition in all three enzymes. The binding potential of the triazole with zinc may not be 
strong enough to bind the inhibitor in the pocket. In comparison to the hydroxamic acid, 
the hydrogen bond with the NH would be missing in the 1,2,3-triazole inhibitors we 
designed. This hydrogen bonding interaction could be replaced with a H-bond between 
the C(5)-H of the triazole and the imidazole of the histidine residue (Figure 4.9). An 
additional hypothesis is that the 1,2,3-triazole may be too bulky to appropriately fit into 
the catalytic pocket. Furthermore, the 1,2,3-triazole might also be too polar for the 
hydrophobic channel leading to the catalytic zinc binding domain. Triazoles are known 
to be much more polar than their amide bond counterparts12 which may prevent access 
to the catalytic pocket. 
To test these hypotheses, the compounds could be mixed with a zinc (II) salt to see if a 
complex forms. The zinc triazole complex may require increased temperature, which 
would not be biologically relevant. To test the other theory, modeling could be utilized to 
predict the lowest energy conformation of the molecule. Some preliminary modeling 
studies showed that especially with the longer linker, the molecule would adopt an 
almost U-shaped conformation. Since these were preliminary studies, we weren’t 
confident in the parameters used to optimize the geometry. We initially thought this was 
due more to inexperience with modeling software than the actual geometry. A closer 










Figure 4.9 Comparison of interaction with A) hydroxamic acid and B) proposed inhibitor. 
 
 
The terminal 1,2,4-triazoles as a zinc binding group did not fare any better in the 
enzyme assay (Figure 4.10). There was no distinguishable activity for the four 1,2,4-
triazoles  synthesized. Even the hydroxamic acid substituted 1,2,4-triazole did not show 
any inhibitory activity of any of the three HDAC isoforms tested. In hindsight, this 
followed similar results observed by Shen et. al.122 Their research described attachment 
of a hydroxamic acid to a 1,2,3-triazole, but their compounds were not significantly 
active for HDAC inhibition, with the largest percentage of inhibited HDAC activity being 
20% with 500 nM of test compound. Of the synthesized inhibitors, the only one that 
showed any activity against HDAC was the control compound that was synthesized to 
match a previously reported compound.118 As with the 1,2,3-triazoles, the increased 
polarity of the zinc binding group or the size could be preventing the synthesized 
compounds from interacting with the enzyme active site. Further modeling or evaluation 













A small library of compounds was designed and synthesized as inhibitors of various 
HDAC isoforms. The goal of the research was to investigate the potential of 1,2,3- or 
1,2,4-triazoles as zinc binding groups. A solid phase route was originally carried out, but 
led to additional byproducts that were difficult to separate on such a small scale. A 
similar solution phase synthesis was designed and successfully carried out. This led to 
the synthesis of a series of molecules containing 1,2,3-triazoles in both the cap group 
and zinc binding domain. Additional molecules containing a 1,2,4-triazole in the zinc 
binding domain and a 1,2,3-triazole in the cap group were also synthesized. In an effort 
to match the zinc binding ability of hydroxamic acids, a compound containing a 1,2,4-
triazole substituted with a hydroxamic acid was also designed and synthesized. A 
control compound that had been previously reported with activity against HDAC was 
also synthesized to serve as a positive control.  
Despite evidence that would suggest triazoles as effective zinc binding groups, the 
designed molecules did not show activity for the enzymes tested. The molecules were 
screened against two enzymes from Class I (HDAC-1 and HDAC-8) to look for isoform 
specificity and one enzyme from Class II-b (HDAC-6) to examine class specificity. The 
only molecule to show activity was an already published inhibitor that was synthesized 
as a control. Future work could include more modeling studies in the design process or 
the screening of these molecules against other metalloenzymes, specifically ones that 
had wider enzyme active sites or that involved more polar amino acid residues. 
 
4.7. Experimental 
Materials and General Methods. Reagents and solvents were purchased from various 
commercial sources and used without further purification unless otherwise stated.  
Anhydrous solvents were purified using a Grubbs solvent system.  Analytical thin-layer 
chromatography (TLC) was performed using aluminum backed silica gel TLC plates 
with UV indicator from Sorbent Technologies.  Flash column chromatography was 
performed using 40 – 63 μm (230 x 400 mesh) silica gel from Sorbent Technologies. 
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Microwave reactions were performed in sealed vials using a Biotage Initiator 
Microwave. 1H and 13C NMR were recorded at 600 MHz and 151 MHz, respectively, on 
a Varian Inova spectrometer or at 500 MHz and 125 MHz, respectively, on a Varian 
VNMRS spectrometer.  All chemical shifts were reported in δ units relative to 
tetramehtylsilane or the corresponding deuterated solvent. High resolution mass spectra 
(HRMS) were obtained on a JEOL AccuTOF DART spectrometer.  Infrared spectra 
were recorded on a Varian 4100 FT-IR using KBr pellets or KBR salt plates.  Absorption 
spectra were collected on a Thermo Scientific Evolution 600. High pressure liquid 
chromatography (HPLC) was performed using a Beckman Coulter System equipped 
with a UV-Vis detector, autosampler, Varian C18 column, and a mobile phase 
composed of acetonitrile and trifluoracetic acid.  
 
General Diazide Procedure:  Dibromide (4 mmol) was dissolved in dimethylformamide 
and water (9:1 mL). Sodium azide (9 mmol) was added as a solid and the solution 
stirred overnight at room temperature. Progress of the reaction was monitored by GC-
MS. Upon completion, the reaction was quenched with 30 mL of water (exothermic) and 
stirred until reaching room temperature. The solution was then extracted with diethyl 
ether (3x). The combined organics were washed with water (2x), copper sulftate (1x) 
and brine (1x). The solution was dried over sodium sulfate, filtered, and concentrated in 
vacuo to yield the desired diazide. 
 
1,3-diazidopropane (4-8).  Prepared using the General Diazide 
Procedure from 1,3-dibromopropane. Isolated as a pale yellow oil in 86% yield.  1H 
NMR (CDCl3, 600 MHz) δ 3.42 (t, 4H, J = 6.6 Hz), 1.84 (q, 2H, J = 6.6 Hz).  
13C NMR 
(CDCl3, 151 MHz) δ 48.6, 28.5.  MS (ESI) m/z calculated 70.05 (C3H6N2, [M-N2-N2]
+), 
m/z observed  70.10. (C6H6N2, [M-N2-N2]
+). 
 
1,4-diazidobutane (4-9).  Prepared using the General Diazide 
Procedure from 1,4-dibromobutane. Isolated as a pale yellow oil in 98% yield.  1H NMR 
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(CDCl3, 600 MHz) δ 3.33 (t, 4H, J = 6.0 Hz), 1.69 (q, 4H, J = 3.0 Hz).  
13C NMR (CDCl3, 
151 MHz) δ 51.1, 26.3.  MS (ESI) m/z calculated 84.07 (C4H8N2, [M-N2-N2]
+), m/z 
observed 84.10. (C4H8N2, [M-N2-N2]
+). 
 
1,5-diazidopentane (4-10).  Prepared using the General Diazide 
Procedure from 1,5-dibromopentane. Isolated as a pale yellow oil in 90% yield.  1H 
NMR (CDCl3, 600 MHz) δ 3.29 (t, 4H, J = 6.6 Hz), 1.63 (q, 4H, J = 6.6 Hz), 1.44 – 1.50 
(m, 2H).  13C NMR (CDCl3, 151 MHz) δ 51.4, 28.6, 24.1.  MS (ESI) m/z calculated 98.08 
(C5H10N2, [M-N2-N2]
+), m/z observed 98.10. (C5H10N2, [M-N2-N2]
+). 
 
1,6-diazidohexane (4-11).  Prepared using the General Diazide 
Procedure from 1,6-dibromohexane. Isolated as a pale yellow oil in 98% yield.  1H NMR 
(CDCl3, 600 MHz) δ 3.28 (t, 4H, J = 6.6 Hz), 1.59 – 1.65 (m, 4H), 1.39 – 1.44 (m, 4H).  
13C NMR (CDCl3, 151 MHz) δ 51.5, 28.9, 26.5.  MS (ESI) m/z calculated 112.10 
(C6H12N2, [M-N2-N2]
+), m/z observed 112.10. (C6H12N4, [M-N2-N2]
+). 
 
General Procedure for Azido 1,2,3-triazoles:  Diazide (2.5 mmol) was dissolved in 
acetonitrile (10 mL). Phenylacetylene (1 mmol) and triethylamine (1 mmol) were added. 
A solution of triazine 2-17 (0.01 mmol) in acetonitrile was added, followed by a solution 
of tetrakis(acetonitrle-N)copper(I) tetrafluoroborate (0.01 mmol) in acetonitrile. The 
resulting solution was stirred at room temperature overnight. Reaction progress was 
followed by TLC. Upon completion, the mixture was concentrated in vacuo and purified 
via silica gel chromatography eluting with a gradient of hexanes and ethyl acetate to 
yield the desired azidoalkyl phenyl-1,2,3-triazole. 
 
1-(3-azidopropyl)-4-phenyl-1H-1,2,3-triazole (4-12). 
Prepared using General Procedure for Azido 1,2,3-triazoles 
from 1,3-diazidopropane (4-8) and isolated as pale yellow 
solid in 27% yield.  1H NMR (d6-DMSO, 600 MHz) δ 8.61 (s, 1H), 7.84 (d, 2H, J = 8.4 
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Hz), 7.45 (t, 2H, J = 7.2 Hz), 7.33 (t, 1H, J = 7.2 Hz), 4.47 (t, 2H, J = 6.6 Hz), 3.42 (t, 2H, 
J = 6.6 Hz), 2.13 (q, 2H, J = 6.6 Hz).  13C NMR (d6-DMSO, 151 MHz) δ 146.4, 130.8, 
128.9, 127.9, 125.2, 121.5, 47.9, 47.0, 29.0.  HRMS (ESI) m/z calculated 229.12017 
(C11H13N6, [M+H]




Prepared using General Procedure for Azido 1,2,3-triazoles 
from 1,4-diazidobutane (4-9) and isolated as an off-white 
solid in 60% yield  1H NMR (d6-DMSO, 600 MHz) δ 8.59 (s, 1H), 7.84 (d, 2H, J = 7.2 
Hz), 7.45 (t, 2H, J = 7.2 Hz), 7.33 (t, 1H, J = 7.2 Hz), 4.44 (t, 2H, J = 7.2 Hz), 3.39 (t, 2H, 
J = 6.6 Hz), 1.93 (q, 2H, J = 7.2 Hz), 1.54 (q, 2H, J = 6.6 Hz).  13C NMR (d6-DMSO, 151 
MHz) δ 146.3, 130.8, 128.9, 127.8, 125.1, 121.3, 50.0, 49.0, 26.9, 25.4.  HRMS (ESI) 
m/z calculated 243.13582 (C12H15N6, [M+H]




Prepared using General Procedure for Azido 1,2,3-
triazoles from 1,5-diazidopentane (4-10)  and isolated as 
an off-white solid in 68% yield.  1H NMR (d6-DMSO, 600 MHz) δ 8.58 (s, 1H), 7.84 (d, 
2H, J = 7.8 Hz), 7.44 (t, 2H, J = 7.8 Hz), 7.33 (t, 1H, J = 7.2 Hz), 4.40 (t, 2H, J = 7.2 Hz), 
3.32 (t, 2H), 1.89 (q, 2H, J = 7.2 Hz), 1.57 (q, 2H, J = 7.2 Hz), 1.32 (q, 2H, J = 7.2 Hz).  
13C NMR (d6-DMSO, 151 MHz) δ 146.3, 130.9, 128.9, 127.8, 125.1, 121.3, 50.4, 49.3, 
29.1, 27.6, 23.1.  HRMS (ESI) m/z calculated 257.15147 (C13H17N6, [M+H]
+), m/z 




Prepared using General Prodedure for Azido 1,2,3-
triazoles from 1,6-diazidohexane (4-11)  and isolated as 
an off-white solid in 47% yield.  1H NMR (d6-DMSO, 600 MHz) δ 8.58 (s, 1H), 7.84 (d, 
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2H, J = 8.4 Hz), 7.44 (t, 2H, J = 7.8 Hz), 7.33 (t, 1H, J = 7.8 Hz), 4.39 (t, 2H, J = 6.6 Hz), 
3.31 (t, 2H, J = 6.6 Hz), 1.87 (q, 2H, J = 7.2 Hz), 1.52 (q, 2H, J = 7.2 Hz), 1.36 (q, 2H, J 
= 7.2 Hz), 1.29 (q, 2H, J = 7.2 Hz).  13C NMR (d6-DMSO, 151 MHz) δ 146.3, 130.9, 
128.9, 127.8, 125.1, 121.2, 50.5, 49.4, 29.4, 28.0, 25.5, 25.4.  HRMS (ESI) m/z 
calculated 271.16712 (C14H19N6, [M+H]
+), m/z observed 271.16567. (C14H19N6, [M+H]
+). 
 
General Procedure for Bistriazoles:  Azidoalkyl-phenyl 1,2,3-triazole (1.0 mmol) was 
dissolved in acetonitrile (2.5 mL). Propargyl or homopropargyl alcohol (1 mmol) and 
triethylamine (1 mmol) were added. A solution of triazine 2-17 (0.01 mmol) in 
acetonitrile (750 μL) was added, followed by a solution of tetrakis(acetonitrle-
N)copper(I) tetrafluoroborate (0.01 mmol) in acetonitrile (750 μL). The resulting solution 
was stirred 60°C overnight. Reaction progress was followed by TLC. Upon completion, 
the mixture was concentrated in vacuo and purified via silica gel chromatography eluting 
with a gradient of ethyl acetate and methanol to yield the desired bistriazoles. 
 
(1-(3-(4-phenyl-1H-1,2,3-triazol-1-yl)propyl)-1H-
1,2,3-triazol-4-yl)methanol (4-16). Prepared using 
General Procedure for Bistriazoles from 4-12 and 
propargyl alcohol with following modification: isolated 
by filtration to yield a white solid in 82% yield. 1H NMR (d6-DMSO, 600 MHz) δ 8.59 (s, 
1H), 8.02 (s, 1H), 7.84 (d, 2H, J = 7.8 Hz), 7.45 (t, 2H, J = 7.8 Hz), 7.34 (t, 1H, J = 7.8 
Hz), 5.17 (t, 1H, J = 6.0 Hz), 4.51 (d, 2H, J = 6.0 Hz), 4.42 (q, 4H, J = 7.2 Hz), 2.46 (q, 
2H, J = 7.2 Hz).  13C NMR (d6-DMSO, 151 MHz) δ 148.1, 146.4, 130.7, 128.9, 127.9, 
125.1, 122.9, 121.5, 55.1, 46.9, 46.5, 30.2.  HRMS (ESI) m/z calculated 285.14638 
(C14H17N6O, [M+H]




1,2,3-triazol-4-yl)ethanol (4-17). Prepared using 
General Procedure for Bistriazoles from 4-12 and 
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homopropargyl alcohol and isolated as a white solid in 76% yield.  1H NMR (d6-DMSO, 
500 MHz) δ 8.58 (s, 1H), 7.90 (s, 1H), 7.83 (d, 2H, J = 7.0 Hz), 7.45 (t, 2H, J = 7.5 Hz), 
7.33 (tt, 1H, J = 7.8 Hz, J = 1.5 Hz), 4.67 (t, 1H, J = 5.5 Hz), 4.44 (t, 2H, J = 7.0 Hz), 
4.39 (t, 2H, J = 7.0 Hz), 3.62 (q, 2H, J = 7.0 Hz), 2.76 (t, 2H, J = 7.0 Hz), 2.45 (q, 2H, J 
= 7.0 Hz).  13C NMR (d6-DMSO, 125 MHz) δ 146.4, 144.4, 130.7, 128.9, 127.8, 125.1, 
122.6, 121.5, 60.3, 46.9, 46.5, 30.1, 29.2.  HRMS (ESI) m/z calculated 299.16203 
(C15H19N6O, [M+H]




1,2,3-triazol-4-yl)methanol (4-18). Prepared 
using General Procedure for Bistriazoles from 4-13 
and propargyl alcohol and isolated as a white solid in 48% yield.  1H NMR (d6-DMSO, 
600 MHz) δ 8.56 (s, 1H), 7.96 (s, 1H), 7.83 (d, 2H, J = 7.2 Hz), 7.44 (t, 2H, J = 7.2 Hz), 
7.33 (t, 1H, J = 7.2 Hz), 5.15 (t, 1H, J = 6.0 Hz), 4.50 (d, 2H, J = 6.0 Hz), 4.43 (t, 2H, J = 
6.6 Hz), 4.38 (t, 2H, J = 6.6 Hz) 1.81 – 1.84 (m, 4H).  13C NMR (d6-DMSO, 151 MHz) δ 
148.0, 146.3, 130.8, 128.9, 127.8, 125.1, 122.7, 121.4, 55.1, 48.9, 48.6, 26.9, 26.8.  
HRMS (ESI) m/z calculated 299.16203 (C15H19N6O, [M+H]





1H-1,2,3-triazol-4-yl)ethanol (4-19).  Prepared 
using General Procedure for Bistriazoles from 4-
13 and homopropargyl alcohol and isolated as a white solid in 64% yield.  1H NMR (d6-
DMSO, 600 MHz) δ 8.56 (s, 1H), 7.85 (s, 1H), 7.83 (d, 2H, J = 6.6 Hz), 7.44 (t, 2H, J = 
7.8 Hz), 7.33 (t, 1H, J = 7.8 Hz), 4.67 (t, 1H, J = 5.4 Hz), 4.43 (t, 2H, J = 6.6 Hz), 4.35 (t, 
2H, J = 6.6 Hz), 3.61 (q, 2H, J = 6.6 Hz), 2.75 (t, 2H, J = 6.6 Hz), 1.77 – 1.87 (m, 4H).  
13C NMR (d6-DMSO, 151 MHz) δ 146.3, 144.3, 130.8, 128.9, 127.8, 125.1, 122.6, 
121.3, 60.4, 48.9, 48.4, 29.2, 26.8, 26.7.  HRMS (ESI) m/z calculated 313.17768 
(C16H21N6O, [M+H]






1,2,3-triazol-4-yl)methanol (4-20).  Prepared 
using General Procedure for Bistriazoles from 4-
14 and propargyl alcohol and isolated as a white 
solid in 84% yield.  1H NMR (d6-DMSO, 500 MHz) δ 8.56 (s, 1H), 7.95 (s, 1H), 7.83 (d, 
2H, J = 7.0 Hz), 7.45 (t, 2H, J = 7.5 Hz), 7.33 (tt, 1H, J = 7.5 Hz, J = 1.5 Hz), 5.14 (t, 1H, 
J = 6.0 Hz), 4.49 (d, 2H, J = 6.0 Hz), 4.39 (t, 2H, J = 7.0 Hz), 4.33 (t, 2H, J = 7.0 Hz), 
1.82 – 1.94 (m, 4H), 1.21 – 1.28 (m, 2H).  13C NMR (d6-DMSO, 125 MHz) δ 147.9, 
146.2, 130.8, 128.9, 127.8, 125.1, 122.5, 121.2, 55.0, 49.3, 48.9, 29.1, 29.0, 22.8.  
HRMS (ESI) m/z calculated 313.17768 (C16H21N6O, [M+H]






21).  Prepared using General Procedure for 
Bistriazoles from 4-14 and homopropargyl alcohol and isolated as a white solid in 64% 
yield.  1H NMR (d6-DMSO, 600 MHz) δ 8.55 (s, 1H), 7.82 – 7.85 (m, 3H), 7.45 (t, 2H, J = 
7.8 Hz), 7.33 (tt, 1H, J = 7.8 Hz, J = 1.2 Hz), 4.66 (t, 1H, J = 5.4 Hz), 4.38 (t, 2H, J = 7.2 
Hz), 4.29 (t, 2H, J = 7.2 Hz), 3.60 (q, 2H, J = 6.6 Hz), 2.73 (t, 2H, J = 6.6 Hz), 1.89 (q, 
2H, J = 7.2 Hz), 1.84 (q, 2H, J = 7.2 Hz), 1.21 – 1.27 (m, 2H).  13C NMR (d6-DMSO, 151 
MHz) δ 146.2, 144.3, 130.8, 128.9, 127.8, 125.1, 122.2, 121.2, 60.4, 49.2, 48.8, 29.2, 
29.1, 29.0, 22.8.  HRMS (ESI) m/z calculated 327.19333 (C17H23N6O, [M+H]
+), m/z 




1H-1,2,3-triazol-4-yl)methanol (4-22).  
Prepared using General Procedure for 
Bistriazoles from 4-15 and propargyl alcohol and isolated as a white solid in 87% yield.  
1H NMR (d6-DMSO, 500 MHz) δ 8.57 (s, 1H), 7.95 (s,1H), 7.83 (d, 2H, J = 7.0 Hz), 7.44 
(t, 2H, J = 7.5 Hz), 7.32 (tt, 1H, J = 7.5 Hz, J = 1.5 Hz), 5.13 (t, 1H, J = 5.5 Hz), 4.37 (t, 
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2H, J = 7.5 Hz), 4.31 (t, 2H, J = 7.0 Hz), 1.85 (q, 2H, J = 7.0 Hz), 1.80 (q, 2H, J = 7.0 
Hz), 1.25 – 1.31 (m, 4H).  13C NMR (d6-DMSO, 125 MHz) δ 147.9, 146.2, 130.8, 128.9, 
127.7, 125.1, 122.5, 121.2, 55.1, 49.4, 49.0, 29.5, 29.4, 25.25, 25.23.  HRMS (ESI) m/z 
calculated 327.19333 (C17H23N6O, [M+H]





23). Prepared using General Procedure for 
Bistriazoles from 4-15 and homopropargyl alcohol and isolated as a white solid in 81% 
yield.  1H NMR (d6-DMSO, 600 MHz) δ 8.57 (s, 1H), 7.82 – 7.85 (m, 3H), 7.44 (t, 2H, J = 
7.8 Hz), 7.32 (t, 1H, J = 7.8 Hz), 4.67 (t, 1H, J = 5.4 Hz), 4.37 (t, 2H, J = 7.2 Hz), 4.27 (t, 
2H, J = 6.6 Hz), 3.61 (q, 2H, J = 6.6 Hz), 2.74 (t, 2H, J = 6.6 Hz), 1.85 (q, 2H, J = 7.2 
Hz), 1.85 (q, 2H, J = 7.2 Hz), 1.78 (q, 2H, J = 7.2 Hz), 1.26 – 1.31 (m, 4H).  13C NMR 
(d6-DMSO, 151 MHz) δ 146.3, 144.3, 130.9, 128.9, 127.8, 125.1, 122.2, 121.2, 60.4, 
49.4, 49.0, 29.5, 29.4, 29.2, 25.29, 25.26.  HRMS (ESI) m/z calculated 341.20898 
(C18H25N6O, [M+H]
+), m/z observed 341.21026. (C18H25N6O, [M+H]
+). 
 
General procedure for azido bromo-alkanes: Dibromide (1.2 mmol) was dissolved in 
dimethylformamide and water (9:1 mL). Sodium azide (1 mmol) was added as a solid 
and the solution stirred overnight at room temperature. Progress of the reaction was 
monitored by GC-MS. This reaction resulted in a mixture of unreacted dibromide, the 
desired azidobromoalkane, and diazidoalkane. The reaction was quenched with 20 mL 
of water (exothermic) and stirred until reaching room temperature. The solution was 
then extracted with diethyl ether (3x). The combined organics were washed with water 
(2x), copper sulftate (1x) and brine (1x). The solution was dried over sodium sulfate, 
filtered, and concentrated in vacuo to yield the crude azidobromoalkane as a pale 




General procedure for bromo 1,2,3-triazoles: Using the crude azidobromoalkane, it 
was assumed (based on GC-MS results) that ~30% of the mixture was desired 
azidobromoalkane. Excess azidobromoalkane (1 mmol) was measured out (mmol were 
calculated by multiplying mass by 0.3 and using molecular weight of desired 
azidobromoalkane) and dissolved in acetonitrile (8 mL). ). Phenylacetylene (3.3 mmol) 
and triethylamine (3.3 mmol) were added. A solution of triazine 2-17 (0.033 mmol) in 
acetonitrile (4 mL) was added, followed by a solution of tetrakis(acetonitrle-N)copper(I) 
tetrafluoroborate (0.033 mmol) in acetonitrile (4 mL).  The resulting solution was stirred 
at room temperature overnight. Reaction progress was followed by TLC. Upon 
completion, the mixture was concentrated in vacuo and purified via silica gel 
chromatography eluting with a gradient of hexanes and ethyl acetate to yield the desired 
bromoalkyl phenyl-1,2,3-triazole. 
 
1-(3-bromopropyl)-4-phenyl-1H-1,2,3-triazole (4-28).  
Prepared using General Procedure for bromo-1,2,3-triazoles 
from 1-azido-3-bromopropane 4-24 and isolated as a white 
solid in 28% yield.  1H NMR (CDCl3, 600 MHz) δ 7.84 (d, 2H, J = 7.8 Hz), 7.82 (s, 1H), 
7.43 (t, 2H, J = 7.8 Hz), 7.34 (t, 1H, J = 7.8 Hz), 4.61 (t, 2H, J = 6.6 Hz), 3.40 (t, 2H, J = 
6.0 Hz), 2.52 (q, 2H, J = 6.6 Hz).  13C NMR (CDCl3, 151 MHz) δ 147.9, 130.6, 129.0, 
128.4, 125.9, 120.4, 48.3, 32.7, 29.7.  HRMS (ESI) m/z calculated 266.02929 
(C11H13BrN3, [M+H]
+), m/z observed 266.02908. (C11H12BrN3, [M+H]
+). 
 
1-(4-bromobutyl)-4-phenyl-1H-1,2,3-triazole (4-29).  
Prepared using General Procedure for bromo-1,2,3-triazoles 
from 1-azido-4-bromobutane 4-25 and isolated as a white 
solid in 34% yield.  1H NMR (CDCl3, 600 MHz) δ 7.83 (d, 2H, J = 7.2 Hz), 7.77 (s, 1H), 
7.43 (t, 2H, J = 7.8 Hz), 7.34 (t, 1H, J = 7.8 Hz), 4.45 (t, 2H, J = 6.6 Hz), 3.44 (t, 2H, J = 
6.6 Hz), 2.14 (q, 2H, J = 7.2 Hz), 1.92 (q, 2H, J = 7.2 Hz).  13C NMR (CDCl3, 151 MHz) 
δ 148.1, 130.7, 129.0, 128.3, 125.8, 119.5, 49.5, 32.6, 29.4, 28.9.  HRMS (ESI) m/z 
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calculated 280.04494 (C12H15BrN3, [M+H]
+), m/z observed 280.04348. (C12H15BrN3, 
[M+H]+). 
 
1-(5-bromopentyl)-4-phenyl-1H-1,2,3-triazole (4-30).  
Prepared using General Procedure for bromo-1,2,3-
triazoles from 1-azido-5-bromopentane 4-26 and isolated 
as a white solid in 29% yield.  1H NMR (CDCl3, 600 MHz) δ 7.83 (d, 2H, J = 7.8 Hz), 
7.75 (s, 1H), 7.43 (t, 2H, J = 7.8 Hz), 7.33 (t, 1H, J = 7.8 Hz), 4.42 (t, 2H, J = 7.2 Hz), 
3.40 (t, 2H, J = 6.6 Hz), 2.00 (q, 2H, J = 7.2 Hz), 1.92 (q, 2H, J = 7.2 Hz), 1.50 – 1.56 
(m, 2H).  13C NMR (CDCl3, 151 MHz) δ 148.0, 130.8, 129.0, 128.3, 125.8, 119.6, 50.2, 
33.3, 32.1, 29.7, 25.2.  HRMS (ESI) m/z calculated 294.06059 (C13H17BrN3, [M+H]
+), 




Prepared using General Procedure for bromo-1,2,3-
triazoles from 1-azido-6-bromohexane 4-27 and isolated 
as a white solid in 32% yield.  1H NMR (CDCl3, 600 MHz) δ 7.83 (d, 2H, J = 7.8 Hz), 
7.75 (s, 1H), 7.43 (t, 2H, J = 7.8 Hz), 7.33 (t, 1H, J = 7.2 Hz), 4.41 (t, 2H, J = 7.2 Hz), 
3.40 (t, 2H, J = 6.6 Hz), 1.98 (q, 2H, J = 7.8 Hz), 1.86 (q, 2H, J = 7.2 Hz), 1.52 (q, 2H, J 
= 7.2 Hz), 1.39 (q, 2H, J = 7.8 Hz).  13C NMR (CDCl3, 151 MHz) δ 148.0, 130.8, 129.0, 
128.3, 125.8, 119.5, 50.3, 33.7, 32.5, 30.3, 27.6, 25.8.  HRMS (ESI) m/z calculated 
308.07624 (C14H19BrN3, [M+H]
+), m/z observed 308.07481. (C14H19BrN3, [M+H]
+). 
 
General procedure for 1,2,4-triazolyl-12,3-triazoles:  Bromoalkyl phenyl-1,2,3-triazole 
(1 mmol) was dissolved in DMF (4 mL). 1H-1,2,4-triazole (1 mmol) was added along 
with solid K2CO3 (2 mmol). This heterogeneous mixture was stirred at room temperature 
overnight. Reaction progress was followed by TLC. Reaction mixture was diluted with 
water and extracted with ethyl acetate (3x). Combined organics were washed with water 
(1x) and saturated sodium chloride (1x). The organic layer was dried over sodium 
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triazole (4-32).  Prepared using the general procedure for 
1,2,4-triazolyl-1,2,3-triazoles from  bromide 4-28 and 1H-
1,2,4-triazole. Isolated as a white solid in 76% yield.  1H NMR (CDCl3, 600 MHz) δ 8.17 
(s, 1H), 8.00 (s, 1H), 7.83 (m, 3H), 7.44 (t, 2H, J = 7.8 Hz), 7.35 (t, 1H, J = 7.8 Hz), 4.43 
(t, 2H, J = 6.6 Hz), 4.25 (t, 2H, J = 6.6 Hz), 2.55 (q, 2H, J = 6.6 Hz).  13C NMR (CDCl3, 
151 MHz) δ 152.6, 148.2, 144.4, 130.4, 129.1, 128.5, 125.9, 120.3, 46.8, 45.9, 30.4.  
HRMS (ESI) m/z calculated 255.13582 (C13H15N6, [M+H]





triazole (4-33).  Prepared using the general procedure 
for 1,2,4-triazolyl-1,2,3-triazoles from  bromide 4-29 and 
1H-1,2,4-triazole. Isolated as a white solid in 44% yield.  1H NMR (CDCl3, 600 MHz) δ 
8.05 (s, 1H), 7.95 (s, 1H), 7.82 (d, 2H, J = 7.8 Hz), 7.72 (s, 1H), 7.43 (t, 2H, J = 7.8 Hz), 
7.34 (t, 1H, J = 7.8 Hz), 4.44 (t, 2H, J = 6.0 Hz), 4.22 (t, 2H, J = 6.0 Hz), 1.97 – 1.99 (m, 
4H).  13C NMR (CDCl3, 151 MHz) δ 152.4, 148.2, 143.2, 130.6, 129.0, 128.4, 125.8, 
119.6, 49.6, 48.8, 27.4, 27.0.  HRMS (ESI) m/z calculated 269.15147 (C14H17N6, 




triazole (4-34).  Prepared using the general procedure 
for 1,2,4-triazolyl-1,2,3-triazoles from  bromide 4-30 
and 1H-1,2,4-triazole. Isolated as a white solid in 76% yield.  1H NMR (CDCl3, 600 MHz) 
δ 8.03 (s, 1H), 7.93 (s, 1H), 7.82 (d, 2H, J = 7.2 Hz), 7.72 (s, 1H), 7.43 (t, 2H, J = 7.2 
Hz), 7.34 (t, 1H, J = 7.2 Hz), 4.39 (t, 2H, J = 6.6 Hz), 4.16 (t, 2H, J = 6.6 Hz), 1.93 – 
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2.02 (m, 4H), 1.33 – 1.40 (m, 2H).  13C NMR (CDCl3, 151 MHz) δ 152.2, 148.0, 143.2, 
130.7, 129.0, 128.3, 125.8, 119.6, 50.1, 49.4, 29.9, 29.3, 23.6.  HRMS (ESI) m/z 
calculated 283.16712 (C15H19N6, [M+H]




1,2,3-triazole (4-35).  ).  Prepared using the general 
procedure for 1,2,4-triazolyl-1,2,3-triazoles from  
bromide 4-31 and 1H-1,2,4-triazole. Isolated as a white solid in 84% yield.  1H NMR 
(CDCl3, 600 MHz) δ 8.03 (s, 1H), 7.93 (s, 1H), 7.83 (d, 2H, J = 7.2 Hz), 7.73 (s, 1H), 
7.42 (t, 2H, J = 7.8 Hz), 7.33 (t, 1H, J = 7.8 Hz), 4.39 (t, 2H, J = 6.6 Hz), 4.15 (t, 2H, J = 
7.2 Hz), 1.95 (q, 2H, J = 7.2 Hz), 1.89 (q, 2H, J = 6.6 Hz), 1.32 – 1.42 (m, 4H).  13C 
NMR (CDCl3, 151 MHz) δ 152.1, 148.0, 143.0, 130.7, 129.0, 128.3, 125.8, 119.5, 50.2, 
49.5, 30.2, 29.7, 26.02, 25.99.  HRMS (ESI) m/z calculated 297.18277 (C16H21N6, 




yl)hexanoate (4-36).  1,2,3-Triazoyl carboxylic acid 
3-3k (1 mmol) was dissolved in methanol (2.5 mL) with a catalytic amount of H2SO4 
(100 μL). The mixture was refluxed overnight and reaction progress monitored by TLC. 
Solution was concentrated in vacuo, and residue redissolved in DCM and water. The 
aqueous layer was made neutral by dropwise addition of 6 M NaOH and extracted with 
DCM (3x). The combined organics were washed with 2 M NaOH (1x), H2O (1x), and 
saturated NaCl (1x). The organic layer was dried over sodium sulfate, filtered, and 
concentrated in vacuo to yield an off-white solid in 85% yield. 
 
N-hydroxy-6-(4-phenyl-1H-1,2,3-triazol-1-
yl)hexanamide (4-37).  Triazolyl methyl ester 4-36 
(1 mmol) was added to a microwave vial. To this 
was added methanol (5 mL), hydroxylamine hydrochloride (3 mmol) and crushed NaOH 
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(6 mmol). The heterogeneous mixture was microwaved at 120°C for 30 minutes. 
Starting material consumption was confirmed by TLC and methanol was removed in 
vacuo. Water and DCM were added to the residue and the aqueous layer acidified to 
pH of 4-5 with glacial acetic acid. The water layer was then extracted with DCM (3x). 
Combined organics were washed with ammonium chloride and saturated NaCl. The 
organic layer was dried over sodium sulfate, filtered, and concentrated in vacuo to yield 
an off-white solid in 60% yield. 
 
5-bromo-N-phenylpentanamide (4-40).  5-bromopentanoic 
acid (1 mmol) was dissolved in DCM (2.85 mL) and cooled to 
0°C in ice bath. A solution of oxalyl chloride in DCM (2M, 1.1 
mmol) was added dropwise along with a catalytic amount of DMF (0.1 mmol). The ice 
bath was removed and the solution stirred at room temperature for 1 hour. TLC 
confirmed consumption of starting material. Volatiles were removed under a stream of 
N2. The resulting residue was dissolved in DCM (4.25 mL) and cooled to 0°C in an ice 
bath. Dropwise add a solution of DIEA (2.1 mmol) and aniline (1.2 mmol) dissolved in 
DCM (0.5 mL). Remove ice bath and stir overnight at room temperature. Reaction 
progress was monitored by TLC. Upon completion, water was added and extracted with 
DCM (3x). The combined organics were washed with 1 M HCl, saturated sodium 
bicarbonate, and saturated NaCl. The organic layer was then dried over sodium sulfate, 
filtered, and concentrated in vacuo to yield a pale pink solid in 84% yield. 
 
6-bromo-N-phenylhexanamide (4-41).  5-bromopentanoic 
acid (1 mmol) was dissolved in DCM (2.85 mL) and cooled 
to 0°C in ice bath. A solution of oxalyl chloride in DCM (2M, 
1.1 mmol) was added dropwise along with a catalytic amount of DMF (0.1 mmol). The 
ice bath was removed and the solution stirred at room temperature for 1 hour. TLC 
confirmed consumption of starting material. Volatiles were removed under a stream of 
N2. The resulting residue was dissolved in DCM (4.25 mL) and cooled to 0°C in an ice 
bath. Dropwise add a solution of DIEA (2.1 mmol) and aniline (1.2 mmol) dissolved in 
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DCM (0.5 mL). Remove ice bath and stir overnight at room temperature. Reaction 
progress was monitored by TLC. Upon completion, water was added and extracted with 
DCM (3x). The combined organics were washed with 1 M HCl, saturated sodium 
bicarbonate, and saturated NaCl. The organic layer was then dried over sodium sulfate, 
filtered, and concentrated in vacuo to yield an off-white solid in 82% yield. 
 
methyl 1-(5-oxo-5-(phenylamino)pentyl)-1H-1,2,4-
triazole-3-carboxylate (4-42).  5-bromo-N-
phenylpentanamide 4-40 (1 mmol) was dissolved in 
DMF (4 mL). Methyl 1-H-1,2,4-triazole-3-carboxylate 
and K2CO3 were added as solids. The heterogeneous mixture was stirred overnight at 
room temperature. Reaction progress was monitored by TLC. Upon completion, a small 
amount of water was added and extracted with ethyl acetate (3x). The organic layer was 
dried over sodium sulfate, filtered, and concentrated in vacuo. Crude material still 
contained DMF. Purify via silica gel chromatography eluting with gradient of hexanes 
and ethyl acetate to yield a white solid in 39% yield.  Experiments on 600 NMR – HMBC 
in particular showed correlation between CH of triazole and CH2 of alkyl linker.  
1H NMR 
(CDCl3, 500 MHz) δ 8.18 (s, 1H), 7.49 (d, 2H, J = 7.5 Hz), 7.35 (br, 1H), 7.31 (t, 2H, J = 
7.5 Hz), 7.10 (t, 1H, J = 7.5 Hz), 4.28 (t, 2H, J = 7.0 Hz), 3.91 (s, 3H), 2.40 (q, 2H, J = 
7.0 Hz), 2.04 (q, 2H, J = 7.0 Hz).  13C NMR (CDCl3, 125 MHz) δ 170.3, 160.3, 155.1, 
144.7, 137.8, 129.2, 124.6, 120.0, 52.9, 50.4, 36.6, 29.3, 22.2.  HRMS (ESI) m/z 
calculated 303.1457 (C15H19N4O3, [M+H]
+), m/z observed 304.14590. (C15H19N4O3, 
[M+H]+). 
N-hydroxy-1-(5-oxo-5-(phenylamino)pentyl)-1H-
1,2,4-triazole-3-carboxamide (4-44).  Methyl ester 4-
42 (1 mmol) was suspended in methanol (5 mL) in a 
microwave vial. Hydroxylamine hydrochloride (3 
mmol) and crushed NaOH (6 mmol) were added as solids and the resulting 
heteroenous mixture was microwaved for 1 hour at 120°C. Starting material 
consumption was confirmed by TLC and methanol was removed in vacuo. Water and 
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ethyl acetate were added to the residue and the aqueous layer acidified to pH of 4-5 
with glacial acetic acid. The water layer was then extracted with ethyl acetate (3x). 
Combined organics were dried over sodium sulfate, filtered, and concentrated in vacuo 
to yield a white solid in 58% yield.  1H NMR (d6-DMSO, 600 MHz) δ 11.22 (s, 1H), 9.88 
(s, 1H), 9.10 (s, 1H), 8.62 (s, 1H), 7.57 (d, 2H, J = 7.8 Hz), 7.27 (t, 2H, J = 7.2 Hz), 7.01 
(t, 1H, J = 7.8 Hz), 4.24 (t, 2H, J = 6.6 Hz Hz), 2.34 (t, 2H, J = 7.2 Hz), 1.84 (q, 2H, J = 
6.6 Hz), 1.54 (q, 2H, J = 7.2 Hz).  13C NMR (d6-DMSO, 151 MHz) δ 170.8, 156.8, 155.7, 
144.9, 139.2, 128.6, 123.0, 119.0, 49.0, 35.6, 28.8, 22.0.  HRMS (ESI) m/z calculated 
303.1331 (C14H17N5O3, [M+H]
+), m/z observed 303.13299. (C14H17N5O3, [M+H]
+). 
 
 6-azido-N-phenylhexanamide (4-43). Bromoamide 4-41 (1 
mmol) was dissolved in dimethylformamide and water (2.25 
mL : 0.25 mL). Sodium azide (1.25 mmol) was added as a 
solid and the solution stirred overnight at room temperature. Progress of the reaction 
was monitored by TLC. Upon completion, the reaction was quenched with 30 mL of 
water (exothermic) and stirred until reaching room temperature. The solution was then 
extracted with DCM (3x). The combined organics were washed with water (3x), copper 
sulftate (1x) and brine (1x). The solution was dried over sodium sulfate, filtered, and 
concentrated in vacuo to yield the desired azide as a yellow-orange oil in 75% yield. 
 
 6-(4-(hydroxymethyl)-1H-1,2,3-triazol-1-yl)-N-
phenylhexanamide (4-46).  Azide 4-41 (1 mmol) 
was dissolved in acetonitrile (3.0 mL). Propargyl 
alcohol (1.05 mmol) and triethylamine (1 mmol) were added. A solution of triazine 2-17 
(0.01 mmol) in acetonitrile (1000 μL) was added, followed by a solution of 
tetrakis(acetonitrle-N)copper(I) tetrafluoroborate (0.01 mmol) in acetonitrile (1000 μL). 
The resulting solution was stirred 60°C overnight. Reaction progress was followed by 
TLC. Upon completion, the mixture was concentrated in vacuo and purified via silica gel 
chromatography eluting with a gradient of ethyl acetate and methanol to yield the 













Chapter 5.  
Conclusions and Future Work  
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5.1. Concluding Remarks 
In this dissertation, efforts to design new ligands for copper-catalyzed azide–alkyne 
cycloadditions were discussed. A series of 1,2,4-triazine ligands was successfully 
synthesized by varying the substituents at the 3-position and 5- and 6-positions. The 
triazine core scaffold was replaced with other nitrogen containing heterocycles. These 
compounds were then screened for CuAAC activity. Work is still needed to make this a 
true “click” reaction as our isolation technique still involved chromatographic separation. 
The use of water as a solvent was not explored in our optimization conditions, and 
should be given more focus in the future. 
1,2,4-Triazine ligands were also attached to solid supports to create heterogeneous 
catalysts for CuAAC. Both polystyrene and silica catalysts were effective catalysts with 
simple isolation of triazole products. The use of water proved to be beneficial for both 
heterogeneous systems. This should also be explored more in the future. Decreased 
temperatures might be achievable by altering the solvent or other parameters. 
Recyclability studies and copper retention were not examined with respect to reactions 
carried out in water. These results would give additional information on the future 
viability of these supports. 
Finally, 1,2,4-triazine ligands were used to synthesize a library of compounds containing 
1,2,3- or 1,2,4-triazoles as mimics of hydroxamic acid zinc-binding groups. Although, 
the synthesis was successful, the HDAC inhibition data was not promising. Modeling 
studies could help to design a better scaffold of inhibitors for future work. Additional 
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